Breast cancer detected and missed by screen-film and digital screening mammography: Studies on trends in classification and surgical treatment in the south of the Netherlands since 1997 by Nederend, J. (Joost)


Breast cancer detected and 
missed by screen-film and digital 
screening mammography 
Studies on trends in classification and surgical treatment in
the south of the Netherlands since 1997
Joost Nederend
Design: Publiciteitsfotografie Henk Swinkels, Eindhoven
Printing: drukkerij GVO Drukkers & Vormgevers BV | Ponsen & Looijen
ISBN: 978 90 807955 0 1
Coverphoto: Publiciteitsfotografie Henk Swinkels, Eindhoven
Executive Publisher: Publiciteitsfotografie Henk Swinkels, Eindhoven
© 2014 Joost Nederend
All rights reserved. No part of this thesis may be produced, stored in a retrieval system or transmitted in any form or by 
any means without permission of the author, or, when appropriate, of the publishers of the publications.
The publication of this thesis was financially supported by:
Catharina ziekenhuis Eindhoven; Bracco imaging Europe B.V.; Guerbet Nederland B.V.; Intergraal kankercentrum
Nederland, locatie Eindhoven; Bevolkingsonderzoek Zuid; Tromp Medical B.V.
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de 
rector magnificus
Prof. dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
vrijdag 19 september 2014 om 11:30 uur
Joost Nederend,
geboren te ‘s Gravenhage
Breast Cancer Detected and Missed by Screen-
film and Digital Screening Mammography
Studies on trends in classification and surgical treatment in the south 
of the Netherlands since 1997
Borstkanker gedetecteerd en gemist door 
analoge en digitale screeningsmammografie
Studies naar trends in classificatie en chirurgische behandeling in het 
zuiden van Nederland sinds 1997
Promotor:  Prof.dr. J.W.W. Coebergh
Overige leden:  Prof.dr. M.A.A.J. van den Bosch
   Dr. M.J. Broeders
   Prof.dr. C. Verhoef
Copromotoren:  Dr. L.E.M. Duijm
   Dr. A.C. Voogd
Chapter 1  General introduction 7
Chapter 2  Trends in incidence and detection of advanced breast cancer at
 screening mammography in the south of the Netherlands 19
Chapter 3  Trends in the management of women referred at screening mammography
  in the south of the Netherlands 
 3.1  Trends in breast biopsies for abnormalities detected at 
  screening mammography 41
 3.2  Trends in surgery for screen-detected and interval breast cancers 61
Chapter 4  Impact of the introduction of full-field digital mammography 
 screening on screening outcome in the south of the Netherlands 
 
 4.1  Impact of the transition from screen-film screening mammography 
  to digital screening mammography on screening outcome 83
 4.2 Impact of the transition from screen-film screening mammography 
  to digital screening mammography on interval cancer characteristics
  and treatment 99
Chapter 5  General discussion 119
Chapter 6  Summary and Acknowledgements 
 6.1 Summary 143
 6.2 Samenvatting 153
 6.3  Dankwoord 163
 6.4 Curriculum Vitae 169
 6.5 Portfolio 173
Contents
Breast cancer detected and missed by screen-film and digital screening mammography
C
h
a
p
te
r 1
Chapter 1
General Introduction
C
h
a
p
te
r 1
8 Breast cancer detected and missed by screen-film and digital screening mammography
C
h
a
p
te
r 
1
9General Introduction
General introduction
In the South of the Netherlands there is a long-standing cancer registry which has recorded the 
marked changes in incidence, detection, stage, staging, treatment of and mortality from breast 
cancer already since 19551,2. Since the introduction in 1995 of mammography screening in the 
region around Eindhoven, a southern part of the Netherlands, over 700,000 screens have been 
performed, and thanks to extensive data collection of screening results by one of the screening 
radiologists in this region a unique database has been created. 
This thesis will explore screening outcome throughout the years, focusing on the impact of the 
introduction of digital mammography at breast cancer screening since 2009 in the Netherlands. 
This general introduction describes:
	 •	 the	epidemiology	of	breast	cancer;
	 •	 the	background	of	population-based	screening	for	breast	cancer;
	 •	 the	on-going	debate	on	the	effectiveness	of	breast	cancer	screening;
	 •	 screening	specificity;
	 •	 the	need	of	monitoring	incidence	of	advanced	breast	cancer;
	 •	 the	transition	from	screen-film	to	digital	screening	mammography;
	 •	 the	outline	of	this	thesis;
	 •	 and	methods	and	population.
Epidemiology of breast cancer
Breast cancer is the most common malignancy in women in the Western world. In the Nether-
lands, a country with 16.7 million inhabitants, currently about 14,000 women are diagnosed 
with breast cancer yearly, mostly localized to the breast or lymph nodes. The lifetime risk for 
developing breast cancer nowadays is 1 in 7 for women living in the Netherlands3.  Breast 
cancer	is	the	second	most	common	cause	of	cancer	death	for	Dutch	women;	lung	cancer	is	
the most common cause since 20064.
In the Netherlands, the incidence of breast cancer is still rising, from 9,500 newly diagnosed 
breast cancer cases in 1995 to 14,600 in 2013, and is among the highest in Europe4. Also 
when looking at the standardized incidence rates, a remarkable increase in the incidence of 
breast	cancer	can	be	observed	during	the	last	decades;	between	1989	And	2011,	the	European	
Standardized Rate increased from 85 per 100,000 women per year to almost 155 per 100,000 
per year4. The cause of this increase is multifactorial and includes the introduction of the natio-
nal screening programme, an increased awareness among women of early symptoms of breast 
cancer, as well unfavourable developments in the exposure to risk factors, especially increasing 
age at first birth and lower parity5.
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Population based screening for breast cancer
Early detection of breast cancer has become an important aspect of current breast cancer 
management. Evidence for the effectiveness of breast cancer screening dates back to the early 
1960’s, when Shapiro at al. showed a 25% reduction of breast cancer deaths in a screened 
population6,7. The Netherlands is regarded as a pioneer in the field of breast cancer screening 
and the first pilot projects date back to the seventies with the DOM project in Utrecht (‘Di-
agnostisch Onderzoek Mammacarcinoom’), a research project on causes of breast cancer8, 
the experiment on breast examination by volunteers in Leiden9, and the radiology-born breast 
cancer mammography screening pilot in Nijmegen10, in which breast cancer mortality was 
compared to the unscreened female population of the neighbouring city of Arnhem. In 1985, 
after the positive results of the Utrecht and Nijmegen studies and the equally positive results 
of the Swedish two county trial11, the decision was taken to introduce breast cancer screening 
in the Netherlands. Because of lengthy discussions about standards for the quality of mammo-
graphy, pathology and surgical treatment, and the time needed for the training and recruitment 
of specialist radiographers, the screening programme did not start until 1989. From that year 
on, the screening programme was introduced region by region.
The Dutch breast cancer-screening programme offers biennial mammography screening to 
women aged 50-70 years of age. In 1998 – again after much debate and consultation of experts 
– the upper age-limit was extended to 75 years. In the Southern Netherlands, mass screening 
was gradually introduced between 1991 and 1995, first in Breda and Venlo, and in 1995 in the 
region of Eindhoven. 
In 1996, the Comprehensive Cancer Centre South (IKZ) developed a so called ‘visie-lering’ 
(see and learn) project, in which a small committee consisting of a surgeon, pathologist and 
radiologist together with an epidemiologist visited all hospitals performing diagnostics and 
treatment of early breast cancer. The aim of this project was to improve the quality of the care 
for those women referred to the hospital because of a positive screening test. 
On-going debate on usefulness / effectiveness of screening
In spite of the generally positive outcomes of several trials and population-based studies, the 
effectiveness of breast cancer screening has been under discussion since its introduction. Es-
pecially the simultaneous decrease of the mortality rate in unscreened women (both women 
younger than 50 years of age and women in countries without a mass screening programme) 
is the main argument for questioning the degree of effectiveness of breast cancer screening 
(Figure 2).  Several factors have simultaneously contributed to the lowering of the breast cancer 
mortality rate through the years: 
	 •	 improved	treatment	breast	cancer,	also	of	recurrent	and/or	progressive	disease;			
	 •	 the	introduction	of	breast	cancer	screening;	
	 •	 and	increased	cancer	awareness	among	women12-14. 
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11General Introduction
However, the continuous rise of the background incidence of breast cancer may have had the 
opposite effect on breast cancer mortality1,15. As a result, it is almost impossible to quantify the 
contribution of each factor to the decreased breast cancer mortality, also because of the long 
duration of the disease once it has been diagnosed16. 
Other arguments in the discussion on the effectiveness of screening include the harms of mam-
mography screening, especially the consequences of false-positive findings.
Figure 1. Age-specific incidence of invasive breast cancer in the Netherlands  Source: www.ikcnet.nl
Figure 2. Age-specific mortality of invasive breast cancer  Source: www.ikcnet.nl
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In 2000, a Danish review of the Nordic Cochrane Centre17, by Peter Gøtzsche and colleagues, 
criticized the methodological quality of the breast cancer screening trials. Several other studies 
have refuted the conclusions of the Nordic Cochrane Centre18,19, with the Dutch conclusion 
being that “There seems no reason to change or halt the current nation-wide population-
based screening programmes. Nor is there any justifiable reason for negative reports towards 
women or professionals”19. The conclusions from the mentioned Cochrane review17, and other 
reports and publications, have not resulted in ending breast cancer screening. Nonetheless, 
there remains criticism of the effectiveness of breast cancer screening, mostly on the substan-
tial risk for women of experiencing a false positive screening result or an interval cancer, which 
is breast cancer detected after screening mammography yielded a negative result. Another 
subject of debate is the risk of over-diagnosis. Over-diagnosis is the diagnosis of “disease” that 
will never (or after a very long time, i.e. more than 15 years) cause symptoms or lead to death 
during a patient’s lifetime. Without screening most of these cancers would not have been de-
tected. Estimates of the risk of over-diagnosis vary widely, from 2% in a Dutch study20 to 52% 
in a study by Jorgensen et al.21. As mentioned recently by the Dutch researchers, the disparity 
of the estimates between the two studies is probably the result of methodological differences, 
lack of sufficient follow-up and differences in screening characteristics and performance22. 
Furthermore, the true problem might not be over-diagnosis, but overtreatment23. This issue is 
especially relevant in the current era of digital screening where more ductal carcinoma in-situ 
and small, low-grade invasive malignancies are detected. Complications of surgery (both local 
and axillary) and adjuvant therapy can cause significant morbidity and therefore over-treatment 
should be avoided. Further research, preferably in the form of randomised controlled trials, is 
needed to determine whether certain diagnosed invasive cancers and/ or in-situ carcinomas 
can be monitored rather than treated by surgery. 
Screening specificity 
A false positive referral is a potential harm of breast cancer screening, even more so if the 
women involved are not appropriately informed about this risk when invited for screening. 
Especially since the introduction of digital mammography screening, false positive referrals 
have become a subject of debate, as digital screening has a lower positive predictive value than 
screen-film mammography. Several studies have shown that a false-positive referral causes 
stress, anxiety, and could negatively influence re-attendance to the screening programme24-27. 
The observed severity of psychological distress in referred women with a benign outcome was 
higher than the psychological distress observed in women who were not referred25. Further-
more, screen-related costs increase due to unnecessary use of diagnostic tests, hereby compro-
mising the cost-effectiveness of the screening programme28,29.
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The need of monitoring incidence of advanced breast cancer 
Most breast cancer deaths occur in women with advanced breast cancer, diagnosed when the 
disease has already spread to lymph nodes or distant organs. Breast cancer screening aims 
to detect breast cancer at an early stage, when the disease has a better prognosis. Screening 
therefore is expected to lower the incidence of advanced breast cancer, followed by a reduc-
tion in breast cancer mortality. A critical view on breast cancer screening related to its impact 
on the incidence of advanced breast cancer, is expressed by a French research collaboration, 
led by Philippe Autier. Several studies of this collaboration showed the incidence of advanced 
breast cancer remained stable after the introduction of breast cancer screening, which suggests 
that it did not play a significant role in the observed reduction in mortality caused by breast 
cancer30-32. However, Autier et al. do not take into account that incidence of breast cancer, 
whether advanced or not, may just have risen because of later age at first birth as such but 
also as an indicator of (breast tissue favourable) lifestyle of young women5. Albeit certainly im-
portant, monitoring of the incidence of advanced breast cancer does not provide unequivocal 
information of the impact of screening on breast cancer mortality in the general population as 
advocated by Autier et al.32.
Digital mammography: the Holy Grail for breast cancer screening?
Digital mammography screening was introduced in 2009 in the Eindhoven screening region. 
The technique was already available in the early 1980’s33, and the potential for digital mammo-
graphy to improve the detection performance of radiologists for microcalcifications is already 
known since the early nineties34. Until today screen-film mammography was considered as the 
gold standard for breast cancer screening17,35. There is emerging evidence showing that digital 
mammography is superior to screen-film mammography with respect to sensitivity, especi-
ally in women under the age of 50 years and women with radiographically dense breasts36,37. 
Furthermore, digital mammography significantly improves workflow, especially important in 
a screening programme. These advantages have lead to the replacement of screen-film mam-
mography by digital mammography in most western screening programmes. 
Little is known about the influence of the introduction of digital mammography screening on 
screening sensitivity and breast cancer mortality. There is little data on interval cancers in 
the era of digital screening, cancers that arise between two screening rounds after a negative 
screen38,39. The overall higher cancer detection rate at digital screening comes with higher re-
ferral rates. Reports on the impact on positive predictive value vary, but on average the higher 
referral rate to digital mammography increases the number of women falsely referred40-44. Con-
sequently, a larger proportion of screened women will experience unnecessary anxiety24,25,45. 
Finally, no data is available on the impact of digital screening on breast cancer mortality.
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The scope of this thesis
The main objective of this thesis is the in-depth evaluation of varying aspects of the breast can-
cer programme in the south of the Netherlands as a way to identify key issues for improvement. 
This will be done by evaluating classification of breast cancer both detected and missed by 
mammography screening, as well as by determining the management of referred women with 
and without breast cancer since 1997. 
The specific aims of this thesis are to: 
	 •	 determine	trends	in	incidence	and	detection	of	advanced	cancer	at	screening	mammo-
  graphy in the south of the Netherlands (Chapter 2).
	 •	 examine	trends	in	the	use	of	biopsies	in	referred	women	(Chapter	3.1)	and	surgical	ma-
  nagement of screen-detected breast cancer (Chapter 3.2).
	 •	 further	explore	effects	of	 the	 introduction	of	digital	mammography	 screening	on	 the	
  following screening outcome parameters: 
	 	 –	 surgical	management	of	invasive	and	in	situ	breast	cancer;
	 	 –	 interval	cancer	rate;	
  – characteristics of screen-detected and interval cancers (Chapter 4).
Finally, in chapter 5, the main results of the studies in this thesis are discussed, as well as their 
significance for the current and future breast cancer-screening programme in (the south of) the 
Netherlands.
Population, patients and methods
Since the implementation of breast cancer screening in the Eindhoven region in the Southern 
Netherlands from 1995, screening outcome has been closely monitored and registered. Since 
the start of the screening programme in 1995, over 700,000 screens have been made in one 
mobile and one stationary mammography centre (from 2009: 2 mobile centres and 3 mobile 
centres from 2013). In 1995 nine screening radiologists double read about 15,000 screens. 
Currently, a team of 13 certified screening radiologists double read 60,000 screens annually.  
All data of referred women and those who presented with an interval cancer were recorded 
in an Excel-database, kept by the screening radiologist Lucien Duijm who is also a radiologist 
in one of the larger hospitals. This database was used for professional quality assurance of the 
screening programme in our region as well as for various scientific purposes. Furthermore, 
ample information is available on coinciding increasing adjuvant and palliative systemic treat-
ment of women with breast cancer in the region46,47.
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Chapter 2
Trends in incidence and detection of 
advanced breast cancer at screening 
mammography in the south of 
the Netherlands
Published as: Nederend J, Duijm LE, Voogd AC, Groenewoud JH, Jansen FH, Louwman MW. 
Trends in incidence and detection of advanced breast cancer at biennial screening mam-
mography in The Netherlands: a population based study. Breast Cancer Res 2012 9; 14: R10.
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Abstract 
Background: The aims of this study were to determine trends in the incidence of advanced 
breast cancer at screening mammography and the potential of screening to reduce it.
Methods: We included a consecutive series of 351,009 screening mammograms of 85,274 
women aged 50-75 years, who underwent biennial screening at a Dutch breast screening regi-
on in the period 1997-2008. Two screening radiologists reviewed the screening mammograms 
of all advanced screen-detected and advanced interval cancers and determined whether the 
advanced cancer (tumour > 20 mm and/or lymph node positive tumour) had been visible at 
a previous screen. Interval cancers were breast cancers diagnosed in women after a negative 
screening examination (defined as no recommendation for referral) and before any subsequent 
screen. Patient and tumour characteristics were compared between women with advanced 
cancer and women with non- advanced cancer, including ductal carcinoma in situ.
Results: A total of 1,771 screen-detected cancers and 669 interval cancers were diagnosed 
in	2,440	women.	Rates	of	advanced	cancer	remained	stable	over	the	12-year	period;	the	in-
cidence of advanced screen-detected cancers fluctuated between 1.5 - 1.9 per 1,000 scree-
ned women (mean 1.6 per 1,000) and of advanced interval cancers between 0.8 - 1.6 per 
1,000 screened women (mean 1.2 per 1,000). Of the 570 advanced screen-detected cancers, 
106	(18.6%)	were	detected	at	 initial	screening;	265	(46.5%)	cancers	detected	at	subsequent	
screening had been radiologically occult at the previous screening mammogram, 88 (15.4%) 
had shown a minimal sign, and 111 (19.5%) had been missed. Corresponding figures for ad-
vanced interval cancers were 50.9% (216/424), 24.3% (103/ 424) and 25.1% (105/424), res-
pectively. At multivariate analysis, women with a > 30 months interval between the latest two 
screens had an increased risk of screen-detected advanced breast cancer (OR 1.63, 95%CI: 
1.07-2.48) and hormone replacement therapy increased the risk of advanced disease among 
interval cancers (OR 3.04, 95%CI: 1.22-7.53).
Conclusion: We observed no decline in the risk of advanced breast cancer during 12 years 
of biennial screening mammography. The majority of these cancers could not have been pre-
vented through earlier detection at screening.
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Introduction
Most breast cancer deaths are due to advanced disease, diagnosed when it has already spread 
to lymph nodes or distant organs. Therefore, many countries have introduced breast cancer 
screening programs in order to detect breast cancer at an early stage.  In the Netherlands, 
a nation-wide biennial screening program for women aged 50-69 years was implemented 
between 1989 and 1997. In 1998, the upper age limit for breast screening was extended to 75 
years. The attendance rate at our screening region is 84%1. 
Several studies have shown that screening mammography is effective in reducing breast cancer 
mortality2-4. However, the authors of a recent comprehensive review stated that the positive 
results of randomized trials of mammography screening on breast cancer mortality should 
be interpreted with caution as these trials were carried out in an era before the use of anti-
hormonal therapies and before major advances in other aspects of breast cancer treatment5. 
Autier et al. compared breast cancer mortality in 30 European countries and concluded that 
the reduction in breast cancer mortality was more profound in non-screened women (-37%) 
than in screened women (-21%)6. It remains a question of debate which part of the reduction 
can be attributed to screening and which part can be explained by other factors, such as the 
more extensive use of adjuvant systemic treatment7,8. Compared with rates in 1986-1988, Otto 
et al. reported a 19.9% reduction in breast cancer mortality rate in 2001 as a result of routine 
mammography screening in the Netherlands4.  Kalager et al. calculated that only one third of 
the reduction in breast cancer mortality in Norway could be attributed to screening8. Jørgensen 
et al. did not find any effect of breast cancer screening on breast cancer mortality in Denmark 
and they contributed the lower mortality to changes in risk factors and improved treatment9. 
If a mortality reduction were due to screening rather than the result of adjuvant systemic the-
rapy, one would expect that it is preceded by a decrease in risk of a diagnosis of advanced 
breast cancer. Screening may not be that effective if no stage shift is observed. Although Fra-
cheboud et al. initially found a significant decrease in the incidence rate of advanced disease 
in women who participated in the Dutch screening program, they later reported an increase in 
advanced cancers detected at screening10,11. For more recent years of nation-wide screening, 
the National Evaluation Team for Breast Cancer Screening in The Netherlands found a more 
or less stable tumour size distribution of screen-detected cancers, as well as a stable rate of 
lymph node positive breast cancers12. Autier et al.13 observed no significant changes in advan-
ced breast cancer rates in several European countries, despite good participation at screening 
mammography programs. 
So far, no data are available for predictors for a diagnosis of advanced disease. The primary 
goal of our population based study was to determine the trends in incidence and detection of 
advanced breast cancer in the Southern Region of the nationwide breast screening program in 
the Netherlands, during twelve years of biennial screening mammography. We also assessed 
the proportion of advanced cancers that potentially could have been prevented through earlier 
detection at screening and we identified patient and tumour characteristics that were related to 
an increased risk of advanced breast cancer. 
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Methods
Study population
We included 351,009 consecutive screens (46,155 initial screens and 304,854 subsequent 
screens) of 85,274 women, who underwent biennial screening mammography at two speciali-
zed analogue screening units in the Southern Region (BOBZ, Bevolkings Onderzoek Borstkan-
ker Zuid) of the Dutch nationwide breast cancer screening program between January 1, 1997 
and January 1, 2009. All but three women had given written informed consent to use their 
screening and follow-up data for evaluation purposes. The Central Committee on Research 
Involving Human Subjects (CCMO) in The Hague, The Netherlands, waived ethical approval 
for this study.
Screening procedure and referral
Details of our nation-wide breast cancer screening program, offering biennial screening mam-
mography for women aged 50-75 years, are described elsewhere14,15. In brief, all mammograms 
were obtained by specialized screening mammography technologists and independently dou-
ble read by certified screening radiologists. In the Southern Region, technologists have been 
actively participating in the assessment of screening mammograms, in addition to the double 
reading by the radiologists16. Fifteen certified screening radiologists were involved, all of who 
evaluated at least 5,000 screening mammograms yearly. Prior screening mammograms were 
always available for comparison at the time of subsequent screening. Women were asked to 
fill in a questionnaire prior to screening mammography with questions about date, type and 
reason of previous breast surgery, family history of breast cancer and hormonal replacement 
therapy. For all women with a positive screening mammogram or interval cancer, we recorded 
the information of this questionnaire in a database that is used for quality assurance of our 
screening program. We consulted the clinical records of the hospital to which a woman had 
been referred for the completion of seldom cases of insufficient data.
If screening mammography showed a suspicious or malignant lesion, the woman was referred 
to a surgical oncologist or breast clinic for further analysis of the mammographic abnormality. 
Workup facilities at hospitals
A total of 16 hospitals in the southern region were involved in the diagnostic workup, of which 
four centrally located hospitals accounted for the workup of 93% (4,137/4,450) of referred wo-
men17. These four hospitals performed between 2,000-3,500 diagnostic mammographic exa-
minations yearly. Further evaluation depended on the workup protocols and facilities availa-
ble, and consisted of additional mammographic views, breast ultrasound, magnetic resonance 
mammography, percutaneous fine needle aspiration or core biopsy (usually image guided), or 
open surgical biopsy. Outpatient breast clinics were introduced between 1999 and 2007, and 
systematic discussion of positive screens by a multidisciplinary team of physicians between
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2002 and 2007. New diagnostic techniques were also introduced over time, including Magne-
tic Resonance Mammography (2000-2004), 14-Gauge stereotactic core needle biopsy (2000-
2007), axillary ultrasound with lymph node sampling (1998-2000), and 9- or 10-Gauge stereo-
tactic vacuum-assisted core biopsy (2004-2007). One hospital mainly performed ultrasound 
guided fine needle aspiration cytology of solid breast lesions, whereas the other three hospitals 
gradually replaced cytology by 14-18 Gauge core biopsies.
Follow-up procedure
During a follow-up period of two years, we collected data on diagnostic and surgical procedu-
res, histopathology and TNM (tumour-node-metastasis) classification18 of all screen-detected 
cancers and interval cancers. Interval cancers were defined as breast cancers diagnosed in 
women after a screening examination yielded negative results (defined as no recommendation 
for referral) and before any subsequent screen was performed. Procedures for the detection of 
interval cancers have been described previously19. 
Breast	cancers	were	divided	into	ductal	carcinoma	in-situ	and	invasive	cancers;	lobular	carci-
noma in-situ was considered to be a benign lesion. Ductal carcinoma in situ was included in 
the group of non-advanced breast cancers. Advanced cancers were defined as cancers with 
TNM stage IIA or higher, i.e. tumour size exceeding 20 mm (T2) and/or presence of lymphatic 
metastasis in the sentinel node or axillary lymph nodes. Sentinel nodes were classified negative 
if they harboured isolated tumour cells or sub-micrometastases (<0.2 mm) and were conside-
red positive (N+) if they contained micrometastases (0.2-2 mm) or macrometastases (>2 mm). 
A further subdivision of advanced cancers in T1N+, T2+N- and T2+N+ was also made to be 
able to determine a possible effect of the introduction of sentinel node biopsy and concomitant 
stage migration on our findings analysed our data using different definitions (T1N+, T2+N- or 
T2+N+) of advanced cancer.
Incidence rates of advanced cancers in the South-eastern Netherlands between 1985 and 2009 
were calculated for women aged 50-75 years (whether screened or not) using the population-
based Eindhoven Cancer Registry20.
Invitation letters for screening mammography are routinely sent 23-26 months after the previ-
ous screening round. If a woman is not able to attend screening, she is given the opportunity 
to make a new appointment within 6 months. Screening intervals exceeding 30 months usually 
involve women who have missed one or more screening rounds. Therefore, we considered a 
screening interval of more than 30 months to be a prolonged screening interval. For each wo-
man with a screen-detected cancer and a screening interval of more than 30 months prior to 
the latest screening examination, we determined if she had undergone clinical mammography 
at any of the hospitals located at our screening region within 30 months prior to final screening. 
If the latter was the case (n=6), then the woman was considered to have a screen interval of 
less than 30 months. 
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Review of screening mammograms of advanced breast cancers
Two experienced screening radiologists (LD, FJ) reviewed the two most recent screening mam-
mograms of all women with advanced screen-detected breast cancers at a subsequent screen. 
Older screening examinations were available for comparison if desired by the radiologists. 
They determined whether or not the cancer had been missed, had shown a minimal sign21 or 
had been occult at the previous screen. For each advanced interval cancer, the radiologists 
correlated the clinical mammogram, on which the interval cancer had been diagnosed, with 
the latest screening examination and also determined whether the cancer had been visible at 
the latest screen. The radiologists classified the mammographic abnormality of each advanced 
breast cancer into one of the following, mutually exclusive, categories: 
	 1.	Suspicious	high	density	(e.g.,	spiculated	density	or	density	with	indistinct	borders);	
 2. Suspicious microcalcifications (e.g., pleomorphic, branching, or amorphous/indistinct 
	 	 microcalcifications);	
	 3.	High	density	in	combination	with	microcalcifications;	
	 4.	Architectural	distortion	or;
 5. Breast parenchyma asymmetry. 
Finally, the breast density of the latest screen (and of the last but one screen in case of sub-
sequent screening) was assessed, according to the BI-RADS criteria22. The radiologists were 
initially blinded to each other’s review and consensus reading followed discrepant readings. 
Figure 1. Mammography screening outcome at 2-year follow-up
SDC = screen‐ detected cancer; IC = interval cancer
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Statistical analysis
Statistical analyses were performed per 2-year screening periods. All data were entered into a 
computerized	spreadsheet	(Excel;	Microsoft,	Redmond,	WA,	USA).	Statistics	were	performed	
using	the	SAS	program	version	9.1.3	(Statistical	Analysis	Software;	SAS/STAT	software®,	Cary,	
NC, USA). A double sided t-test was used to test differences between continuous variables, and 
the χ²-test to test differences between categorical variables. Logistic regression was performed 
to investigate which factors significantly affected the risk of a diagnosis of advanced breast 
cancer among patients with screen-detected and interval breast cancer. The significance level 
was set at 5%.
Results
Overall screening results
The biennial number of screening examinations gradually increased from 48,721 (1997/1998) 
to 67,530 (2007/2008) and the biennial referral rate varied between 0.9% and 1.6% (mean 
1.3%). Breast cancer was diagnosed in 1,771 of 4,450 referred women (including 287 ductal 
carcinomas in situ), resulting in an overall cancer detection rate of 5.1 per 1,000 screens and 
an overall positive predictive value of 39.8% (Table 1, Figure 1). In addition, 669 interval 
Figure 2. Time trend in incidence of advanced breast cancer among women aged 40-49 years and 50-75 years
in southeastern Netherlands, 1980-2009
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cancers (including 27 ductal carcinomas in situ) were diagnosed. Mean sensitivity of breast 
cancer screening was 72.6% (1,771/2,440). Screening sensitivity was higher for non-dense 
breasts (ACR breast density category I+II), that is, 75.3% (1,189/1,580), than for dense breasts
(ACR breast density category III+IV), that is, 67.7% (582/860) (p < 0.001). The proportion of 
advanced cancers among all cancers was 40.7% (994/2,440). This proportion did not change 
significantly through the years and ranged from 37.8% (1997/1998) to 45.5% (2001/2002) (p = 
0.6, Table 1). Visibility of screen-detected cancers and interval cancers on previous screening 
rounds remained constant during the twelve year screening period and the proportion of oc-
cult cancers, minimal signs and missed cancers for both groups neither changed (p = 0.4 and 
p = 0.5, respectively). Figure 2 shows that the ESR standardized rate for advanced cancer was 
stable between 1985-2009 and showed no decline after the introduction of screening mam-
mography in southeastern Netherlands. 
Advanced breast cancers detected at screening
Of screen-detected cancers, 570 were advanced cancers and 1,164 non advanced cancers. 
The tumour stages of the remaining 37 screen-detected cancers could not be properly classi-
fied, including TxN- cancers (negative lymph nodes but unknown tumour size) and T1Nx can-
cers	(invasive	cancers	<20	mm	with	unknown	lymph	node	status);	these	were	excluded	from	
further analysis. The proportion of advanced screen-detected cancers per 2-year screening 
period fluctuated between 28.7% (2003/2004) and 35.4% (2007/2008) (p=0.6, Table 1). Uni-
variate analysis showed no statistically significant differences between women with advanced 
or non-advanced breast cancer regarding family history of breast cancer, use of hormone repla-
cement therapy, percentage initial screens, interval between screens, prior visibility or breast 
density (Table 2). Compared to non-advanced cancers, advanced screen-detected cancers 
were more frequently characterized by abnormal densities and less frequently by suspicious 
microcalcifications at screening (p<0.001) and comprised more invasive lobular cancers and 
fewer invasive ductal cancers (p<0.001, Table 2). 
After adjustment for all other variables (Table 3), we found that an interval of 30 months or 
more between the latest two screens was associated with increased risk of advanced screen-
detected breast cancer (OR 1.63, 95% CI: 1.07-2.48). High breast density was borderline signi-
ficantly associated with increased risk of advanced breast cancer (OR 1.25, 95% CI: 0.99-1.57), 
as was a family history of breast cancer (OR 1.20, 95% CI: 0.93-1.56).
Of the 570 advanced screen-detected cancers, 106 (18.6%) had been detected at the initial 
screen and 464 (81.6%) at a subsequent screen. Of the latter, 265 (57.1%) were considered 
mammographically	occult	at	the	last	but	one	screen	at	retrospect;	whereas	88	(19.0%)	showed	
a minimal sign and 111 (23.9%) were missed at the last but one screen. Thus, at least 65.1% 
(106+265/570) of advanced cancers could not have been diagnosed at an earlier stage. We ob-
served no significant changes in the proportions of T1N+, T2+N- and T2+N+ screen-detected 
cancers during our twelve-year screening period (Figure 3).
Advanced interval breast cancers
Advanced breast cancers comprised 63.4% (424/669) of all interval cancers (Figure 1). Of 
advanced interval cancers, 35.8% (152/424) were diagnosed in the first year after the latest 
negative screen, and 64.2% (272/424) in the second year. Of interval cancers diagnosed in the 
first or the second year after the latest negative screen, respectively 65.0% (152/234, 95%CI: 
58.8–72.1) and 62.5% (272/435, 95%CI: 60.0–67.1) were advanced cancers. At review, 50.9% 
(216/424) of advanced interval cancers were considered mammographically occult at the latest 
screen, whereas 103 (24.3%) showed a minimal sign and 105 (24.8%) had been missed. At 
univariate analysis, we found no significant difference between advanced and non-advanced 
interval cancers in family history of breast cancer, percentage initial screens, interval between 
screens, prior visibility, tumour histology, or breast density (Table 2). Compared to the non-
advanced cancers, advanced interval cancers were more frequently characterized by breast 
parenchymal asymmetries and less frequently by suspicious microcalcifications or abnormal 
densities (p = 0.04) and more women with advanced interval cancer used hormone replace-
ment therapy (p = 0.005), (Table 2). The use of hormone replacement therapy was an indepen-
dent risk factor for advanced breast cancer at multivariate analysis (OR 3.04, 95% CI: 1.22-7.53, 
Table 3). Similar to advanced screen-detected cancers, we found no significant changes in the 
proportions of T1N+, T2+N- and T2+N+ interval cancers during twelve years of screening 
(Figure 3). 
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Figure 3. Distribution of breast cancer stage at 6 consecutive 2-year screening periods
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Screening period 1997/1998 1999/2000 2001/2002 2003/2004 2005/2006 2007/2008 Total
Mammograms, No 48,721 53,718 53,489 61,251 66,300 67,530 351,009
Referral, No 536 499 553 985 874 1003 4450
Referral rate, % (95% CI) 1.1 (1.0‐1.2) 0.9 (0.9‐1.0) 1.0 (1.0‐1.1) 1.6 (1.5‐1.7) 1.3 (1.2‐1.4) 1.5 (1.4‐1.6) 1.3 (1.2‐1.3)
Screen detected breast cancers, No 224 274 254 345 321 353 1,771
   Advanced cancers, No (rate*; 95% CI) 74
(1.5; 1.2‐1.9)
87
(1.6; 1.3‐2.0)
88
(1.6; 1.3‐2.0)
99
(1.6; 1.3‐1.9)
97
(1.5; 1.2‐1.8)
125
(1.9; 1.5‐2.2 )
570
(1.6; 1.5‐1.8)
   Non‐advanced cancers, No (rate*; 95% CI) 147
(3.0; 2.5‐3.5)
178
(3.3; 2.8‐3.8)
160
(3.0; 2.5‐3.5 )
239
(3.9; 3.4‐4.4)
218
(3.3; 2.9‐3.7)
222
(3.3; 2.9‐3.7)
1,164
(3.3; 3.1‐3.5)
   Unknown tumor stage, No (rate*; 95% CI) 3
(0.1; 0.0‐0.1)
9 
(0.2; 0.1‐0.3)
6
(0.1; 0.0‐0.2)
7
(0.1; 0.0‐0.2)
6
(0.1; 0.0‐0.2)
6
(0.1; 0.0‐0.2)
37
(0.1; 0.1‐0.1)
Cancer detection rate* (95% CI) 4.6 (4.0‐5.2) 5.1 (4.5‐5.7) 4.7 (4.2‐5.3) 5.6 (5.0‐6.2) 4.8 (4.3‐5.4) 5.2 (4.7‐5.8) 5.1 (4.8‐5.3)
PPV of referral, % (95% CI) 41.8 (37.6‐46.0) 54.9 (50.8‐59.5) 45.9 (41.9‐50.2) 35.0 (32.0‐38.0) 36.7 (33.5‐39.9) 35.2 (32.1‐38.0) 39.8 (38.3‐41.2)
Interval cancers, No 75 94 128 116 139 117 669
   Advanced cancers, No (rate*; 95% CI) 39
(0.8; 0.5‐1.1)
63
(1.2; 0.9‐1.5)
86
(1.6; 1.3‐1.9)
79
(1.3; 1.0‐1.6)
87
(1.3; 1.0‐1.6)
70
(1.0; 0.8‐1.3)
424 
(1.2; 1.1‐1.3)
   Non‐advanced cancers, No (rate*; 95% CI) 33
(0.7; 0.4‐0.9)
30
(0.6; 0.4‐0.8)
39
(0.7; 0.5‐1.0)
35
(0.6; 0.4‐0.8)
50
(0.8; 0.5‐1.0)
46
(0.7; 0.5‐0.9)
233 
(0.7; 0.6‐0.7)
   Unknown tumor stage, No (rate*; 95% CI) 3
(0.1; 0.0‐0.1)
1
(0.0; 0.0‐0.1)
3
(0.1; 0.0‐0.1)
2
(0.0; 0.0‐0.1)
2
(0.0; 0.0‐0.1)
1
(0.0; 0.0‐0.0)
12   
(0.0; 0.0‐0.1)
Sensitivity, % (95% CI) 74.9 (70.3‐80.1) 74.5 (70.0‐78.9) 66.5 (61.8‐71.2) 74.8 (70.9‐78.8) 69.8 (65.6‐74.0) 75.1 (72.0‐79.8) 72.6 (71.0‐74.5)
Proportion of advanced cancers among screen detected cancers + 
interval cancers, % (95% CI)
37.8 (32.4‐43.4) 40.7 (36.3‐46.3) 45.5 (40.0‐50.0) 38.6 (34.2‐43.1) 39.9 (35.7‐44.7) 41.5 (37.0‐46.0) 40.7 (38.8‐42.7)
*per 1,000 women screened; CI = confidence interval; PPV = positive predictive value
Table 1. Screening results at 6 consecutive 2-year screening periods
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Screening period 1997/1998 1999/2000 2001/2002 2003/2004 2005/2006 2007/2008 Total
Mammograms, No 48,721 53,718 53,489 61,251 66,300 67,530 351,009
Referral, No 536 499 553 985 874 1003 4450
Referral rate, % (95% CI) 1.1 (1.0‐1.2) 0.9 (0.9‐1.0) 1.0 (1.0‐1.1) 1.6 (1.5‐1.7) 1.3 (1.2‐1.4) 1.5 (1.4‐1.6) 1.3 (1.2‐1.3)
Screen detected breast cancers, No 224 274 254 345 321 353 1,771
   Advanced cancers, No (rate*; 95% CI) 74
(1.5; 1.2‐1.9)
87
(1.6; 1.3‐2.0)
88
(1.6; 1.3‐2.0)
99
(1.6; 1.3‐1.9)
97
(1.5; 1.2‐1.8)
125
(1.9; 1.5‐2.2 )
570
(1.6; 1.5‐1.8)
   Non‐advanced cancers, No (rate*; 95% CI) 147
(3.0; 2.5‐3.5)
178
(3.3; 2.8‐3.8)
160
(3.0; 2.5‐3.5 )
239
(3.9; 3.4‐4.4)
218
(3.3; 2.9‐3.7)
222
(3.3; 2.9‐3.7)
1,164
(3.3; 3.1‐3.5)
   Unknown tumor stage, No (rate*; 95% CI) 3
(0.1; 0.0‐0.1)
9 
(0.2; 0.1‐0.3)
6
(0.1; 0.0‐0.2)
7
(0.1; 0.0‐0.2)
6
(0.1; 0.0‐0.2)
6
(0.1; 0.0‐0.2)
37
(0.1; 0.1‐0.1)
Cancer detection rate* (95% CI) 4.6 (4.0‐5.2) 5.1 (4.5‐5.7) 4.7 (4.2‐5.3) 5.6 (5.0‐6.2) 4.8 (4.3‐5.4) 5.2 (4.7‐5.8) 5.1 (4.8‐5.3)
PPV of referral, % (95% CI) 41.8 (37.6‐46.0) 54.9 (50.8‐59.5) 45.9 (41.9‐50.2) 35.0 (32.0‐38.0) 36.7 (33.5‐39.9) 35.2 (32.1‐38.0) 39.8 (38.3‐41.2)
Interval cancers, No 75 94 128 116 139 117 669
   Advanced cancers, No (rate*; 95% CI) 39
(0.8; 0.5‐1.1)
63
(1.2; 0.9‐1.5)
86
(1.6; 1.3‐1.9)
79
(1.3; 1.0‐1.6)
87
(1.3; 1.0‐1.6)
70
(1.0; 0.8‐1.3)
424 
(1.2; 1.1‐1.3)
   Non‐advanced cancers, No (rate*; 95% CI) 33
(0.7; 0.4‐0.9)
30
(0.6; 0.4‐0.8)
39
(0.7; 0.5‐1.0)
35
(0.6; 0.4‐0.8)
50
(0.8; 0.5‐1.0)
46
(0.7; 0.5‐0.9)
233 
(0.7; 0.6‐0.7)
   Unknown tumor stage, No (rate*; 95% CI) 3
(0.1; 0.0‐0.1)
1
(0.0; 0.0‐0.1)
3
(0.1; 0.0‐0.1)
2
(0.0; 0.0‐0.1)
2
(0.0; 0.0‐0.1)
1
(0.0; 0.0‐0.0)
12   
(0.0; 0.0‐0.1)
Sensitivity, % (95% CI) 74.9 (70.3‐80.1) 74.5 (70.0‐78.9) 66.5 (61.8‐71.2) 74.8 (70.9‐78.8) 69.8 (65.6‐74.0) 75.1 (72.0‐79.8) 72.6 (71.0‐74.5)
Proportion of advanced cancers among screen detected cancers + 
interval cancers, % (95% CI)
37.8 (32.4‐43.4) 40.7 (36.3‐46.3) 45.5 (40.0‐50.0) 38.6 (34.2‐43.1) 39.9 (35.7‐44.7) 41.5 (37.0‐46.0) 40.7 (38.8‐42.7)
*per 1,000 women screened; CI = confidence interval; PPV = positive predictive value
Table 1. Screening results at 6 consecutive 2-year screening periods (continued)
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Screen detected cancer Interval cancer
Advanced
N = 570
Non‐advanced
N = 1,164
P‐
value
Advanced
N = 424
Non‐advanced
N = 233
P‐
value
Mean age, years (95%CI) 62.0 (61.3 – 62.6) 62.4 (62.0 – 62.8) 0.24 59.5 (58.9 – 60.2) 59.3 (58.4 – 60.2) 0.76
Family history of breast cancer±, No (%) 123 (21.6) 218 (18.7) 0.16 76 (17.9) 43 (18.5) 0.87
Previous breast surgery#   58 (10.0) 130 (11.2) 0.53 72 (15.6) 34 (15.0) 0.43
Use of hormone replacement therapy, 
No (%) 59 (10.4) 95 (8.2) 0.13 70 (13.1) 20 (6.3) 0.005
Initial screens, No (%)      106 (18.6) 183 (15.7) 0.13 64 (13.5) 32 (11.8) 0.64
Interval between 2 latest screens, 
No (%) 0.08 ‐ ‐
< 30 months       527 (92.5) 1,101 (94.1)
> 30 months          43  (7.5)              63   (5.4)
Breast density at latest screening mam‐
mogram, No (%) 0.45 0.49
<50%       375 (65.8) 787 (67.4) 243 (60.7) 140 (60.1)
>50%       195 (34.2)           377 (32.4) 181 (39.3) 93 (39.9) 
Mammographic abnormality, No (%) < 0.001 0.04
     Density       426 (74.8) 740 (63.6) 133 (64.6) 78 (70.9)
     Microcalcifications         35   (6.1)           280 (24.1) 26 (12.6) 18 (16.4)
     Density with microcalcifications         82 (14.4)           112   (9.6) 16 (7.8) 6 (5.5)
     Architectural distortion         22   (3.9)             24   (2.1) 11 (5.3) 7 (6.4)
     Breast parenchyma asymmetry            4   (0.9)               8   (0.7) 20 (9.7) 1 (0.9)
Breast cancer visible at previous screen‐
ing mammogram      199 (42.9)*           418 (42.7)
¥ 0.95 208 (47.6) 112 (47.4) 0.81
Tumor histology of invasive cancers, 
No (%) < 0.001 0.09
     Ductal       414 (72.6) 682 (77.7) 304 (71.8) 155 (77.7)
     Lobular         93 (16.3)             85   (9.7) 87 (21.3) 30 (10.9)
     Mixed ductal‐lobular         37   (6.5)             41   (4.7) 18 (4.0) 10 (5.9)
     Invasive other         24   (4.2)             68   (7.7) 11 (2.0) 11 (5.5)
     Unknown           2   (0.4)               2   (0.2) 4 (0.9) 0 (0.0)
±At least one first-degree relative (mother, sister, daughter) with a diagnosis of breast cancer before the age of 50 
years or at least two second-degree relatives with breast cancer
#Surgery for benign conditions (e.g., excisional biopsy, breast reduction, breast augmentation, mastitis) and malig‐
nant conditions (lumpectomy, mastectomy)
*464 subsequent screens; ¥979 subsequent screens
Table 2. Characteristics of women with breast cancer
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1. Calculated for invasive cancers only
2. Not calculated because all 4 patients with unknown histology had advanced breast cancer
Table 3. Odds of having advanced breast cancer among women with breast cancer, each variable adjusted for
               all others
Advanced vs. non‐advanced 
screen detected cancers
Advanced vs. non‐advanced 
interval cancers
OR 95%CI P‐value OR 95%CI P‐value
Age 50‐59
 60‐69
 70+
1
0.73
0.83
0.57‐0.95
0.61‐1.12
0.02
0.2
1
1.41
0.71
0.80‐2.48
0.33‐1.52
0.2
0.4
Family history of breast cancer  No
 Yes
1
1.20 0.93‐1.56 0.16
1
1.24 0.66‐2.33 0.5
Previous breast surgery  No
 Yes
1
0.90 0.64‐1.26 0.5
1
0.90 0.41‐2.04 0.8
Use of hormone replacement therapy  No
 Yes
1
1.16 0.80‐1.68 0.4
1
3.04 1.22‐7.53 0.02
Initial screen  No
 Yes
1
1.19 0.88‐1.61 0.2
1
0.91 0.41‐2.04 0.8
Interval between 2 latest screens
     < 30 months 1
1.63 1.07‐2.48
‐
     > 30 months 0.02
Breast density at latest screening mammogram
     <50% 1 1
     >50% 1.25 0.99‐1.57 0.06 1.03 0.62‐1.72 0.9
Mammographic abnormality
     Density 1 1
     Microcalcifications 0.20 0.14‐0.29 0.0001 1.41 0.64‐3.13 0.4
     Density with microcalcifications 1.24 0.91‐1.69 0.2 0.39 0.11‐1.42 0.2
     Architectural distortion 1.49 0.82‐2.72 0.2 0.98 0.35‐2.73 1.0
     Breast parenchyma asymmetry 0.79 0.23‐2.66 0.7 1.43 0.52‐3.94 0.5
Tumor histology of invasive cancers1
     Ductal 1 1
     Lobular 2.00 1.44‐2.78 0.0001 1.48 0.70‐3.14 0.3
     Mixed ductal‐lobular 1.55 0.97‐2.48 0.07 0.65 0.20‐2.06 0.5
     Invasive other 0.63 0.39‐1.02 0.07 0.84 0.21‐3.32 0.8
     Unknown 1.70 0.23‐12.3 0.6 ‐2
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Discussion
 
During twelve years of biennial screening, we did not observe a decline in advanced breast 
cancers. After review of previous mammograms, it had to be concluded that the majority of 
advanced breast cancers could not have been detected at an earlier tumour stage. Multivariate 
analysis showed that a screening interval of 30 months or more significantly increased the risk 
of detecting breast cancer in an advanced stage. 
In a meta-analysis on randomized controlled mammography screening trials, Autier et al. cal-
culated an equal decrease in breast cancer mortality for each unit decrease in incidence of ad-
vanced breast cancer23. We expected to find a reduction of advanced cancers in our screened 
population over time, as a result of increasing experience of the screening radiologists, conti-
nuous quality assurance, introduction of additional film reading by technologists and the incre-
ased use of 2-view mammography at subsequent screening mammography16,24. The incidence 
rate of advanced screen-detected cancers and advanced interval cancers remained constant 
in our study and this finding is in line with a recent meta-analysis of regional and nation-wide 
screening programs, where annual per cent changes in advanced breast cancer were stable or 
even increasing back to pre-screening rates13. As expected, the incidence of advanced breast 
cancer was lower in subsequent screens due to lead-time.
The majority of advanced cancers in our biennial screening program of women aged 50-75 
years could not have been detected earlier. More than half of advanced breast cancers detec-
ted at a subsequent screen were not visible at previous screening mammography. This high 
percentage may partly be due to our definition of advanced cancer, which included small 
(<20 mm) but lymph node positive invasive cancers. Almost one-fifth of all advanced screen-
detected cancers had been discovered during the first screening round. 
A previous study showed that the introduction of sentinel node biopsy in the Southeast region 
of The Netherlands had led to stage migration, as was reflected by an increased proportion of 
patients with positive axillary lymph nodes after adjustment for tumour size and age25. In order 
to prevent bias in our findings by this stage migration, we therefore analysed our data using dif-
ferent definitions of advanced breast cancer. We found no decrease in advanced cancers over 
time, neither when advanced cancers were defined as invasive tumours exceeding 20 mm in 
size, nor when a definition of lymph node positive tumours was used for advanced cancers. 
Although introduction of the sentinel node technique has changed the diagnostic procedure for 
lymph node involvement, it is likely that determination of tumour size has remained constant 
over time and across institutions.
Almost 20% of our advanced screen-detected cancers showed a minimal sign at the previous 
screen. Earlier referral of these women may potentially decrease the proportion of advanced 
cancers. However, minimal signs were found to be present in 10% of screening mammograms, 
whereas less than 1% of these lesions turned out to be malignant21. The Dutch screening pro-
gram would no longer be cost-effective if all these women are being referred26. Moreover, the 
maximum reduction in advanced cancers will probably be less than 20% as some minimal 
signs may be early signs of already advanced tumours, and thus will compromise the gain. 
One quarter of advanced screen-detected cancers had been missed at the previous screening 
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examination and this proportion did not change significantly over time. In 2009, just after the 
end of our study, digital units replaced the two analogue screening units in the Southern Re-
gion. Moreover, independent double reading has been replaced by blinded double reading and 
all screening radiologists receive information about their individual screening performance at 
regular intervals. Full-field digital mammography has been shown to have similar or higher sen-
sitivity and higher specificity than conventional mammographic screening and may ultimately 
lead to a decrease of advanced cancers detected at screening27,28. The introduction of digital 
screening in the Netherlands has resulted in increased referral rates and increased overall 
cancer detection rates29,30. The ultimate impact of all these changes on the future incidence of 
advanced cancers at screening mammography is not yet known. 
At multivariate analysis, a prolonged screening interval was independently associated with 
advanced screen-detected breast cancer and women aged 60-69 were also at risk of being 
diagnosed with advanced cancer. Further research on the reasons for skipping one or several 
screening rounds is needed in the effort to maximize screening adherence and thus minimize 
extended intervals between two screens. Cancers characterized by suspicious microcalcifi-
cations at screening were associated with a lower risk of advanced screen-detected cancer, 
which can be explained by the fact that ductal carcinoma in-situ frequently shows microcal-
cifications as the only mammographic abnormality. This finding confirms the high sensitivity 
of mammography for the detection of calcium deposits that are typical of ductal, often in situ, 
non-dangerous	breast	cancers.	Screening	sensitivity	is	lower	in	dense	breasts	and,	in	our	study;	
high breast density was borderline significantly associated with advanced cancer detected at 
screening. Postmenopausal women taking hormone replacement therapy are at increased risk 
of breast cancer31,32 and, in our study, in women with interval cancers, hormone therapy was 
associated with an increased risk of having the cancer diagnosed at an advanced tumour stage.
Tumour histology differed significantly between advanced cancers and early cancers detected 
at screening. Invasive lobular cancer was diagnosed more frequently in the advanced cancer 
group. Compared to invasive ductal cancers, invasive lobular cancers are more difficult to 
detect at mammography as these tumours more commonly present as subtle architectural dis-
tortions or focal asymmetric densities resembling that of normal breast parenchyma, or show 
no mammographic abnormalities at all33. 
The percentage of advanced cancers among women with interval breast cancer was almost 
twice the percentage of advanced cancers among women with screen-detected cancer and 
also remained stable throughout our twelve-year screening period. Our observation that tu-
mour stages of interval cancers were worse than those of screen-detected cancers is expected 
and in line with previous reports34,35. Similar to advanced cancers detected at screening, half of 
the advanced interval cancers were mammographically occult at the latest screen and another 
quarter had been missed. Other studies also retrospectively classified 20-35% of all interval 
cancers as missed cancers36,37. Our observation of a similar proportion of advanced interval 
cancers among the total group of interval cancers diagnosed in the first and second year is in 
line with the findings reported by Porter et al37. The finding that a majority of both early stage 
and advanced interval cancers were diagnosed in the second year after the latest negative 
screen suggests that shortening of our screening interval may potentially lower the number of 
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advanced interval cancers. For screen-detected cancers however, two US studies found no 
increase in late-stage disease for women aged 50 years or older with a 2-year versus 1-year 
screening interval38,39. Moreover, annual screening will be more expensive and the concomi-
tant larger numbers of false positive referrals probably increases patient anxiety and thus may 
have a negative impact on future screening adherence. For these reasons, investigators still 
argue about the optimal screening interval40. 
In the Netherlands, the incidence of breast cancer is still increasing, with a current lifetime risk 
of 13%41. Although screening is effective in reducing breast cancer mortality, a possible future 
decrease in breast cancer mortality in screened women may rather be the result of advances 
in breast cancer treatment than the result of improved detection at screening mammography. 
Moreover, the rate of advanced cancer after implementation of screening mammography was 
comparable to pre-screening rates. Another detrimental effect of screening is the generation of 
false positive referrals, leading to increased levels of anxiety and additional diagnostic work-up 
costs42,43. Finally a potential harmful effect of screening is the phenomenon of so-called over-
diagnosis of breast cancers, i.e. diagnosis of breast cancers that if left undiscovered, would 
never become clinically evident and, thus, would never become lethal44,45. 
While non-advanced cancer rates have increased since the introduction of screening20, we did 
not observe an expected decrease in advanced breast cancer rates. This finding may partly 
be explained by differences in tumour biology between non-advanced cancers and advanced 
cancers and our results suggest that screening may not be effective in detecting highly prolife-
rative, aggressive breast cancers at an early stage. The stable rate of advanced cancers in our 
study also implies that a significant portion of breast cancers detected at screening represents 
over-diagnosis. A gradual increase in advanced breast cancer rate was observed in women 
below 50 years of age and this upward trend may reflect an underlying increase in background 
incidence of advanced disease. 
Our study has several strengths and limitations. To our knowledge, this is the first study with 
virtually complete follow-up in which we determined the percentage of unavoidable advanced 
cancers at screening and assessed risk factors for advanced cancer at an individual level. Un-
fortunately, a stratified analysis of stage III and IV tumours was not possible due to low numbers 
of these cancers in our study. Furthermore, extrapolation of our results to other screening pro-
grams may be limited as the study designs of these programs show considerable variations. For 
example, the Dutch nation-wide screening program is characterized by a much lower referral 
rate than that of other screening programs. Moreover, screening outcome parameters will be 
influenced by the screening interval used at screening programs. Many European programs, 
including the Dutch one, offer biennial screening for women aged 50-75 years. In contrast, 
women are screened every 3 years in the UK and US programs often offer annual screening2,46.
In summary, we found no decline in advanced screen-detected cancers and advanced interval 
cancers during twelve years of screening mammography and a majority of these advanced 
cancers could not be prevented at biennial screening. In order to obtain a modest reduction 
of advanced cancers detected a screening, efforts are needed to minimize extended screening 
intervals. 
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Chapter 3
Trends in the management of women 
referred at screening mammography in 
the south of the Netherlands
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Chapter 3.1
Trends in breast biopsies for abnormalities
detected at screening mammography
Published as: van Breest Smallenburg V, Nederend J, Voogd AC, Coebergh JW, van Beek M, 
Jansen FH, Louwman WJ, Duijm LE. Trends in breast biopsies for abnormalities detected at 
screening mammography: a population-based study in the Netherlands. Br J Cancer. 2013 
Jul 9;109(1):242-8. doi: 10.1038/bjc.2013.253. Epub 2013 May 21.
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Abstract
Background: Diagnostic	surgical	breast	biopsies	have	several	disadvantages;	therefore,	they	
should be used with hesitation. We determined time trends in types of breast biopsies for the 
workup of abnormalities detected at screening mammography. We also examined diagnostic 
delays.
Methods: In a Dutch breast cancer screening region 6230 women were referred for an ab-
normal screening mammogram between 1 January 1997 and 1 January 2011. During two-year 
follow-up clinical data, breast imaging-, biopsy-, surgery- and pathology- reports were collec-
ted of these women. Furthermore, breast cancers diagnosed 43 months after referral (delays) 
were examined, this included review of mammograms and pathology specimens to determine 
the cause of the delays.
Results: In 41.1% (1997–1998) and in 44.8% (2009–2010) of referred women imaging was 
sufficient for making the diagnosis (p<0.0001). Fine-needle aspiration cytology decreased 
from 12.7% (1997–1998) to 4.7% (2009–2010) (p<0.0001), percutaneous core-needle biopsies 
(CBs) increased from 8.0 to 49.1% (p<0.0001) and surgical biopsies decreased from 37.8 to 
1.4% (p<0.0001). Delays in breast cancer diagnosis decreased from 6.7 to 1.8% (p = 0.003).
Conclusion: The use of diagnostic surgical breast biopsies has decreased substantially. They 
have mostly been replaced by percutaneous CBs and this replacement did not result in an 
increase of diagnostic delays.
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Introduction
Breast cancer is worldwide the most frequently diagnosed cancer, and the leading cause of 
cancer death among females1. Also in the Netherlands, breast cancer is an important threat for 
public health. Breast cancer incidence in the Netherlands is among the highest in the world 
with the age-standardised rate being 128 out of 100000 person years (European Standardised 
Rate) and the incidence is still increasing2. Breast cancer survival has, fortunately, improved 
over the last decades3-5, and this improved survival is probably due to the introduction of 
mammography screening and improvements in breast cancer treatment5,6. In the Netherlands, 
women aged 50–75 years are invited every 2 years to undergo mammography screening and 
in case of a mammographic abnormality, women are referred to a hospital for further diag-
nostic workup. This workup may consist of additional imaging and biopsy. There are various 
breast biopsy procedures, including percutaneous fine-needle aspiration cytology (FNAC), 
percutaneous core-needle biopsy (CB) (ultrasound-guided or stereotactic vacuum-assisted) 
and invasive surgical biopsy. Surgical biopsies for diagnostic purposes should be omitted, as 
they increase unnecessary psychological distress in false-positive referrals7,8 and benign breast 
surgery complicates interpretation of subsequent mammograms due to postoperative chan-
ges9-13. Surgical biopsy should also not be used for histological confirmation of a radiologically 
suspicious or malignant lesion. Confirmation of breast cancer by percutaneous biopsy allows a 
better preoperative planning14,15 and it is associated with a lower likelihood of multiple breast 
surgeries16,17. In the current population- based study, we determined time trends in types of 
breast biopsies for abnormalities detected at screening mammography. We also determined 
the proportion of referred women who experienced a delay in breast cancer diagnosis and 
examined the causes of these delay.
Methods
Study population
We included all women who were referred after screening mammography at one of two speci-
alised screening units (one fixed unit and one mobile unit) in a breast cancer screening region 
in the south of the Netherlands between 1 January 1997 and 1 January 2011. Women partici-
pating in the Dutch screening programme are asked to give written informed consent regarding 
the use of their screening and follow-up data for evaluation purposes. All women, except for 
three, approved. The three women who did not approve were not included in our study po-
pulation. According to the Dutch Central Committee on Research involving Human subjects, 
institutional review board approval was not required for our type of study.
Screening procedure and diagnostic workup. Details of the nation-wide breast cancer 
screening programme have been described previously18,19. The Dutch nation-wide breast can-
cer screening programme offers biennial screening mammography to women aged 50–75 
years. Digitisation of the breast cancer screening programme has recently been completed and 
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in our breast screening region, transformation from analogue to digital screening took place in 
May 2009. Specialised screening mammography radiographers obtained all mammograms in 
this study, and a group consisting of 12 certified screening radiologists independently double 
read the examinations. Each of the screening radiologists evaluates at least 5000 screening 
mammograms yearly. From 2003, in addition to radiologist double reading, the radiographers 
also actively participated in the assessment of the screening mammograms20. Prior screening 
mammograms were always available for comparison in case of subsequent screening. In case 
of suspicious or malignant findings at screening mammography, the woman was referred by her 
general practitioner to a surgical oncologist at a regional hospital. A total of 16 hospitals were 
involved in the diagnostic workup of the referred women. The women underwent a physical 
examination by an oncologist, which was followed by mammographic workup of all suspect 
areas. The radiologist classified the radiological findings according to the American College 
of Radiology BI-RADS21 and decided whether additional procedures such as breast ultrasono-
graphy, MRI and/or biopsy were indicated. The choice of additional procedures depended on 
the diagnostic workup protocols and the facilities available at the specific hospital involved in 
the workup. The radiologists’ decision furthermore depended on national guidelines. In 2000, 
the first Dutch national guideline for breast cancer screening was published. This guideline 
required a target for preoperative diagnoses in women with suspected breast cancer of at least 
70%. The guideline also suggested that one should use a percutaneous method, either FNAC 
or CB, for making the preoperative diagnosis22. In 2008, a new guideline increased the target 
for preoperative diagnoses to 90%23. Radiologists always performed biopsy of non-palpable 
lesions in our study population, whereas sampling of palpable lesions was done either by sur-
geons or radiologists. During the 14-year period of our study, various breast biopsy procedures 
were used for the diagnostic workup, including FNAC, CB (ultrasound-guided or stereotactic 
vacuum-assisted) and open surgical biopsy. Between 1999 and 2007, out-patient breast clinics 
became available at the hospitals involved in this study and between 2002 and 2007 multidis-
ciplinary teams were implemented for the routine evaluation of the clinical, radiological and 
biopsy results of all referred women.
Follow-up procedure
For each referred woman, we collected data on radiology, pathology and surgical procedures 
at the hospitals where the mammographic screening abnormalities were evaluated. The follow-
up period for all screened women included the time through the next screening round (the 
screening interval was >2 years).
Delay in breast cancer diagnosis. A definite diagnosis of breast cancer 43 months after referral 
was considered as a diagnostic delay24. To determine whether a diagnostic delay could be at-
tributed to an erroneous radiologic assessment, two breast radiologists (LD, FJ) independently 
reviewed the clinical breast images of all women with a diagnostic delay. Each reviewer classi-
fied the lesions according to BI-RADS and discrepant assessments were resolved by consensus 
reading. To determine whether a delay in cancer diagnosis could be attributed to a false- ne-
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gative histopathological result, a pathologist reviewed the biopsy specimen of women with
a delay in breast cancer diagnosis who had had a prior breast biopsy with benign outcome. 
False-negative results due to erroneous pathologic assessments and due to sampling errors 
were both regarded as false-negative biopsy results. At review, both the radiologists and the 
pathologist knew that they reassessed cases with a delay in cancer diagnosis.
Statistical analysis
Statistical analyses were performed per 2-year screening periods. The primary outcome mea-
sures were the time trends of imaging only, FNAC, percutaneous CBs, surgical biopsies at 
workup and the percentage of women who experienced a delay in breast cancer diagnosis. All 
data	were	entered	into	a	computerised	spreadsheet	(Excel;	Microsoft,	Redmond,	WA,	USA).	
Statistics were performed using the SAS programme version 9.1.3 (Statistical Analysis Soft-
ware;	SAS/STAT	Software,	Cary,	NC,	USA).	A	χ²-test was used to test the differences between 
categorical variables. Mean age according to hospital was tested using the ANOVA model. A 
regression analysis was performed to calculate odds ratios and their confidence intervals for 
determination of time trends in various breast biopsy types, adjusting for age and hospital. The 
significance level was set at 5%.
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Results
Overall screening results
From 1 January 1 1997 to 1 January 2011 a total of 417 013 screening examinations had been 
performed (Figure 1). Altogether, 6230 women were referred for further diagnostic workup of 
a mammographic abnormality (referral rate, 1.5%). Breast cancer was diagnosed in 2214 refer-
red women, yielding a cancer detection rate of 5.3 per 1000 screening examinations and a 
true-positive referral rate of 35.5%. Nine women had either not been referred by their general 
practitioner or their follow-up was unknown, and 4007 (64.4%) women had a benign outcome 
(i.e., false-positive referrals).
Diagnostic workup after referral
In 2486 (40.0%) of the 6230 referred women, evaluation of the abnormality detected at 
screening mammography consisted of imaging only (additional mammographic views, breast 
ultrasonography and/or MRI). In the remaining 3731 (60.0%) women, imaging was not suf-
ficient for the establishment of a final diagnosis. Many women underwent a combination of 
biopsy types because of inconclusive results from FNAC and/or percutaneous CB (Table 1). A 
final diagnosis was obtained by FNAC in 704 (11.3%) referred women, by CB in 2399 (38.6%) 
women and by surgical biopsy in 628 (10.1%) women (Table 1). The use of FNAC sharply 
decreased	in	the	final	years	of	the	study	period;	in	1997–1998	12.7%	(68	out	of	535)	of	the	
Figure 1. Mammography screening outcome January 1997- January 2011
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diagnoses was made by FNAC, compared with 4.7% (84 out of 1777) in 2009–2010 (p < 
0.0001) (Figure 2). The percentage of women with a diagnosis obtained by CB increased from 
8.0% (202 out of 535) in 1997–1998 to 49.1% (24 out of 1777) in 2009–2010 (p < 0.0001). Si-
multaneously, the percentage with a diagnosis made by surgical biopsy decreased from 37.8% 
(70 out of 535) in 1997– 1998 to 1.4% (20 out of 1777) in 2009–2010 (p < 0.0001) (Table 1, 
Figure 2). Also after adjustment for age and hospital, FNAC significantly decreased, diagnoses 
made by percutaneous CBs significantly increased and surgical biopsies significantly decre-
ased (Table 2). The mean age of referred women was 60 and this was comparable between 
the 16 hospitals (p = 0.3). Main reasons for performing a surgical biopsy in women referred 
in 2009–2010 were possible (pre)cancerous lesions or inconclusive results at FNAC or CB (19 
out of 24, 79.2%).
’97
-’9
8
Figure 2. Trends in biopsy procedures after referral, January 1997-January 2011
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Diagnostic delays
In 96 of the 2214 women with breast cancer (4.3%), the diagnosis was made >3 months after 
referral. This delay in breast cancer diagnosis was 4–6 months in 26 (27.1%) women, 7–12 
months in 36 women (37.5%), 13–24 months in 21 women (21.9%) and >24 months (24–28 
months) in 13 women (13.8%). Most women presented with a delay within 12 months because 
a follow-up had been recommended at the assessment after referral from screening. The causes 
of the delays, the tumour stage distribution and axillary lymph node status are presented in 
Table 3. A total of 27 women with a delay (28.1%) had an advanced tumour stage at the time of 
diagnosis (advanced cancers were defined as invasive cancers with a tumour size >20 mm (T2) 
and/ or the presence of metastasis in axillary lymph nodes). The total amount of women with 
a diagnostic delay decreased, from 6.7% (15 out of 224) in 1997–1998 to 1.8% (8 out of 344) 
in 2009–2010 (p = 0.003). The majority of the diagnostic delays resulted from an erroneous BI-
RADS assessment (57.3%, 55 out of 96) or false- negative biopsy result (32.3%, 31 out of 96). 
Ten delays resulted from other reasons, including errors made by surgeons and patient-related 
delays. The majority of the delays (68.8%) that resulted from false-negative biopsies consisted 
of CB. Details of the biopsy procedures are also presented in Table 3. The pathologist reported 
that all false-negative biopsy results were due to sampling errors and not the result of erroneous 
pathologic assessments.
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Discussion
Surgical biopsies for diagnostic purposes have several disadvantages. We have reported in ear-
lier studies that benign breast surgery, including surgical biopsy, can result in a lower sensitivity 
for breast cancer detection at subsequent screening mammography12,13. Furthermore, invasive 
assessments increase the unnecessary psychological distress of false-positive referrals7,8. In ma-
lignant cases, it is also desirable to avoid diagnostic surgical biopsies as a preoperative confirma-
tion of breast cancer gives the patient and surgeon the possibility to discuss treatment options. 
A preoperative diagnosis also allows a better surgery planning14,15 and it is associated with a 
lower likelihood of multiple breast surgeries16,17. During the 14-year period of our study, the 
use of FNAC fluctuated and then decreased in the most recent years. Fine-needle aspiration 
cytology is important for the assessment of cystic lesions and is, therefore, still useful in the 
workup of breast abnormalities23. However, for solid lesions, FNAC has a higher insufficient 
sample rate and a lower diagnostic accuracy than other biopsy methods. Additional CB is fre-
quently required following inconclusive FNAC results25-27, thus extending the period of anxiety 
and uncertainty before the final diagnosis has been made. For these reasons, FNAC should not 
be considered the diagnostic procedure of first choice for solid breast lesions. We attribute the 
strong decrease of FNAC in 2009 and 2010 to the implementation of digital screening in 2009. 
Digital screening especially increased the referral rate of women with suspicious microcalcifi-
cations28, which in turn resulted in an increase in the use of stereotactic-guided percutaneous 
vacuum-assisted CBs. The diagnostic workup of suspicious breast lesions by percutaneous CBs 
showed a substantial increase during the 14-year period of our study, whereas surgical biop-
sies became rare. Percutaneous CBs are equally accurate to surgical biopsies and have several 
advantages over surgical biopsy, including lower costs, a more rapid way of providing a diag-
nosis and lower complication rates29-32. As a result, percutaneous CB is currently a widely used 
technique for evaluating breast abnormalities and CB has worldwide been accepted as a reli-
able alternative to surgical biopsy33-35. Despite the high diagnostic accuracy of CBs, equivocal 
biopsy results or discordance between radiological and histological findings is present in B10% 
of core-needle biopsy procedures, necessitating repeated biopsy36. Obviously, it is desirable 
to obtain a diagnosis in one biopsy session. More than one tissue sample should be taken and 
it is also advisable to assess the characteristics of these samples at biopsy. If the core sample 
is stiff, predominantly white, and sinks as soon as it is put in formalin, it is likely a diagnostic 
biopsy36. Only in a limited number of cases surgical biopsies still have an additional value.
A surgical biopsy is, for example, justified in case of a non- representative CB and in cases sho-
wing high-risk lesions or premalignant findings at CB23,37,38. Furthermore, a surgical biopsy can 
be the biopsy-method of choice when patient characteristics (for example, extreme obesity or 
dementia) impede percutaneous biopsy. The replacement of surgical biopsies by percutaneous 
CBs was probably mainly the result of the introduction and revision of Dutch breast cancer gui-
delines. As mentioned before, the 2000 guideline required a target for a preoperative diagnosis 
in women with suspected breast cancer of at least 70% by using either FNAC or CB22, and the 
2008 guideline increased this target to 90%23.
C
h
a
p
te
r 3
.1
50 Breast cancer detected and missed by screen-film and digital screening mammography
Besides the trends in biopsies, we also determined the frequency and causes of diagnostic 
delays in referred women, because the replacement of surgical biopsies by CBs may hypotheti-
cally have resulted in more false-negative biopsies and a higher proportion of women that ex-
perienced a delay in breast cancer diagnosis. The amount of delays in breast cancer diagnosis 
in our study population, however, decreased from 6.7 to 1.8% (p = 0.003). The introduction of 
breast-care units and multidisciplinary teams in the Dutch hospitals probably mainly explains 
this decline in delays. Also the introduction of breast cancer guidelines and the growing im-
portance of quality indicators in Dutch breast cancer care have probably contributed to the 
decline in delays. The importance of multidisciplinary teams to improve the assessment of 
breast lesions has been described in several studies and the use of these teams is also recom-
mended by breast cancer guidelines23,39,40. The majority of diagnostic delays in our study resul-
ted from erroneous BI-RADS assessments (57.3%) and false-negative biopsy results (32.3%). 
Diagnostic delays due to erroneous mammographic assessments are not uncommon, lesions 
can be missed, misinterpreted or overlooked41-43. Also false-negative biopsy results are known 
as probable causes of diagnostic delays36. The majority of false-negative biopsy results in our 
study	consisted	of	CBs	 (68.8%);	 all	were	due	 to	 sampling	 errors.	Researchers	describe	 that	
≈4% of CB results, both ultrasound- and stereotactic guided, are false negative23. Therefore, 
attention for radiologic–histologic correlation is very important36,44,45 and sometimes a repeated 
biopsy is needed. False-negative results and delays in diagnosis from both erroneous BI-RADS 
assessments and false-negative biopsies can be reduced with optimisation of multidisciplinary 
approach and clear post-biopsy protocols. An additional time trend finding of our study was 
the increase of false-positive referrals from 57.9 to 75.5%. The most important explanation for 
this finding is probably the transition from screen-film mammography to full-field digital mam-
mography screening in 2009, which resulted in increased referral rates, with a concomitant 
increase in both cancer detection rate and false-positive referral28.
There are certain strengths and limitations of our study. First, both the radiologists and the 
pathologist knew that they reassessed cases with a delay in cancer diagnosis. The pathologist 
did not find any erroneous pathologic assessments, however, radiologist review bias may have 
resulted in a higher amount of cases judged as ‘missed cancers’ due to erroneous BI-RADS as-
sessments. Second, extrapolation of our results to other screening programmes may be limited 
by the fact that the design of the Dutch breast cancer screening programme and workup stra-
tegies differs from other countries. The Dutch referral rate of 1.5–2.5% is much lower than the 
3–6% referral rates observed in other European countries and the referral rate of 10% or more 
in the United States46,47. Furthermore, the incidence of open surgical biopsy is much higher in 
the United States than in the United Kingdom and the Netherlands. Recent data suggest that 
in the United States, 30–40% of diagnostic breast biopsies still consist of surgical biopsies48,49. 
One of the strengths of our study is that with the information on biopsy time trends we are 
able to verify whether national guidelines are followed at our screening region. Furthermore, 
women who attend the screening programme can now be optimally informed on the steps that 
will be taken following referral.
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We conclude that women in a southern screening region of the Netherlands are nowadays ra-
rely confronted with a diagnostic surgical biopsy for the workup of a screening mammography 
abnormality. Diagnostic surgical biopsies have mostly been replaced by percutaneous CBs. 
The replacement of surgical biopsies by percutaneous CBs did not increase the amount of 
delays in breast cancer diagnosis.
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Table 1. Diagnostic procedures after referral for a screening mammography abnormality
97-98 99-00 01-02 03-04 05-06 07-08 09-10 Totaal p-value
Total screens 48,721    53,718 53,489 61,251 66,300 67,530 66,004 417,013
Referrals, No (%) 537 (1.1) 499 (0.9) 553 (1.0) 985 (1.6) 874 (1.3) 1,003 (1.5) 1,779 (2.7) 6,230 (1.5)
False positive referrals (FP), No (%)   311 (57.9)   223 (44.7) 299 (54.1) 632 (64.2) 550 (62.9) 648 (64.6) 1,344 (75.5) 4,007 (64.3)
True positive referrals (TP), No (%)   224 (41.7)   276 (55.3) 254 (45.9) 350 (35.5) 323 (37.0) 354 (35.3) 433 (24.3) 2,214 (35.5)
Referrals unknown outcome, No (%)     2 (0.4)     0 (0.0) 0 (0.0) 3 (0.3) 1 (0.1) 1 (0.1) 2 (0.1) 9 (0.1)
total FP+TP 535 499 553 982 873 1,002 1,777 6,221
imaging alone, No (%)  220 (41.1)   149 (29.9) 198 (35.8) 383 (39.0) 323 (37.0) 417 (41.6) 796 (44.8) 2,486 (40.0) <0.0001
FNAC   68 (12.7)     76 (15.2) 85 (15.4) 135 (13.7) 138 (15.8) 118 (11.8) 84 (4.7) 704 (11.3)
FNAC+CB   7 (1.3)   22 (4.4) 29 (5.2) 36 (3.7) 48 (5.5) 28 (2.8) 32 (1.8) 202 (3.2)
CB  36 (6.7)    86 (17.2) 146 (26.4) 349 (35.5) 330 (37.8) 410 (40.9) 840 (47.3) 2,197 (35.3)
CB+ surgical biopsy  43 (8.0)   43 (8.6) 43 (7.8) 53 (5.4) 24 (2.7) 24 (2.4) 22 (1.2) 252 (4.1)
Surgical biopsy  159 (29.7)   123 (24.6) 51 (9.2) 26 (2.6) 10 (1.1) 5 (0.5) 2 (0.1) 376 (6.0)
Unknown   2 (0.4)     0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 4 (0.1)
Total FNAC, No (%)    68 (12.7)      76 (15.2)   85 (15.4) 135 (13.7) 138 (15.8) 118 (11.8) 84 (4.7)    704 (11.3) <0.0001
Total CB, No (%)  43 (8.0)    108 (21.6) 175 (31.6) 385 (39.2) 378 (43.3) 438 (43.7) 872 (49.1) 2,399 (38.6) <0.0001
Total surgical biopsy, No (%)  202 (37.8)    166 (33.3)   94 (17.0) 79 (8.0) 34 (3.9) 29 (2.9) 24 (1.4)    628 (10.1) <0.0001
surg biopsy/1,000 screens 4.15    3.09 1.76 1.29 0.51 0.43 0.36 1.51 <0.0001
Table 2. Trends in biopsies adjusted for age and hospital
Odds 95% CI p-value
FNAC 1997‐1998 1
2009‐2010 0.40 0.28‐0.57 <0.0001
CB 1997‐1998 1
2009‐2010 9.95 7.15‐13.85 <0.0001
SB 1997‐1998 1
2009‐2010 0.03 0.02‐0.04 <0.0001
FNAC= fine-needle aspiration cytology / CB=core-needle biopsy / SB=sugical biopsy
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97-98 99-00 01-02 03-04 05-06 07-08 09-10 Totaal p-value
Total screens 48,721    53,718 53,489 61,251 66,300 67,530 66,004 417,013
Referrals, No (%) 537 (1.1) 499 (0.9) 553 (1.0) 985 (1.6) 874 (1.3) 1,003 (1.5) 1,779 (2.7) 6,230 (1.5)
False positive referrals (FP), No (%)   311 (57.9)   223 (44.7) 299 (54.1) 632 (64.2) 550 (62.9) 648 (64.6) 1,344 (75.5) 4,007 (64.3)
True positive referrals (TP), No (%)   224 (41.7)   276 (55.3) 254 (45.9) 350 (35.5) 323 (37.0) 354 (35.3) 433 (24.3) 2,214 (35.5)
Referrals unknown outcome, No (%)     2 (0.4)     0 (0.0) 0 (0.0) 3 (0.3) 1 (0.1) 1 (0.1) 2 (0.1) 9 (0.1)
total FP+TP 535 499 553 982 873 1,002 1,777 6,221
imaging alone, No (%)  220 (41.1)   149 (29.9) 198 (35.8) 383 (39.0) 323 (37.0) 417 (41.6) 796 (44.8) 2,486 (40.0) <0.0001
FNAC   68 (12.7)     76 (15.2) 85 (15.4) 135 (13.7) 138 (15.8) 118 (11.8) 84 (4.7) 704 (11.3)
FNAC+CB   7 (1.3)   22 (4.4) 29 (5.2) 36 (3.7) 48 (5.5) 28 (2.8) 32 (1.8) 202 (3.2)
CB  36 (6.7)    86 (17.2) 146 (26.4) 349 (35.5) 330 (37.8) 410 (40.9) 840 (47.3) 2,197 (35.3)
CB+ surgical biopsy  43 (8.0)   43 (8.6) 43 (7.8) 53 (5.4) 24 (2.7) 24 (2.4) 22 (1.2) 252 (4.1)
Surgical biopsy  159 (29.7)   123 (24.6) 51 (9.2) 26 (2.6) 10 (1.1) 5 (0.5) 2 (0.1) 376 (6.0)
Unknown   2 (0.4)     0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 4 (0.1)
Total FNAC, No (%)    68 (12.7)      76 (15.2)   85 (15.4) 135 (13.7) 138 (15.8) 118 (11.8) 84 (4.7)    704 (11.3) <0.0001
Total CB, No (%)  43 (8.0)    108 (21.6) 175 (31.6) 385 (39.2) 378 (43.3) 438 (43.7) 872 (49.1) 2,399 (38.6) <0.0001
Total surgical biopsy, No (%)  202 (37.8)    166 (33.3)   94 (17.0) 79 (8.0) 34 (3.9) 29 (2.9) 24 (1.4)    628 (10.1) <0.0001
surg biopsy/1,000 screens 4.15    3.09 1.76 1.29 0.51 0.43 0.36 1.51 <0.0001
Table 1. Diagnostic procedures after referral for a screening mammography abnormality (continued)
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Table 3. Details of delays in breast cancer diagnosis after referral
 97-98 99-00 01-02 03-04 05-06 07-08 09-10 Total
Total true positive referrals*. No (%) 224 276 254 350 323 354 433 2,214
Delay in cancer diagnosis, No (%) 15 (6.7) 17 (6.2) 17 (6.7) 17 (4.9) 13 (4.0) 9 (2.5) 8 (1.8) 96 (4.3)
Length of diagnostic delay
4-6 months 5 (33.3) 5 (29.4) 4 (23.5) 4 (23.5) 5 (38.5) 2 (22.2) 1 (12.5) 26 (27.1)
7-12 months 7 (46.7) 6 (35.3) 8 (47.1) 6 (35.3) 3 (23.1) 3 (33.3) 3 (37.5) 36 (37.5)
13-24 months 3 (20.0) 3 (17.6) 0 (0.0) 7 (41.2) 4 (30.8) 2 (22.2) 2 (25.0) 21 (21.9)
>24 months 0 (0.0) 3 (17.6) 5 (29.4) 0 (0.0) 1 (7.7) 2 (22.2) 2 (25.0) 13 (13.5)
Causes of diagnostic delay
Incorrect BI‐RADS 12 (80.0) 11 (64.7) 10 (58.8) 10 (58.8) 5 (38.5) 2 (22.2) 5 (62.5) 55 (57.3)
False negative biopsy 3 (20.0) 4 (23.5) 5 (29.4) 5 (29.4) 6 (46.2) 6 (66.7) 2 (25.0) 31 (32.3)
Other reason 0 (0.0) 2 (11.8) 2 (11.8) 2 (11.8) 2 (15.4) 1 (11.1) 1 (12.5) 10 (10.4)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
False negative biopsy according to type of biopsy procedure
FNAC 2 (66.7) 1 (20.0) 0 (0.0) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (12.5)
CB 1 (33.3) 0 (0.0) 1 (20.0) 3 (60.0) 6 (10.,0) 3 (50.0) 1 (50.0) 15 (46.9)
FNAC and CB 0 (0.0) 2 (40.0) 0 (0.0) 1 (20.0) 0 (0.0) 3 (50.0) 1 (50.0) 7 (21.9)
Surgical biopsy 0 (0.0) 2 (40.0) 4 (80.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (18.8)
Tumor size of cancers with diagnostic delay
DCIS 4 (26.7) 5 (29.4) 2 (11.8) 6 (35.3) 1 (7.7) 1 (11.1) 2 (25.0) 21 (21.9)
T1a‐b 4 (26.7) 5 (29.4) 7 (41.2) 2 (11.8) 5 (38.5) 2 (22.2) 2 (25.0) 27 (28.1)
T1c 6 (40.0) 4 (23.5) 6 (35.3) 9 (52.9) 4 (30.8) 3 (33.3) 1 (12.5) 33 (34.4)
T2+ 1 (6.7) 3 (17.6) 2 (11.8) 0 (0.0) 3 (23.1) 2 (22.2) 3 (37.5) 14 (14.6)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (11.1) 0 (0.0) 1 (1.0)
Axillary lymph node status
N+ 3 (20.0) 1 (5.9) 4 (23.5) 6 (35.3) 2 (15.4) 3 (33.3) 0 (0.0) 19 (19.8)
N‐ 12 (80.0) 14 (82.4) 13 (76.5) 9 (52.9) 10 (76.9) 6 (66.7) 8 (100.0) 72 (75.0)
Nx 0 (0.0) 2 (11.8) 0 (0.0) 2 (11.8) 1 (7.7) 0 (0.0) 0 (0.0) 5 (5.2)
*women diagnosed with breast cancer after referral
FNAC = fine needle aspiration cytology; CB = core biopsy; DCIS = ductal carcinoma in-situ
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 97-98 99-00 01-02 03-04 05-06 07-08 09-10 Total
Total true positive referrals*. No (%) 224 276 254 350 323 354 433 2,214
Delay in cancer diagnosis, No (%) 15 (6.7) 17 (6.2) 17 (6.7) 17 (4.9) 13 (4.0) 9 (2.5) 8 (1.8) 96 (4.3)
Length of diagnostic delay
4-6 months 5 (33.3) 5 (29.4) 4 (23.5) 4 (23.5) 5 (38.5) 2 (22.2) 1 (12.5) 26 (27.1)
7-12 months 7 (46.7) 6 (35.3) 8 (47.1) 6 (35.3) 3 (23.1) 3 (33.3) 3 (37.5) 36 (37.5)
13-24 months 3 (20.0) 3 (17.6) 0 (0.0) 7 (41.2) 4 (30.8) 2 (22.2) 2 (25.0) 21 (21.9)
>24 months 0 (0.0) 3 (17.6) 5 (29.4) 0 (0.0) 1 (7.7) 2 (22.2) 2 (25.0) 13 (13.5)
Causes of diagnostic delay
Incorrect BI‐RADS 12 (80.0) 11 (64.7) 10 (58.8) 10 (58.8) 5 (38.5) 2 (22.2) 5 (62.5) 55 (57.3)
False negative biopsy 3 (20.0) 4 (23.5) 5 (29.4) 5 (29.4) 6 (46.2) 6 (66.7) 2 (25.0) 31 (32.3)
Other reason 0 (0.0) 2 (11.8) 2 (11.8) 2 (11.8) 2 (15.4) 1 (11.1) 1 (12.5) 10 (10.4)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
False negative biopsy according to type of biopsy procedure
FNAC 2 (66.7) 1 (20.0) 0 (0.0) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (12.5)
CB 1 (33.3) 0 (0.0) 1 (20.0) 3 (60.0) 6 (10.,0) 3 (50.0) 1 (50.0) 15 (46.9)
FNAC and CB 0 (0.0) 2 (40.0) 0 (0.0) 1 (20.0) 0 (0.0) 3 (50.0) 1 (50.0) 7 (21.9)
Surgical biopsy 0 (0.0) 2 (40.0) 4 (80.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (18.8)
Tumor size of cancers with diagnostic delay
DCIS 4 (26.7) 5 (29.4) 2 (11.8) 6 (35.3) 1 (7.7) 1 (11.1) 2 (25.0) 21 (21.9)
T1a‐b 4 (26.7) 5 (29.4) 7 (41.2) 2 (11.8) 5 (38.5) 2 (22.2) 2 (25.0) 27 (28.1)
T1c 6 (40.0) 4 (23.5) 6 (35.3) 9 (52.9) 4 (30.8) 3 (33.3) 1 (12.5) 33 (34.4)
T2+ 1 (6.7) 3 (17.6) 2 (11.8) 0 (0.0) 3 (23.1) 2 (22.2) 3 (37.5) 14 (14.6)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (11.1) 0 (0.0) 1 (1.0)
Axillary lymph node status
N+ 3 (20.0) 1 (5.9) 4 (23.5) 6 (35.3) 2 (15.4) 3 (33.3) 0 (0.0) 19 (19.8)
N‐ 12 (80.0) 14 (82.4) 13 (76.5) 9 (52.9) 10 (76.9) 6 (66.7) 8 (100.0) 72 (75.0)
Nx 0 (0.0) 2 (11.8) 0 (0.0) 2 (11.8) 1 (7.7) 0 (0.0) 0 (0.0) 5 (5.2)
*women diagnosed with breast cancer after referral
FNAC = fine needle aspiration cytology; CB = core biopsy; DCIS = ductal carcinoma in-situ
Table 3. Details of delays in breast cancer diagnosis after referral (continued)
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Abstract
Background: This population-based study aimed to evaluate trends in surgical approach for 
screen-detected cancer versus interval breast cancer, and to determine the factors associated 
with positive resection margins.
Methods: Screening mammograms of women aged 50–75 years, who underwent biennial 
screening in a Dutch breast-screening region between 1997 and 2011, were included. Patient 
and tumour characteristics were compared between women who underwent mastectomy or 
breast-conserving surgery (BCS) for screen-detected or interval cancer, and women with a 
negative or positive resection margin after BCS.
Results: Some 417,013 consecutive screening mammograms were included. A total of 2,224 
screen-detected and 825 interval cancers were diagnosed. The BCS rate remained stable 
(mean	6.1	per	1000	screened	women;	p	=	0.099),	whereas	mastectomy	rates	increased	signi-
ficantly during the study from 0.9 (1997–1998) to 1.9 (2009–2010) per 1000 screened women 
(p < 0.001). The proportion of positive resection margins for invasive cancer was 19.6 and 
7.6 per cent in 1997–1998 and 2009–2010 respectively (p < 0.001), with significant variation 
between hospitals. Dense breasts, preoperative magnetic resonance imaging, microcalcifica-
tions, architectural distortion, tumour size over 20 mm, axillary lymph node metastasis and 
treating hospital were independent risk factors for mastectomy. Interval cancer, image-guided 
tumour localization, microcalcifications, breast parenchyma asymmetry, tumour size greater 
than 20 mm, lobular tumour histology, low tumour grade, extensive invasive component and 
treating hospital were independent risk factors for positive resection margins. 
Conclusion: Mastectomy rates doubled during a 14-year period of screening mammography 
and the proportion of positive resection margins decreased, with variation among hospitals. 
The latter observation stresses the importance of quality control programmes for hospitals tre-
ating women with breast cancer.
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Introduction
Many countries have introduced breast cancer screening programmes with the aim of de-
tecting malignancies at an earlier, non-palpable stage, and thus reducing breast cancer-related 
morbidity and mortality. In the Netherlands, a nationwide breast cancer screening programme 
was implemented gradually from 1989 until 1997, and from 1998 all women aged 50–75 years 
have been invited to attend biennial screening mammography. A preoperative diagnosis of 
breast cancer is currently obtained in more than 90 per cent of patients with breast cancer1. 
Ultrasound-guided or stereotactic core biopsy has become the reference standard for the pre-
operative confirmation of breast cancer, and surgical biopsy for diagnostic purposes is beco-
ming increasingly rare. Cancers detected in the screening programme are usually non-palpable 
and smaller than breast cancers discovered clinically. Exact localization of these non-palpable 
cancers is very important for obtaining clear resection margins. Techniques for preoperative 
tumour localization include ultrasonography, stereotactic guidewire localization, radioactive 
seed localization or intratumoral injection of technetium-99m2,3.
Surgery remains the primary treatment for breast cancer. Since the early 1980s breast-conser-
ving surgery (BCS), rather than mastectomy, has gradually become the standard of treatment 
for early breast cancer. A re-excision is required if the surgical resection margins are positive, 
as this has been shown to be an important risk factor for local recurrence in patients under-
going BCS4–6. The re-excision rates in international hospital-based studies range from 20 to 50 
per cent7–9. Other independent predictors of local recurrence following BCS are young age 
(less than 40 years), larger tumour size, dense breast tissue, and not receiving chemotherapy 
or hormone therapy10,11. 
Although the implementation of guidelines and the results of randomized clinical trials12 have 
resulted in decreased mastectomy rates since the 1990s, several studies8,13,14 have reported 
increasing mastectomy rates over the past few years. These have partly contributed the rising 
mastectomy rate to increased use of magnetic resonance imaging (MRI) and changing prefe-
rences among both surgeons and patients. In another study15, however, which used population-
based data from the Surveillance Epidemiology and End-Results database, this increase in 
mastectomy rates was questioned. 
The present study addressed these issues and the factors associated with positive resection mar-
gins in patients with screen-detected or interval breast cancer, using data from the screening 
mammography programme in the Southeast Netherlands.
Methods
The study included all screening mammography examinations of women who underwent 
biennial screening mammography at one of three specialized screening units in a southern 
breast cancer screening region of the Netherlands (Bevolkings Onderzoek Borstkanker Zuid) 
between 1 January 1997 and 1 January 2011. Before a screening examination women were 
asked whether the screening and follow-up data could be used for evaluation purposes. Three 
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women did not provide written informed consent and were not included in the study. The 
Central Committee on Research Involving Human Subjects in The Hague, The Netherlands, 
waived ethical approval for this study.
Screening procedure and referral
Details of the Dutch nationwide breast cancer screening programme, which offers biennial 
screening mammography for women aged 50–75 years, has been described elsewhere16,17. 
In brief, information on date, type and reason for previous breast surgery, family history of 
breast cancer and use of hormone replacement therapy were obtained from a questionnaire 
filled in by the screened women and from surgical correspondence. Specialized screening 
radiographers obtained all mammograms and these were double-read by a group of 15 cer-
tified screening radiologists. From 2003 onwards, the radiographers participated actively in 
the assessment of screening mammograms and also read the examinations, in addition to the 
two radiologists18. Each screening radiologist evaluated at least 5,000 screening mammograms 
yearly, and previous screening mammograms were always available for comparison at the 
time of subsequent screening. The breast density of both interval and screen-detected cancers 
was assessed by two screening radiologists in a blinded fashion and classified according to 
the American College of Radiology Breast Imaging – Reporting and Data System (BI-RADS) 
criteria19. Discordant readings were solved by consensus. If screening mammography showed a 
suspicious or malignant lesion, the woman was referred to a surgical oncologist or breast clinic 
    
Figure 1. Screening mammography results and breast cancer treatments
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for further analysis of the mammographic abnormality. Depending on the evaluation protocols 
and facilities available, further evaluation consisted of additional mammography, breast ultra-
sound examination, magnetic resonance mammography, percutaneous fine-needle aspiration 
or core biopsy (usually image-guided), or an open surgical biopsy.
Follow-up procedure
During a 2-year follow-up, data were collected on diagnostic and surgical procedures, histopa-
thology and tumour node metastasis (TNM) classification20 of all screen-detected and interval 
cancers. Interval cancers are breast cancers diagnosed in women after a negative screening 
examination (defined as no recommendation for referral) and before any subsequent screen is 
performed. Procedures for the detection of interval cancers have been described previously16. 
A total of 16 hospitals were involved in the diagnostic evaluation, of which four centrally lo-
cated hospitals, categorized as A, B, C and D, treated 88.6 per cent of the women diagnosed 
with breast cancer (2,702 of 3,049).  The other 12 hospitals (pooled under category E) treated 
11.4 per cent of these women. Characteristics of the hospitals in terms of diagnostic breast 
imaging facilities and multidisciplinary approach to newly diagnosed breast cancers have been 
described previously21. 
Tumour characteristics and surgical resection margins
Breast cancers were divided into ductal carcinoma in situ (DCIS) and invasive ductal as well as 
lobular cancers. Lobular carcinoma in situ was considered to be a benign lesion. The presence 
of more than eight ductilobular units with carcinoma in situ beyond the invasive tumour was 
considered as extensive ductal carcinoma in situ. The surgical margin status was recorded for 
all BCS procedures. A resection specimen was considered to have positive margins if more 
than 4 mm of invasive cancer or DCIS was present in the inked resection margin in more than 
two microscopic views at low power (magnification ×10). Specimens with negative resection 
margins or with focal positivity (4 mm or less) in the margins were considered to have negative 
resection margins22,23. 
Statistical analysis
Statistical analyses were performed for 2-year screening intervals. Unpaired t tests were used 
to compare groups with respect to continuous variables, and χ² tests for analysis of categorical 
variables. Logistic regression analyses were carried out to identify factors that significantly in-
fluence the risk of mastectomy and the risk of positive resection margins. Patients with missing 
information on tumour size, lymph node status or tumour histology were excluded from the 
logistic regression analyses, as were the 347 patients treated in hospital E. Patients with missing 
data with respect to any of the other co-variables of the model were included as a separate 
category. The significance level was set at 5 per cent for all analyses. Statistical analyses were 
performed	using	SAS®	version	9.1.3	(SAS	Institute,	Cary,	North	Carolina,	USA).
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Results
Overall screening results
A series of 417,013 consecutive screening mammograms was included. The biennial number of 
screening examinations varied between 48,721 (1997–1998) and 67,530 (2007–2008), and the 
referral	rate	between	0.9	per	cent	(1999–2000)	and	2.7	per	cent	(2009–2010);	the	mean	refer-
ral rate was 1.5 per cent. Breast cancer was diagnosed in 2,224 of 6,230 referred women (inclu-
ding 394 cases of DCIS), resulting in an overall cancer detection rate of 5.3 per 1000 screens, 
and a positive predictive value for  referral of 35.7 per cent. In addition, 825 interval cancers 
(including 35 cases of DCIS) were diagnosed. The mean sensitivity of breast cancer screening 
was 72.9 per cent (2,224 of 3,049) (Table 1). The use of preoperative MRI varied among hos-
pitals:	hospital	A,	12.8	per	cent	(59	of	462);	hospital	B,	13.0	per	cent	(114	of	875);	hospital	C,	
10.3	per	cent	(61	of	590);	hospital	D,	7.1	per	cent	(55	of	775);	and	the	12	hospitals	in	category	
E, 15.9 per cent (55 of 347) (p < 0.001). The use of preoperative MRI gradually increased from 
0.3 per cent (1 of 297) in 1997–1998, to 20.9 per cent (131 of 628) in 2009–2010 (p < 0.001).
Surgical treatment of screen detected cancers and interval cancers
Of the 2,620 women diagnosed with invasive cancer, 443 were treated by mastectomy and 
2,143	underwent	BCS;	34	women	were	not	treated	surgically.	BCS	was	performed	for	a	signifi-
cantly larger proportion of screen-detected cancers than interval cancers: 1,569 (85.7 per cent) 
of 1,830 versus 574 (72.7 per cent) of 790 (p < 0.001). Comparable proportions of women in 
both groups underwent BCS for in situ cancer: 353 (89.6 per cent) of 394 versus 29 (83 per 
cent) of 35 (p = 0.221). The overall mastectomy rate gradually increased from 0.9 per 1000 
screened women in 1997–1998, to 1.9 per 1000 screened women in 2009–2010 (p < 0.001), 
with a mean rate of 1.2 per cent. During the study interval, the BCS rate varied between 5.2 
per cent (1998–1999) and 7.4 per cent (2009–2010) (p = 0.099), with a mean of 6.1 per cent.
 
The proportion of mastectomies for screen-detected DCIS gradually increased from 0 per cent 
(1998–1999) to 16.4 per cent (2009–2010) (P = 0.002), with a concomitant decrease in the pro-
portion	of	women	treated	by	BCS	(100	per	cent	in	1998–1999	to	81.8	per	cent	in	2009–2010;	
p = 0.002). The proportion of mastectomies for screen-detected invasive cancer increased 
from 12.3 per cent (1997–1998) to 20.2 per cent (2007–2008) and then decreased to 14.9 per 
cent for women screened in 2009–2010 (p = 0.001). The proportion of mastectomies for in-
terval	invasive	cancer	was	highest	among	women	screened	in	2009–2010;	it	ranged	from	17.9	
per cent (2001–2002) to 34.0 per cent (2009–2010) (p = 0.01), with a mean of 24.9 per cent 
(Table 1). 
C
h
a
p
te
r 
3
.2
67Trends in surgical treatment
Risk factors for mastectomy
Analysis of the characteristics of women treated surgically for invasive breast cancer, either 
by BCS or mastectomy, is shown in Table 2. After adjusting for all other variables in a logistic 
regression analysis, the risk of mastectomy was higher for women with a tumour larger than 20 
mm, axillary lymph node metastases, dense breasts, and a mammogram showing microcalcifi-
cations or architectural distortion. The risk was also higher if preoperative MRI was performed. 
Treatment in hospital B was associated with a lower relative risk of mastectomy.
Resection margins
The proportion of positive resection margins following BCS was 12.7 per cent (272 of 2,138) 
for patients with invasive cancer and 19.1 per cent (73 of 382) for those with DCIS (p = 0.001). 
Among women with invasive cancer and positive resection margins, 32 (11.8 per cent) of 272 
underwent no further treatment, 109 (40.1 per cent) a second lumpectomy and 131 (48.2 per 
cent) a secondary mastectomy. For women with DCIS and positive resection margins, nine (12 
per cent) of 73 had no further treatment, 12 (16 per cent) a second lumpectomy and 52 (71 per 
cent) a secondary mastectomy (p < 0.001).
The characteristics of women treated surgically for invasive breast cancer are shown with 
respect to resection margins in Table 3. The proportion of positive resection margins for pa-
tients with invasive cancer was 19.6 per cent in 1997–1998 and 7.6 per cent in 2009–2010 
(p < 0.001). 
For invasive cancer, the factors significantly related to positive resection margins were: interval 
cancer, tumour size  larger than 20 mm, axillary lymph node metastasis, lobular histology and a 
diagnosis in the earlier years of the study. There was a significant difference between hospitals, 
with positive resection margin rates varying between 5.8 and 20.3 per cent (p < 0.001).
After adjustment for all other variables in a logistic regression analysis, interval cancer, ima-
ging-guided tumour localization, microcalcifications, breast parenchyma asymmetry, tumour 
size larger than 20 mm, lobular histology, presence of an extensive in situ component, and hos-
pitals C and D were independent risk factors for incomplete tumour resection. Furthermore, 
grade III tumours were associated with a lower relative risk of tumour-positive margins, with an 
odds ratio of 0.44 (95 per cent confidence interval (CI) 0.25 to 0.77). Use of preoperative MRI 
was also associated with a lower risk of positive resections margins, with an odds ratio of 0.42 
(95 per cent CI 0.21 to 0.85).  
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Table 1. Screening and treatment data for seven consecutive 2-year screening intervals
1997–1998 1999–2000 2001–2002 2003–2004
No. of screens 48 721 53 718 53 489 61 251
No. of referred women 537 499 553 985
Referral rate (%) 1.1 0.9 1.0 1.6
Cancer detection rate (per 1000) 4.6 5.1 4.7 5.6
Interval cancer rate (per 1000) 1.5 1.7 2.4 1.8
Sensitivity  (%) 75.4 74.5 66.5 75.2
Mastectomy rate (per 1000) 0.9 0.7 0.9 0.9
Breast‐conserving treatment rate (per 1000) 5.2 6.0 6.1 6.5
Screen‐detected cancer 224 272 252 342
     Ductal carcinoma in situ 29 46 35 62
            Mastectomy 0 (0) 0 (0) 2 (6) 0 (0)
            BCS 29 (100) 46 (100) 33 (94) 62 (100)
            No therapy/unknown 0 (0) 0 (0) 0 (0) 0 (0)
     Invasive cancers 195 226 217 280
            Mastectomy 24 (12.3) 22 (9.7) 24 (11.1) 26 (9.3)
            BCS 171 (87.7) 202 (89.4) 192 (88.5) 252 (90.0)
            No therapy/unknown 0 (0) 2 (0.9) 1 (0.5) 2 (0.7)
Interval cancer 73 93 127 113
     Ductal carcinoma in situ 2 1 4 5
            Mastectomy 0 (0) 0 (0) 0 (0) 1 (20)
            BCS 2 (100) 1 (100) 4 (100) 4 (80)
            No therapy/unknown 0 (0) 0 (0) 0 (0) 0 (0)
     Invasive cancers 71 92 123 108
            Mastectomy 19 (27) 18 (20) 22 (17.9) 27 (25.0)
            BCS 52 (73) 73 (79) 97 (78.9) 78 (72.2)
            No therapy/unknown 0 (0) 1 (1) 4 (3.3) 3 (2.8)
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2005–2006 2007–2008 2009–2010 Total
No. of screens 66 300 67 530 66 004 417 013
No. of referred women 874 1003 1779 6230
Referral rate (%) 1.3 1.5 2.7 1.5
Cancer detection rate (per 1000) 4.8 5.2 7.0 5.3
Interval cancer rate (per 1000) 2.1 1.8 2.5 2.0
Sensitivity  (%) 69.8 74.7 74.0 72.9
Mastectomy rate (per 1000) 1.1 1.5 1.9 1.2
Breast‐conserving treatment rate (per 1000) 5.7 5.3 7.4 6.1
Screen‐detected cancer 317 352 465 2224
     Ductal carcinoma in situ 52 60 110 394
            Mastectomy 6 (12) 11 (18) 18 (16.4) 37 (9.4)
            BCS 45 (87) 48 (80) 90 (81.8) 353 (89.6)
            No therapy/unknown 1 (2) 1 (2) 2 (1.8) 4 (1.0)
     Invasive cancers 265 292 355 1830
            Mastectomy 38 (14.3) 59 (20.2) 53 (14.9) 246 (13.4)
            BCS 226 (85.3) 226 (77.4) 300 (84.5) 1569 (85.7)
            No therapy/unknown 1 (0.4) 7 (2.4) 2 (0.6) 15 (0.8)
Interval cancer 137 119 163 825
     Ductal carcinoma in situ 7 6 10 35
            Mastectomy 1 (14) 1 (17) 3 (30) 6 (17)
            BCS 6 (86) 5 (83) 7 (70) 29 (83)
            No therapy/unknown 0 (0) 0 (0) 0 (0) 0 (0)
     Invasive cancers 130 113 153 790
            Mastectomy 28 (21.5) 31 (27.4) 52 (34.0) 197 (24.9)
            BCS 98 (75.4) 82 (72.6) 94 (61.4) 574 (72.7)
            No therapy/unknown 4 (3.1) 0 (0) 7 (4.6) 19 (2.4)
Values in parentheses are percentages. BCS, breast-conserving surgery
Table 1. Screening and treatment data for seven consecutive 2-year screening intervals (continued)
C
h
a
p
te
r 3
.2
70 Breast cancer detected and missed by screen-film and digital screening mammography
 Univariable analysis Multivariable analysis‡
BCS  Mastectomy P†  Odds ratio* P
Age (years) 50–69 879 (81.0) 206 (19.0) 0.099 1.00 (reference)
60–69 877 (84.4) 162 (15.6) 0.83 (0.61, 1.13) 0.234
 ≥ 70  387 (83.8) 75 (16.2) 1.30 (0.87, 1.94) 0.195
Cancer type Screen‐detected 1569 (86.4) 246 (13.6) < 0.001 1.00 (reference)
Interval 574 (74.4) 197 (25.6) 0.98 (0.68, 1.40) 0.899
Family history No 1755 (82.7) 366 (17.3) 0.718 1.00 (reference)
Yes 388 (83.4) 77 (16.6) 1.08 (0.78, 1.51) 0.636
Previous breast 
surgery
No 1909 (83.6) 374 (16.4) 0.006 1.00 (reference)
Yes, benign 234 (77.2) 69 (22.8) 1.07 (0.71, 1.60) 0.760
Use of hormone 
replacement 
therapy
No 1941 (83.1) 394 (16.9) 0.290 1.00 (reference)
Yes 202 (80.5) 49 (19.5) 0.97 (0.63, 1.49) 0.894
Breast density 
(%)
≤ 50 1460 (85.6) 245 (14.4) < 0.001 1.00 (reference)
> 50 651 (77.8) 186 (22.2) 1.38 (1.04, 1.81) 0.024
Preoperative 
MRI
No 1969 (86.4) 309 (13.6) < 0.001 1.00 (reference)
Yes 174 (56.5) 134 (43.5) 4.20 (2.85, 6.18) < 0.001
Mammographic 
abnormality
Density 1419 (87.4) 204 (12.6) < 0.001 1.00 (reference)
Microcalcifications 151 (70.6) 63 (29.4) 3.72 (2.34, 5.91) < 0.001
Density with microcalcifications 195 (78.6) 53 (21.4) 1.41 (0.90, 2.20) 0.138
Architectural distortion 18 (47) 20 (53) 2.82 (1.18, 6.74) 0.019
Breast parenchyma asymmetry 75 (76) 24 (24) 1.20 (0.62, 2.34) 0.587
Tumour size 
(mm)
≤ 20  1,631 (90.3) 175 (9.7) < 0.001 1.00 (reference)
> 20  501 (67.4) 242 (32.6) 3.39 (2.54, 4.53) < 0.001
Unknown 11 (30) 26 (70) –§
Lymph node 
status
 N0 1,532 (89.5) 180 (10.5) < 0.001 1.00 (reference)
 N+ 577 (69.5) 253 (30.5) 2.41 (1.83, 3.18) < 0.001
 Nx 34 (77) 10 (23) –§
Table 2: Univariable and multivariable analyses of risk factors for mastectomy in patients with invasive cancers
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Univariable analysis Multivariable analysis‡
BCS Mastectomy P† Odds ratio* P
Tumour
histology
Ductal 1,661 (84.5) 304 (15.5) < 0.001 1.00 (reference)
Lobular 249 (73.5) 90 (26.5) 1.44 (1.00, 2.09) 0.051
Mixed ductal–lobular 102 (75.6) 33 (24.4) 1.41 (0.84, 2.36) 0.200
Other invasive 124 (89.9) 14 (10.1) 0.90 (0.44, 1.85) 0.769
Unknown 7 (78) 2 (22) 2.06 (0.22, 19.62) 0.531
Tumour grade I 719 (85.0) 127 (15.0) 0.003 1.00 (reference)
II 718 (81.4) 164 (18.6) 1.04 (0.74, 1.46) 0.818
III 276 (77.5) 80 (22.5) 1.35 (0.88, 2.07) 0.163
DCIS
component
No 1,039 (80.9) 245 (19.1) 0.022 1.00 (reference)
Yes 719 (85.5) 122 (14.5) 0.98 (0.71, 1.34) 0.876
Extensive invasive component 385 (83.5) 76 (16.5) 0.89 (0.61, 1.31) 0.563
Hospital  A 325 (83.3) 65 (16.7) < 0.001 1.00 (reference)
 B 654 (88.5) 85 (11.5) 0.63 (0.42, 0.94) 0.024
 C 409 (79.4) 106 (20.6) 1.27 (0.84, 1.90) 0.257
 D 546 (84.0) 104 (16.0) 1.03 (0.69, 1.53) 0.905
 E 209 (71.6) 83 (28.4) –§
Year of
diagnosis
 1997–1998 223 (83.8) 43 (16.2) < 0.001 1.00 (reference)
 1999–2000 275 (87.3) 40 (12.7) 0.52 (0.27, 1.02) 0.188
 2001–2002 289 (86.3) 46 (13.7) 0.70 (0.36, 1.33) 0.057
 2003–2004 330 (86.2) 53 (13.8) 0.60 (0.31, 1.15) 0.272
 2005–2006 324 (83.1) 66 (16.9) 0.67 (0.34, 1.32) 0.123
 2007–2008 308 (77.4) 90 (22.6) 0.69 (0.34, 1.40) 0.247
 2009–2010 394 (79.0) 105 (21.0) 0.69 (0.39, 1.20) 0.305
Values in parentheses are percentages unless indicated otherwise; *values in parentheses are 95 per cent confidence in‐
tervals. MRI, magnetic resonance imaging; DCIS, ductal carcinoma in situ. †χ² test; ‡logistic regression analysis, with odds 
ratios for mastectomy versus breast-conserving surgery; §excluded from multivariable analysis.
Table 2: Univariable and multivariable analyses of risk factors for mastectomy in patients with invasive cancers  
 (continued).
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Univariable analysis Multivariable analysis‡
Negative/focal 
positive Positive P† Odds ratio* P
Age (years) 50–69 754 (85.9) 124 (14.1) 0.267 1.00 (reference)
60–69 770 (88.2) 103 (11.8) 0.75 (0.53, 1.06) 0.102
≥ 70 342 (88.4) 45 (11.6) 0.88 (0.56, 1.38) 0.575
Cancer type Screen‐de‐
tected 
1387 (88.7) 177 (11.3) 0.002 1.00 (reference)
Interval 479 (83.4) 95 (16.6) 1.83 (1.17, 2.87) 0.009
Family history No 1522 (87.0) 228 (13.0) 0.367 1.00 (reference)
Yes 344 (88.7) 44 (11.3) 0.71 (0.48, 1.06) 0.096
Previous breast 
surgery
No 1670 (87.7) 235 (12.3) 0.125 1.00 (reference)
Yes, benign 196 (84.1) 37 (15.9) 1.11 (0.71, 1.76) 0.643
Use of hormone re‐
placement therapy
No 1964 (89.0) 243 (11.0) 0.446 1.00 (reference)
Yes 172 (85.6) 29 (14.4) 0.89 (0.54, 1.47) 0.532
Breast density (%) ≤ 50 1287 (88.3) 170 (11.7) 0.063 1.00 (reference)
> 50 550 (84.7) 99 (15.3) 1.32 (0.95, 1.83) 0.105
Preoperative MRI No 1710 (87.0) 255 (13.0) 0.233 1.00 (reference)
Yes 156 (90.2) 17 (9.8) 0.42 (0.21, 0.85) 0.015
Tumour localization Palpable 719 (87.2) 106 (12.8) 0.890 1.00 (reference)
Guided 1147 (87.4) 166 (12.6) 1.96 (1.36, 2.84) < 0.001
Mammographic 
abnormality
Density 1281 (90.6) 133 (9.4) < 0.001 1.00 (reference)
Microcalcifica‐
tions 
110 (72.8) 41 (27.2) 2.53 (1.48, 4.33) 0.001
Density with 
microcalcifica‐
tions 
164 (84.1) 31 (15.9) 1.98 (1.16, 3.37) 0.012
Architectural 
distortion 
14 (78) 4 (22) 2.77 (0.71, 10.88) 0.144
Breast paren‐
chyma asym‐
metry 
56 (80) 14 (20) 2.34 (1.19, 4.59) 0.014
Tumour size (mm) ≤ 20   1456 (89.5) 170 (10.5) < 0.001 1.00 (reference)
> 20   403 (80.4) 98 (19.6) 2.10 (1.47, 3.00) < 0.001
Unknown 7 (64) 4 (36) –§
Lymph node status N0 1359 (88.9) 170 (11.1) < 0.001 1.00 (reference)
N+ 479 (83.3) 96 (16.7) 1.20 (0.85, 1.68) 0.298
Nx 28 (82) 6 (18) –§
Table 3: Univariable and multivariable analyses of risk factors for positive resection margins in patients with
 invasive cancers
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Univariable analysis Multivariable analysis‡
Negative/focal 
positive Positive P† Odds ratio* P
Tumour histology Ductal 1481 (89.3) 177 (10.7) < 0.001 1.00 (reference)
Lobular 183 (73.5) 66 (26.5) 3.94 (2.60, 5.96) < 0.001
Mixed ductal–
lobular 
86 (84.3) 16 (15.7) 1.56 (0.82, 2.99) 0.180
Invasive other 110 (89.4) 13 (10.6) 1.09 (0.53, 2.32) 0.824
Unknown 6 (100) 0 (0) –§
Tumour grade I 633 (88.0) 86 (12.0) 0.066 1.00 (reference)
II 631 (87.9) 87 (12.1) 0.66 (0.45, 0.98) 0.038
III 247 (89.5) 29 (10.5) 0.44 (0.25, 0.77) 0.005
DCIS component No 923 (89.3) 111 (10.7) < 0.001 1.00 (reference)
Yes 672 (93.5) 47 (6.5) 0.68 (0.46, 1.03) 0.066
Extensive 
invasive com‐
ponent 
271 (70.4) 114 (29.6) 4.25 (2.89, 6.27) < 0.001
Hospital A 306 (94.2) 19 (5.8) < 0.001 1.00 (reference)
B 596 (91.4) 56 (8.6) 1.51 (0.84, 2.69) 0.167
C 344 (84.1) 65 (15.9) 3.31 (1.84, 5.94) < 0.001
D 435 (79.7) 111 (20.3) 5.00 (2.85, 8.77) < 0.001
E 185 (89.8) 21 (10.2) –§
Year of diagnosis 1997–1998 176 (80.4) 43 (19.6) < 0.001 1.00 (reference)
1999–2000 233 (84.7) 42 (15.3) 0.50 (0.24, 1.05) 0.132
2001–2002 250 (86.5) 39 (13.5) 0.29 (0.14, 0.62) 0.068
2003–2004 299 (90.6) 31 (9.4) 0.54 (0.26, 1.12) 0.001
2005–2006 281 (87.0) 42 (13.0) 0.80 (0.38, 1.69) 0.097
2007–2008 263 (85.4) 45 (14.6) 0.42 (0.18, 0.96) 0.559
2009–2010 364 (92.4) 30 (7.6) 0.65 (0.38, 1.14) 0.039
Values in parentheses are percentages unless indicated otherwise; *values in parentheses are 95 per cent confi‐
dence intervals. MRI, magnetic resonance imaging; DCIS, ductal carcinoma in situ. †χ² test; ‡logistic regression 
analysis, with odds ratios for positive resection margins versus negative/focal positive margins; §excluded from 
multivariable analysis.
Table 3: Univariable and multivariable analyses of risk factors for positive resection margins in patients with
 invasive cancers (continued).
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Discussion
The mastectomy rate doubled over a 14-year screening period, whereas the BCS rate and 
breast cancer incidence (per 1000 screened women) remained stable. Multivariable analysis 
showed that patients with microcalcifications, large tumours, lymph node metastasis and those 
treated in certain hospitals had a higher risk of undergoing mastectomy. The positive resection 
margin rate declined over time, with wide variation between hospitals. Main independent risk 
factors for positive resection margins of invasive cancers were tumour size larger than 20 mm, 
lobular histology and the treating hospital. Preoperative MRI led to a lower risk of positive 
resection margins, but a substantially higher risk of mastectomy.
As the incidence of smaller tumours detected at screening mammography has increased sig-
nificantly24,25, the expectation was that BCS rates would rise in the present study.  However, a 
twofold increase in the mastectomy rate was observed over the 14 years. There are conflicting 
reports on whether mastectomy rates are increasing7,8,15, although these studies did not focus 
specifically on screened populations. Factors behind the increased mastectomy rates could be 
changes in patients’ preferences, a fear of local recurrence and increased use of preoperative 
MRI24. In the present study of women in a screening programme, the use of preoperative MRI 
was associated with a higher risk of mastectomy and a large variation in the use of MRI was 
observed between hospitals. Again, there are no data available from studies specifically ad-
dressing a screened population, and previous studies24,25 on symptomatic patients reported 
conflicting results on the impact of preoperative MRI on the mastectomy rate.
Increased breast density (American College of Radiology category 3 and 419), invasive tumour 
size larger than 20 mm and axillary lymph node metastasis were also associated with an in-
creased relative risk for mastectomy, in line with previous findings15,26,27. An analysis of risk 
factors for mastectomy in DCIS was not done, owing to the smaller number of mastectomies 
performed. Nevertheless, a significant increase in the mastectomy rate for DCIS was observed 
in the last 4 years of the study.
BCS has been one of the major advances in breast cancer management in the second half of 
the 20th century. Tumour-involved surgical margins are associated with a higher local recur-
rence rate28, which is associated with poorer overall survival29. Several risk factors have been 
described for positive resection margins, including lobular histology, tumour size, DCIS and 
the presence of microcalcifications at mammography30. The size of an appropriate tumour-free 
resection margin is still debated31,32. A small tumour-free or microscopically incomplete margin 
may be acceptable if surgery is followed by radiotherapy to eradicate the tumour cells left be-
hind33. In the present study, 13.7 per cent of women had positive resection margins, with wide 
variation between hospitals. This is in line with previous reports30,34–37 and the Dutch guideli-
nes38, which state that a surgeon should strive for a maximum of 20 per cent positive resection 
margins. Women with DCIS were more likely to have positive resection margins after BCS and 
more likely to undergo a mastectomy as final type of surgery after positive resection margins 
than women with invasive breast cancer. This finding is also in line with other studies30,35,39.
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A	significant	decrease	in	positive	resection	margins	was	observed	over	 time;	comparing	the	
rate of positive margins for invasive cancer during the first and last 2-year intervals, an ab-
solute reduction of 12 per cent (from 19.6 per cent to 7.6 per cent) was found.  In line with 
other studies7,34–36, tumour size greater than 20 mm was an independent risk factor for positive 
resection margins for invasive cancer. Lobular carcinoma is another known risk factor for po-
sitive resection margins, although this does not translate into a higher risk of local recurrence 
compared with that for invasive ductal carcinoma40. The presence of microcalcifications is 
associated with a DCIS component, and the true size of this lesion is often underestimated by 
imaging41. An extensive in situ component is known to influence the surgical margin status, 
and so it is important to identify this by preoperative core biopsy, to help in planning resec-
tion42. Thus the presence of microcalcifications, in situ components on core needle biopsy 
and lobular histology indicate a risk of positive margins at BCS. Another risk factor for positive 
resection margins in patients with invasive cancer was the presence of a non-palpable tumour. 
Improved localization methods for non-palpable breast cancer are needed to reduce the rate 
of positive margins, as recently emphasized in a study from the USA43. Radioactive iodine seed 
localization of non-palpable tumours seems effective in reducing the risk of positive resection 
margins3. Preoperative use of MRI tended to decrease the risk of positive resection margins 
in invasive cancer. Finally, histological grade III tumours were associated with a lower risk of 
tumour-positive resection margins.
The present study has both strengths and limitations.  The surgical management and outcome 
of breast cancer was analysed in a screened population. However, extrapolation of these fin-
dings to other screening programmes may be limited, as these may differ from one another in 
several aspects, including screening interval, age of screened women, reading strategy and re-
ferral rate18,44. The present findings regarding the impact of preoperative use of MRI on mastec-
tomy rate and margin status cannot be compared easily with previous studies, as information 
on the indications for MRI in the present population is not available, and other studies were not 
specifically aimed at asymptomatic, screened women. Furthermore, positive resection margins 
were used as a surrogate endpoint for local recurrence here, as they are an established risk 
factor for local recurrence. Monitoring local recurrence itself would require longer follow-up 
and an even larger numbers of screened women to be useful as a quality indicator of surgery. 
The 5-year local recurrence rate following BCS was only 2.6 (95 per cent CI 2.2 to 3.1) per cent 
for patients treated in 2003, based on a study from the Netherlands Cancer Registry45.
Surgeons performing BCS should try to identify patients at high risk of positive resection mar-
gins before surgery, with a special focus on microcalcifications. Furthermore, a continuous ef-
fort should be made to improve the quality of excisional biopsies, either by using wire-guided 
localization or iodine-125-radiolabelled seeds, and to benchmark performance against that of 
peers.
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Chapter 4
Impact of the introduction of full-field 
digital mammography screening on 
screening outcome in the south of the
Netherlands
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Chapter 4.1
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sum AB, Voogd AC. Impact of transition from analog screening mammography to digital 
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Abstract
Background: Full-field digital mammography (FFDM) has replaced screen-film mammograp-
hy (SFM) in most breast screening programs. We analysed the impact of this replacement on 
screening outcome.
Methods: The study population consisted of a consecutive series of 60,770 analogue and 
63,182 digital screens. During 1-year follow-up, we collected breast imaging reports, biopsy 
results and surgical reports of all referred women.
Results: Referral rate and cancer detection rate at FFDM were respectively 3.0% and 6.6 per 
1,000 screens, compared to 1.5% (p < 0.001) and 4.9 (p < 0.001) at SFM. Positive predictive 
values of referral and percutaneous biopsy were lower at FFDM, respectively 21.9% versus 
31.6% (p < 0.001) and 42.9% versus 62.8% (p < 0.001). Per 1,000 screened women, there was 
a significant increase with FFDM vs. SFM in the detection rate of low- and intermediate grade 
DCIS (+ 0.7), invasive T1a-c cancers (+ 0.9), invasive ductal cancers (+0.9), low-grade (+1,1), 
node-negative invasive cancers (+1.2), oestrogen-receptor or progesterone-receptor positive 
invasive cancers (respectively +0.9 and +1.1) and Her2/Neu negative (+0.8) invasive cancers. 
Mastectomy rates were stable at 1.1 per 1,000 screens.
Conclusion: FFDM significantly increased the referral rate and cancer detection rate, at the 
expense of a lower positive predictive value of referral and biopsy. Extra tumours detected at 
FFDM were mostly low-intermediate grade DCIS and smaller invasive tumours, of more favou-
rable tumour characteristics. Mastectomy rates were not increased in the FFDM population, 
while increased overdiagnosis cannot be excluded.
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Introduction
Many western countries have implemented regional or nation-wide screening mammography 
programs with the aim to detect breast malignancies at an early stage1. High-quality full-field 
digital mammography (FFDM) has been available now for several years and has replaced 
screen-film mammography (SFM) in most programs. FFDM improves workflow and is at least 
as effective as SFM in the detection of breast cancer2,3. However, higher cancer detection 
rates at FFDM may be accompanied by increased referral rates4,5 and lower positive predictive 
values of referral for breast cancer6,7. Moreover, FFDM especially increases the detection of 
ductal carcinoma in situ (DCIS), resulting in a larger proportion of breast cancers being over-
diagnosed8.
The Netherlands has a long tradition in screening mammography and transition to digital 
screening has also resulted in higher referral rates and a significantly enhanced cancer detecti-
on rate6,7. Although emerging data become available with respect to digital screening accuracy, 
little is known about the effects of conversion of analogue to digital screening on additional 
diagnostic tests, tumour stage, histology and biology of screen-detected cancers and surgical 
treatment of these cancers. In a southern breast cancer screening region of the Netherlands, 
we therefore performed a comprehensive evaluation of the changes in referral rate, cancer 
detection rate, utilization of diagnostic tests after referral, characteristics of screen-detected 
cancers and surgical treatment procedures following the introduction of digital screening mam-
mography.
Methods
Study population
We included a consecutive series of 60,770 analogue screens in 60,770 women (6,851 initial 
screens and 53,919 subsequent screens) and 63,182 digital screens in 63,182 women (7,019 
initial screens and 56,163 subsequent screens), obtained at three specialized screening units 
in a southern biennial screening mammography region of the Netherlands (BOZ, Bevolkings 
Onderzoek Zuid) between January 1, 2008 and January 1, 2011. Of the 56,163 women with a 
subsequent digital screen, 29,649 were also represented in the cohort of 60,770 women who 
had received an analogue screen between January 1, 2008 and January 1, 2011. Screen-film 
mammography was replaced by full field digital mammography on respectively May 26, 2009, 
June 3, 2009 and April 6, 2010 at the three units. To determine the possible presence of a lear-
ning curve since the start of digital screening, we divided the total number of digital screens in 
each screening unit in two equal proportions for which we then separately assessed screening 
outcome.  All women had given written informed consent to use their screening and follow-up 
data for evaluation purposes. The Central Committee on Research Involving Human Subjects 
(CCMO) in The Hague, The Netherlands, waived ethical approval for this study.
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Screening procedure and referral
Details of our breast cancer screening program, offering biennial screening mammography for 
women aged 50-75 years, have been described previously9,10. In brief, screen-film mammo-
grams were obtained with commercially available units (Performa, Oldelft, Tuusula, Finland). 
Dedicated mammography screens were utilized (Mamoray MR-R, Agfa, Schroenhausen, Ger-
many).	Both	dedicated	film	(Mamoray	HDR;	Agfa,	Mortsel,	Belgium),	as	well	as	extended-cycle	
dedicated processing were used. All digital mammograms were acquired with a Lorad Selenia 
FFDM system (Hologic Inc, Danbury, CT), with a 70 µm pixel size and a 232x286 mm field of 
view. All mammograms were obtained by specialized screening mammography technologists 
and double read by a team consisting of eleven certified screening radiologists. Prior screening 
mammograms were always available for comparison at the time of subsequent screening. To 
facilitate softcopy reading of subsequent screening examinations at FFDM, the most recent 
prior screen-film screening mammograms were digitized by using a film scanner and archiver 
designed	 for	mammography	 (DigitalNow;	 R2/Hologic).	 The	 original	 hard	 copy	 screen	 film	
mammograms were also available for viewing if desired by the screening radiologist. Women 
with normal or benign mammographic findings, or with a non-specific minimal sign11, were not 
referred. If screening mammography showed a suspicious or malignant lesion, the woman was 
referred to a surgical oncologist or breast clinic for further analysis of the mammographic ab-
normality.  For each referral, the screening radiologists classified the abnormal mammographic 
findings according to one of five categories: suspicious high density (e.g., spiculated density or 
density with indistinct borders), suspicious microcalcifications (e.g., pleomorphic, branching, 
or amorphous/indistinct microcalcifications), density in combination with microcalcifications, 
architectural distortion, or asymmetry. Women with discrepant readings at screening mammo-
graphy (only one of the two screening radiologists considered referral necessary) were always 
referred for further analysis.
Diagnostic workup and surgical treatment of screen-detected cancers
A total of 15 regional and university hospitals were involved in the assessment of screen posi-
tive women. After physical examination by the surgeon, additional mammographic views were 
obtained if necessary. At diagnostic work-up, radiologists classified the radiological findings ac-
cording to the American College of Radiology BI-RADS12. BI-RADS 4 and BI-RADS 5 lesions 
were routinely biopsied, whereas BI-RADS 3 lesions were either biopsied of followed-up with 
mammography. Dependent on the findings at physical examination and mammography and 
dependent on the diagnostic workup protocols and hospital facilities available, further diag-
nostic evaluation could include breast ultrasonography, Magnetic Resonance Mammography, 
percutaneous fine needle aspiration cytology (FNAC) or core biopsy (CB), or open surgical 
biopsy. During one-year follow-up, we collected data on diagnostic imaging procedures, bi-
opsy specimen and surgical procedures of all referred women. Breast cancers were divided 
into	ductal	carcinoma	in-situ	and	invasive	cancers;	lobular	carcinoma	in-situ	was	considered	
to be a benign lesion. Advanced cancers were defined as invasive cancers with Tumour-Node-
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Table 1. Overall screening results
Screen-film
mammography
Digital
mammography p‐value
Mammograms, n         60,770         63,182
    Initial screens, n (%)     6,851 (11.3)     7,019 (11.1)    0.4
    Subsequent screens, n (%)   53,919 (88.7)   56,163 (88.9)
Age distribution, n (%)    0.9
    <50 years     3,870 (6.4)     3,998 (6.3)
    50-69 years   48,999 (80.6)   50,562 980.0)
    >70 years     7,901 (13.0)     8,622 (13.6)
Referral, n (%)       941 (1.5)     1,919 (3.0) <0.001
    Initial screens, n (%)       225 (3.3)        447 (6.4)
    Subsequent screens, n (%)       716 (1.3)     1,472 (2.6)
Mean age of referred women, years (95% CI) 59.9 (59.4‐60.4) 59.4 (59.1‐59.8)
Screen detected cancers, n 297 420
Cancer detection rate* 4.9 6.6
     Initial screens 4.7 7.4 <0.001
     Subsequent screens 4.9 6.6
Positive predictive value of referral, % 31.6 21.9 <0.001
Type of screen detected cancer, n (rate*)   0.003
    Ductal carcinoma in situ        44 (0.7)      100 (1.6)
    Invasive cancer      253 (4.2)      320 (5.1)
Type of surgery, n (rate*)   0.04
    Breast conserving treatment      223 (3.7)      348 (5.5)
    Mastectomy        69 (1.1)        68 (1.1)
    No surgical treatment          5 (0.08)          4 (0.06)
*Per 1,000 screened women.  ±Women are invited in the year they become 50
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Mammographic abnormality Screen-film mammography Digital mammography P‐value±
n Proportion (%)
Referral rate 
(‰)*
TP
(n)
PPV
(%)
n Proportion (%)
Referral
rate (‰)*
TP
(n)
PPV
(%)
Density 663      70.5     10.9   205 30.9 1,068      55.7     16.9   217 20.3 <0.001
Microcalcifications 152      16.2       2.5     53 34.9    580      30.2       9.2   122 21.0 <0.001
Density with 
    microcalcifications
  55        5.8       0.9     24 43.6    120        6.3       1.9     48 40.0 0.7
Asymmetry   46        4.9       0.8       2   4.3      45        2.3       0.7       2   4.4 0.98
Architectural distortion   24        2.6       0.4     12 50.0    101        5.3       1.6     31 30.7 0.07
Other     1        0.1       0.0       1 100        5        0.3       0.1       0   0.0 0.01
Total 941    100      15.5   297 31.6 1,919    100     30.4   420 21.9 < 0.001
TP = true positive. PPV = positive predictive value of referral.   *Per 1,000 screened women.                                                                                                        ±P-value calculated for PPV at screen-film mammography versus digital mammography
Table 2. Lesion characteristics of women referred at screening mammography
Metastases (TNM) stage IIA or higher, i.e. tumour size exceeding 20 mm (T2) and/or presence 
of lymphatic metastasis in the sentinel node or axillary lymph nodes13. Sentinel nodes were 
classified negative if they harboured isolated tumour cells or sub-micrometastases (<0.2 mm) 
and were considered positive (N+) if they contained micrometastases (0.2-2 mm) or macro-
metastases (>2 mm). For women with bilateral disease, the cancer with the highest stage was 
retained;	multiple	foci	of	cancer	in	one	breast	were	counted	as	one	cancer.
Statistical analysis
All	 data	 were	 entered	 into	 a	 computerized	 spreadsheet	 (Excel;	 Microsoft,	 Redmond,	WA,	
USA). Statistics were performed using the SAS program version 9.1.3 (Statistical Analysis Soft-
ware;	SAS/STAT	software®,	Cary,	NC,	USA).	A	double	sided	t-test	was	used	to	test	differences	
between continuous variables, and the χ²-test to test differences between categorical variables. 
The significance level was set at 5%.
Results
Overall screening results
Age distribution and the proportion of initial screens were comparable for SFM and FFDM (Ta-
ble 1). The referral rate and overall cancer detection rate (number of cancers per 1,000 scree-
ned women) were significantly higher at FFDM (3.0% versus 1.5% (p < 0.001) and 6.6 versus 
4.9 (p < 0.001), respectively). The cancer detection rate at initial screens was similar to the one 
observed	at	subsequent	screens	(SFM:	4.7	versus	4.9,	p	=	0.8;	FFDM:	7.6	versus	6.6,	p	=	0.3).	
C
h
a
p
te
r 
4
.1
89Impact of digital screening mammography on screening outcome 
The positive predictive value of referral was significantly lower at FFDM (21.9% versus 31.6%, 
p < 0.001). Per 1,000 screened women, screen-detected DCIS increased from 0.7 at SFM to 
1.6 at FFDM (p < 0.001) and invasive cancer from 4.2 at SFM to 5.1 at FFDM (p < 0.001). The 
proportion of ductal carcinoma in-situ (DCIS) among women with screen-detected cancers 
was significantly higher at FFDM (23.8% versus 14.8%, p = 0.003). Both the referral rate for 
suspicious microcalcifications per 1,000 screens and the proportion of women referred for 
suspicious microcalcifications significantly increased at FFDM (from 2.5 at SFM to 9.2 at FFDM 
(p <  0.001) and from 16.2% at SFM to 30.2% at FFDM (p <  0.001), respectively, Table 2). The 
referral rate for densities was also significantly higher at FFDM (16.9 versus 10.9, p <  0.001), 
but the proportion of women referred for suspicious densities was lower than the one found 
at SFM (55.7% versus 70.5%, p <  0.001). The positive predictive value of referral for densi-
ties and for suspicious microcalcifications decreased from 30.9% at SFM to 20.3% at FFDM 
(p <  0.001), and from 34.9% to 21.0% (p <  0.001), respectively. Most of the extra cancer 
detection at FFDM (1.4 out of 1.7 per 1,000 screens) was in cases showing either calcifications 
alone or calcifications associated with density. Referral rate, cancer detection rate and positive 
predictive value of referral at digital screening were similar for the first half and the second 
half of digitally obtained screens in each screening unit (2.9% versus 3.1% (p = 0.6), 6.9 per 
thousand versus 6.5 per thousand (p = 0.6) and 23.4% versus 20.8% (p = 0.7), respectively). 
Mammographic abnormality Screen-film mammography Digital mammography P‐value±
n Proportion (%)
Referral rate 
(‰)*
TP
(n)
PPV
(%)
n Proportion (%)
Referral
rate (‰)*
TP
(n)
PPV
(%)
Density 663      70.5     10.9   205 30.9 1,068      55.7     16.9   217 20.3 <0.001
Microcalcifications 152      16.2       2.5     53 34.9    580      30.2       9.2   122 21.0 <0.001
Density with 
    microcalcifications
  55        5.8       0.9     24 43.6    120        6.3       1.9     48 40.0 0.7
Asymmetry   46        4.9       0.8       2   4.3      45        2.3       0.7       2   4.4 0.98
Architectural distortion   24        2.6       0.4     12 50.0    101        5.3       1.6     31 30.7 0.07
Other     1        0.1       0.0       1 100        5        0.3       0.1       0   0.0 0.01
Total 941    100      15.5   297 31.6 1,919    100     30.4   420 21.9 < 0.001
TP = true positive. PPV = positive predictive value of referral.   *Per 1,000 screened women.                                                                                                        ±P-value calculated for PPV at screen-film mammography versus digital mammography
Table 2. Lesion characteristics of women referred at screening mammography (continued)
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Diagnostic work-up
Almost half (49.0%) of women referred at SFM or FFDM only received additional breast ima-
ging at diagnostic workup and the number of women who only underwent breast imaging 
at workup almost doubled from 7.6 at SFM to 14.9 at FFDM per 1,000 screens (p < 0.001, 
Table 3). The other half of referred women underwent biopsy in addition to breast imaging 
(either percutaneous biopsy, excisional biopsy, or a combination of percutaneous and surgical 
biopsy). Among the different types of biopsy procedures, the use of stereotactic core needle 
biopsy most markedly increased after conversion from SFM to FFDM (from 2.2 per 1,000 ana-
logue screens to 7.9 per 1,000 digital screens, p < 0.001), the proportion of referred women 
who underwent stereotactic core needle biopsy increased from 14.9% (140/940) at SFM to 
26.4% (506/1,919) at FFDM (p < 0.001). The increase in stereotactic core needle biopsy was 
mainly due to the increase in referral for microcalcifications. The positive predictive value of 
percutaneous biopsy decreased from 62.8% (297/473) at SFM to 42.9% (418/974) at FFDM 
(p < 0.001) and the highest drop in positive predictive value was found for stereotactic core 
needle biopsy (from 40.0% (56/140) at SFM to 26.9% (136/506) at FFDM, p < 0.001). 
Tumour characteristics
Per 1,000 screened women, there was a significant increase with FFDM vs. SFM in the detec-
tion rate of low- and intermediate grade DCIS (+ 0.7), invasive T1a-c cancers (+ 0.9), invasive 
ductal cancers (+0.9), low-grade (+1,1), node-negative invasive cancers (+1.2), oestrogen-re-
ceptor or progesterone-receptor positive invasive cancers (respectively +0.9 and +1.1) and 
Her2/Neu negative (+0.8) invasive cancers (Table 4). 
Type of breast cancer surgery
Compared to women screened with SFM, a significantly higher proportion of women screened 
with FFDM underwent breast conserving surgical treatment of their screen-detected cancer 
(82.9% versus 75.1%, p = 0.04, Table 1). The number of women undergoing breast conserving 
surgery increased from 3.7 per 1,000 screened women at SFM to 5.5 per 1,000 women at 
FFDM (p = 0.04). A similar mastectomy rate of 1.1 per 1,000 screened women was observed 
at SFM and FFDM.
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Diagnostic work-up Screen-film mammography
Digital 
mammography
n
Proportion
(%)
Rate§ 
(‰)
 n
Proportion
(%)
Rate§ 
(‰)
Breast imaging only* 461      49.0    7.6    941       49.0   14.9
Breast imaging + US-guided FNAC or CB 325      34.5    5.3    458       23.9     7.2
Breast imaging + SCNB 134      14.2    2.2    499       26.0     7.9
Breast imaging + excisional biopsy     4        0.4    0.1        2         0.1     0.0
Breast imaging + percutaneous biopsy± +
    excisional biopsy 
  14        1.5    0.2      17         0.9     0.3
None/unknown     3        0.3    0.0         2         0.1     0.0
Total 941  15.5 1,919   30.4
*Mammography, breast ultrasonography, Magnetic Resonance Imaging or any combination of these imaging 
modalities.
±US-guided FNAC, US-guided CB, SCNB or any combination of these biopsy procedures.
§Per 1,000 screened women.
US = ultrasound. FNAC = fine needle aspiration cytology. CB = core biopsy. SCNB = stereotactic core needle 
biopsy.
Table 3. Diagnostic work-up of women referred at screening mammography
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Proportion Rate 
(per 1,000 screened women)
SFM DM P‐value SFM DM P‐value
N (%) N (%)
Ductal carcinoma in situ 0.09
 Low grade 7 (15.9) 28 (28.0) 0.1  0.4 0.001
 Intermediate grade 15 (31.8) 38 (38.0) 0.2  0.6 0.001
 High grade 23 (52.3) 34 (34.0) 0.4  0.5 0.19
Invasive carcinoma 0.4
 Ductal 199 (78.7) 263 (82.2) 3.3 4.2 0.01
 Lobular 30 (11.9) 24 (7.5) 0.5 0.4 0.3
 Mixed ductal/lobular 10 (4.0) 18 (5.6) 0.2 0.3 0.2
 Other 13 (5.1) 14 (4.4) 0.2 0.2 0.9
 Unknown 1 (0.4) 1 (0.3) 0.0 0.0 0.9
Size of invasive cancers 0.5
 T1a‐c 197 (77.9) 258 (80.6) 3.2 4.1 0.01
 T2+ 54 (21.3) 58 (18.1) 0.9 0.9 0.9
 Unknown 2 (0.8) 4 (1.3) 0.0 0.1 0.4
Lymph-node status 0.001
 Positive 80 (31.6) 59 (18.4) 1.3 0.9 0.04
 Negative 171 (67.6) 254 (79.4) 2.8 4.0 <0.001
 Unknown 2 (0.8) 7 (2.2) 0.0 0.1 0.1
Tumor stage <0.001
 Advanced* 105 (41.5) 87 (27.2) 1.7 1.4 0.1
 Non‐advanced 146 (57.7) 226 (70.6) 2.4 3.6 <0.001
 Unknown 2 (0.8) 7 (2.2) 0.0 0.1 0.1
Tumor grade 0.003
 NottinghamI 99 (39.1) 172 (53.8) 1.6 2.7 <0.001
 Nottingham II 115 (45.5) 117 (36.6) 1.9 1.9 0.9
 Nottingham III 32 (12.6) 22 (6.9) 0.5 0.3 0.1
 Unknown 7 (2.8) 9 (2.8) 0.1 0.1 0.7
Estrogen‐receptor 0.6
 Positive 224 (89.2) 291 (91.5) 3.7 4.6 0.01
 Negative 27 (10.8) 27 (8.5) 0.4 0.4 0.9
 Unknown 2 (0.8) 2 (0.6) 0.0 0.0 0.9
Progesterone‐receptor 0.007
 Positive 167 (66.0) 237 (74.1) 2.7 3.8 0.002
 Negative 76 (30.0) 81 (25.3) 1.3 1.3 0.9
 Unknown 10 (4.0) 2 (0.6) 0.2 0.0 0.02
Her2/Neu-receptor 0.9
 Positive 28 (11.1) 33 (10.3) 0.5 0.5 0.6
 Negative 221 (87.4) 281 (87.8) 3.6 4.4 0.03
 Unknown 4 (1.6) 6 (1.9) 0.1 0.1 0.6
Triple-negative receptor 13 (6.3) 18 (5.6) 0.7 0.3 0.3 0.8
Table 4. Tumor characteristics of screen-detected cancers
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Discussion
To our knowledge, the current population-based study is the first that provides a thorough 
overview of the impact of transition of SFM to FFDM on screening outcome as well as on diag-
nostic workup and surgical treatment. This transition resulted in a significantly increased refer-
ral rate and detection rate of ductal carcinoma in-situ and invasive cancers, in combination 
with a significantly decreased positive predictive value of referral and biopsy and an almost 
fourfold increase in the use of stereotactic core needle biopsy. Invasive cancers at FFDM were 
more likely to be diagnosed at an earlier tumour stage, showed a more favourable tumour 
grade and comprised a significantly larger proportion of progesterone-receptor positive can-
cers. Moreover, cancers detected at FFDM were more likely to be treated by breast conserving 
surgery, whereas the mastectomy rate was comparable to the rate observed at SFM.
Studies report conflicting results on the effect of implementation of digital mammography 
on referral rate. Compared to SFM, a significantly higher referral rate3-5,7,14,15 was observed at 
FFDM in several European and US studies, whereas others reported a similar or decreased 
referral rate16,17 at FFDM. Our three per cent referral rate at FFDM is still lower than the one 
observed in most other digital screening mammography programs, but it is in accordance 
with the recommended referral rate in the European guidelines for quality assurance in breast 
cancer screening and diagnosis18. We found a significantly higher overall cancer detection rate 
at FFDM and most of these extra cases (1.4 out of 1.7 per 1,000 screens) either showed micro-
calcifications or microcalcifications associated with a density, which is in line with previous 
studies3-7,15. In other study, a higher detection rate at FFDM was only observed for cancers de-
picted as clustered microcalcifications4. Another Dutch study also reported a better depiction 
of microcalcifications at FFDM leading to a higher SNCB rate7. Finally, several investigators 
found similar detection rates at FFDM and SFM17,19. 
In our study, the detection rate at screen-film mammography was similar for initial and sub-
sequent screens, whereas a higher detection rate for initial screens was observed in another 
Dutch study by Fracheboud et al20. This contradictory finding may be due to differences in 
study populations. Many women will have been included several times by Fracheboud et al 
during their much longer inclusion period, whereas women in our study were included only 
once in the group of analogue screens. Also, a potentially higher detection rate at initial screens 
may have been compensated by an increased baseline cancer-risk for women at subsequent 
screening, as the mean age will be higher for the latter group.
In contrast with most other studies3-5,14,17, we observed a significantly lower positive predictive 
value of referral at FFDM, as compared to SFM. The Dutch nation-wide screen-film mammo-
graphy program has always been characterized by a very low referral rate of less than 1.5%5,9 
and the referral rate at digital screening of 3.0%, that was observed in our study, has inevitably 
resulted in a lower positive predictive value. Yet, our positive predictive value of 21.9% is 
still considerably higher than those reported in other FFDM studies3,5 and one should try to 
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minimize false positive referrals as these women may experience considerable and sustained 
psychological distress21,22.
In both screening groups, 51% of referred women underwent biopsy in addition to diagnostic 
breast imaging procedures. The positive predictive value of percutaneous biopsy decreased 
from 62.8% at SFM to 42.9% at FFDM and the latter percentage is comparable to those repor-
ted in other studies3,5. The increased overall referral rate at FFDM was mainly due to improved 
detection of densities and clustered microcalcifications. The increased detection of lesions 
presenting as microcalcifications resulted in an almost fourfold increase in stereotactic core 
needle biopsies per thousand screened women and, despite an improved cancer detection 
rate, in a marked decrease of the positive predictive value of stereotactic biopsies from 40.0% 
to 26.9%. The increased use of stereotactic core needle biopsy at digital screening will have a 
great impact on the daily practice of the regional breast clinics as it is much more time consu-
ming than ultrasound guided biopsy. 
There are very few data available comparing tumour characteristics of cancers detected at 
SFM and FFDM. We identified a higher proportion of low- to intermediate-grade DCIS at 
FFDM. Sparsely available studies on DCIS have shown conflicting results. In accordance with 
our findings, a US study identified a higher proportion of low- to intermediate-grade DCIS at 
FFDM4. However, a Scandinavian study found a higher proportion of high-grade cases which 
approached statistical significance23. These discrepancies are interesting as they may reflect 
differences in screening education and differences in referral guidelines for microcalcifications 
detected at screening mammography. 
The proportion of advanced cancers was significantly lower at FFDM, due to an increase in the 
detection of smaller, lymph-node negative cancers. In line with an Irish study, we also found a 
significantly higher proportion of low-grade invasive tumours at FFDM, while more grade 2 and 
3 tumours were identified at SFM24. Finally, rates of progesterone-positive, oestrogen-positive 
and Her2/Neu-negative invasive cancer were increased at FFDM. The rates of triple-negative 
invasive cancers did not change. We did not find any previously published data on receptor 
characteristics of cancers detected at FFDM to compare our results with. 
To our knowledge, our study is the first that addresses the influence of transition from SFM to 
FFDM on surgical treatment of screen-detected cancer. There are conflicting reports whether 
the mastectomy rate is higher in screened than in non-screened women25,26. Our data show 
that tumours detected by FFDM were more likely to be treated with breast-conserving surgery. 
The mastectomy rate was similar for both groups and transition to FFDM thus not increases a 
woman’s change to undergo mastectomy. 
A potential harmful effect of screening is the phenomenon of so-called over-diagnosis of breast 
cancers, i.e. diagnosis of breast cancers that, if left undiscovered, would never become cli-
nically evident and, thus, would never become lethal. The detection rate of DCIS more than 
doubled at FFDM (from 0.7 to 1.6), with a significantly larger proportion of low- to intermediate 
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grade DCIS, whereas the enhanced detection rate of invasive cancers was less profound (from 
4.2 to 5.1). Estimates of over-diagnosis vary greatly among studies, from 2-50%, and may be 
explained by the length of follow-up to allow for lead time, or by the denominator that is used 
to define the population at risk26-28. De Gelder et al. calculated that the proportion of over-
diagnosed cancers at the Dutch nation-wide breast screening program will increase from 2.1% 
at SFM to 2.5% at FFDM, without a further significant reduction in breast cancer mortality8. 
Our findings of a marked increase in small invasive cancers and low to intermediate DCIS at 
FFDM suggests that the proportion of overdiagnosed cancers is probably higher than the one 
mentioned by De Gelder et al8.
Our study has certain limitations. Although all screening radiologists received training on di-
gital screening mammography at the National Expert and Training Centre for Breast cancer 
screeningprior to implementation of FFDM and all radiologists had more than 5 years experi-
ence with working in a digital radiology environment, none of them had experience with the 
use of FFDM in screening at the start of the study. It is unlikely, however, that our results will 
have been influenced by a “learning effect”, as referral rate, cancer detection date and positive 
predictive value of referral were similar for the first and second half of the inclusion period for 
digital screens. The FFDM group was restricted to women who were digitally screened for their 
first time and we cannot predict the long-term impact of successive digital screening rounds 
on screening outcome. However, a recent Dutch study found that referral rates at successive 
digital screening decreased and stabilized at a higher level than in conventional screening, yet 
with significantly enhanced cancer detection6. We could not determine screening sensitivity 
at FFDM as follow-up should be continued until the next biennial screen in order to detect all 
interval cancers. 
Finally, we are not certain whether the routine comparison of digital screens with previous 
analogue screens that had been digitized, rather than comparison with the original hard copy 
analogue screens, may have had some effect on the screening results.
In summary, we conclude that the transition from SFM to FFDM resulted in a significantly en-
hanced cancer detection rate for DCIS and invasive cancers, at the expense of an increased 
referral rate and decreased positive predictive value of referral and biopsy. Invasive cancers 
detected at FFDM were more frequently of low grade, showed less lymph node involvement 
and were more frequently progesterone-receptor positive. Women with breast cancer detected 
at FFDM were more likely to be treated by breast conserving surgery, while the mastectomy 
rate was similar at SFM and FFDM.
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Abstract
Background: In most breast screening programs screen-film mammography (SFM) has been re-
placed by full-field digital mammography (FFDM). We compared interval cancer characteristics 
at SFM and FFDM screening mammography.
Methods: We included all 297 screen-detected and 104 interval cancers in 60,770 SFM exa-
minations and 427 screen-detected and 124 interval cancers in 63,182 FFDM examinations, in 
women screened in the period 2008-2010. Breast imaging reports, biopsy results and surgical re-
ports of all cancers were collected. Two radiologists reviewed prior and diagnostic mammograms 
of all interval cancers. They determined breast density, described mammographic abnormalities 
and classified interval cancers as missed, showing a minimal sign abnormality or true negative.
Results: The referral rate and cancer detection rate at SFM were 1.5% and 4.9‰ respectively, 
compared to 3.0% (p<0.001) and 6.6‰ (p<0.001) at FFDM. Screening sensitivity was 74.1% at 
SFM (297/401, 95%CI=69.8%-78.4%) and 77.5% at FFDM (427/551, 95%CI=74.0%-81.0%). 
Significantly more interval cancers were true negative at prior FFDM than at prior SFM screening 
mammography (65.3% (81/124) versus 47.1% (49/104), p=0.02). For interval cancers following 
SFM or FFDM screening mammography, no significant differences were observed in breast den-
sity or mammographic abnormalities at the prior screen, tumour size, lymph node status, recep-
tor status, Nottingham tumour grade or surgical treatment (mastectomy versus breast conserving 
therapy).
Conclusion: FFDM resulted in a significantly higher cancer detection rate, but sensitivity was 
similar for SFM and FFDM. Interval cancers are more likely to be true negative at prior FFDM than 
at prior SFM screening mammography, whereas their tumour characteristics and type of surgical 
treatment are comparable. 
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Introduction
Full-field digital mammography (FFDM) has gradually replaced screen-film mammography (SFM) 
in most Western screening mammography programs. Several studies have shown an increased 
cancer detection rate at FFDM, in combination with higher referral rates and decreased positive 
predictive values of referral1-3. Because of the higher cancer detection rate at digital mammo-
graphy, a decline in interval cancer rate may be expected. Interval cancers are breast cancers 
that are diagnosed in women after a screening examination yields negative results, defined as 
no recommendation for referral, and before any subsequent screen is performed. Furthermore, 
interval cancers show less favourable pathologic characteristics and a worse prognosis compared 
to screen-detected cancers4-9.
Previous analogue screening mammography studies have shown that up to half of interval can-
cers may be true negative at review of prior mammograms10-12. Moreover, a significant portion 
of advanced interval cancers at SFM screening cannot be prevented through earlier detection at 
screening13. There is, however, very limited data about interval cancers diagnosed after digital 
screening mammography and it is not yet clear whether the interval cancers found at screen-
film mammography are similar to interval cancers found at digital mammography screening. 
A recent Norwegian study on interval cancers diagnosed after screen-film or digital screening 
mammography did not find a decline in the interval cancer rate at digital screening and the mam-
mographic features of missed cancers at digital screening were comparable to those missed at 
screen-film mammography screening14. 
To our knowledge, no data have been published on interval cancers at SFM an FFDM screening 
mammography in terms of their tumour biology and surgical treatment. In the current study we 
therefore not only compared the screening sensitivity and mammographic features of interval 
cancers at screen-film mammography and digital screening mammography, but we also deter-
mined tumour biology characteristics, including receptor status and tumour histology grade, and 
the type of surgical treatment (i.e., breast conserving surgery or mastectomy) of these interval 
cancers.
Methods
Study population
We included a consecutive series of 60,770 screen-film screened women (6,851 initial screens 
and 53,919 subsequent screens) and 63,182 digitally screened women (7,019 initial screens and 
56,163 subsequent screens). They were screened at three specialized screening units in a sou-
thern screening mammography region of the Netherlands (BOZ, Bevolkings Onderzoek Zuid) 
between January 1, 2008 and January 1, 2011. Of the 56,163 women with a subsequent digital 
screen, 29,649 were also included in the cohort of screen-film screened women. 
Impact of digital screening mammography on interval cancer
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Screen-film mammography was replaced by full field digital mammography on respectively May 
26, 2009, June 3, 2009 and April 6, 2010 at the three units. All women had given written infor-
med consent to use their screening and follow-up data for evaluation purposes. The Central Com-
mittee on Research Involving Human Subjects (CCMO) in The Hague, The Netherlands, waived 
ethical approval for this study.
Screening procedure and referral
Details of our breast cancer-screening program, offering biennial screening mammography for 
women aged 50-75 years, have been described previously15,16. In brief, screen-film mammo-
grams were obtained with commercially available units (Performa, Oldelft, Tuusula, Finland). 
Dedicated mammography screens were utilized (Mamoray MR-R, Agfa, Schroenhausen, Ger-
many).	Both	dedicated	film	(Mamoray	HDR;	Agfa,	Mortsel,	Belgium),	as	well	as	extended-cycle	
dedicated processing was used. All digital mammograms were acquired with a Lorad Selenia 
FFDM system (Hologic Inc, Danbury, CT), with a 70 µm pixel size and a 232x286 mm field of 
view. All mammograms were obtained by specialized screening mammography technologists 
and double read by a team consisting of eleven certified screening radiologists. Prior screening 
mammograms were always available for comparison at the time of subsequent screening. To 
facilitate softcopy reading of subsequent screening examinations at FFDM, the most recent prior 
screen-film screening mammograms were digitized by using a film scanner and archiver designed 
for	mammography	(DigitalNow;	R2/Hologic).	The	original	hard	copy	screen	film	mammograms	
were also available for viewing if desired by the screening radiologist. Women with normal 
or benign mammographic findings, or with a non-specific minimal sign17, were not referred. If 
screening mammography showed a suspicious or malignant lesion, the woman was referred to 
a surgical oncologist or breast clinic for further analysis of the mammographic abnormality.  For 
each referral, the screening radiologists classified the abnormal mammographic findings accor-
ding to one of five categories: suspicious mass (e.g., spiculated density or density with indistinct 
borders), suspicious microcalcifications (e.g., pleomorphic, branching, or amorphous/indistinct 
microcalcifications), mass in combination with microcalcifications, architectural distortion, or 
asymmetry. Women with discrepant readings at screening mammography (only one of the two 
screening radiologists considered referral necessary) were always referred for further analysis.
Diagnostic workup
A total of 15 regional and university hospitals were involved in the assessment of screen posi-
tive women. After physical examination by the surgeon, additional mammographic views were 
obtained if necessary. At diagnostic work-up, radiologists classified the radiological findings ac-
cording to the American College of Radiology BI-RADS18. BI-RADS 4 and BI-RADS 5 lesions 
were routinely biopsied, whereas BI-RADS 3 lesions were either biopsied of followed-up with 
mammography. Dependent on the findings at physical examination and mammography, further 
diagnostic evaluation could include breast ultrasonography, Magnetic Resonance Mammograp-
hy, percutaneous fine needle aspiration cytology, core biopsy or open surgical biopsy. 
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Follow-up
During two-year follow-up, we collected data on diagnostic imaging procedures, biopsy speci-
men and surgical procedures of all referred women and of interval breast cancers. Interval can-
cers were defined as breast cancers diagnosed in women after a screening examination yielded 
negative results (defined as no recommendation for referral) and before a subsequent biennial 
screen was performed. Procedures for the detection of interval cancers have been described 
previously19.	Breast	 cancers	were	divided	 into	ductal	 carcinoma	 in-situ	 and	 invasive	 cancers;	
lobular carcinoma in-situ was considered to be a benign lesion. Advanced cancers were defined 
as invasive cancers with Tumour-Node-Metastases (TNM) stage IIA or higher, i.e. tumour size 
exceeding 20 mm (T2) and/or presence of lymphatic metastasis in the sentinel node or axillary 
lymph nodes20. Sentinel nodes were classified negative if they harboured isolated tumour cells or 
sub-micrometastases (<0.2 mm) and were considered positive (N+) if they contained microme-
tastases (0.2-2 mm) or macrometastases (>2 mm). For women with bilateral disease, the cancer 
with	the	highest	stage	was	retained;	multiple	foci	of	cancer	in	one	breast	were	counted	as	one	
cancer.
Review of interval cancers
Two experienced screening radiologists (LD, FJ) reviewed the latest screening mammogram of 
each woman with an interval cancer, as well as the clinical mammogram obtained at the time of 
interval cancer detection. They categorized mammographic breast density according to the Ame-
rican College of Radiology18 and the interval cancers were classified as missed, minimal sign17 
or true negative at the previous screen according to the European guidelines21. Finally, in case of 
missed or minimal sign interval cancers, the reviewers classified the mammographic abnormality 
at the prior screening examination into one of the following categories: mass, microcalcifications, 
mass in association with microcalcifications, asymmetry, architectural distortion, or other18. The 
two radiologists were blinded to each other’s review and performed a consensus reading in case 
of discrepant findings.
Statistical analysis
All	data	were	entered	into	a	computerized	spreadsheet	(Excel;	Microsoft,	Redmond,	WA,	USA).	
The	analyses	were	conducted	by	using	statistical	software	(SPSS,	version	20	for	Windows;	SPSS,	
Chicago, Ill). The statistical differences in distributions were explored by using the χ² test or the 
Fisher exact test, when appropriate. A t-test for independent samples was used to compare the 
size of masses. All tests were two sided, and the significance level was set at 5%.
Impact of digital screening mammography on interval cancer
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Results
Overall screening results
The referral rate and overall cancer detection rate (number of cancers per 1,000 screened 
women) were significantly higher at FFDM (3.0% versus 1.5% (p<0.001) and 6.6 versus 4.9 
(p<0.001), respectively, Table 1). The cancer detection rate at initial screens was similar to the 
one	observed	at	subsequent	screens	(SFM:	4.7	versus	4.9,	p=0.8;	FFDM:	7.6	versus	6.6,	p=0.3).	
The positive predictive value of referral was significantly lower at FFDM (21.9% versus 31.6%, 
p<0.001). Although statistically different, the age distributions of both groups were almost similar 
when looking at the percentages in each age category. 
After SFM, 104 interval breast cancers were diagnosed, compared to 124 interval breast cancers 
following FFDM. The interval cancer rate per 1,000 screens was similar for SFM and FFDM, 
namely 1.7 versus 2.0 (p=0.3). Screening sensitivity was 74.1% at SFM (95% CI, 69.8-78.4) and 
77.5% at FFDM (95% CI, 74.0-81.0). Interval cancers showed comparable proportions of ductal 
carcinoma in-situ and invasive cancers at SFM and FFDM (respectively 6.7% (7/97) and 93.3% 
(90/97) versus 7.3% (9/124) and 92.7% (115/124), p=0.9). The proportions of interval breast 
cancers diagnosed within the first year after the latest screen were also similar at SFM and FFDM 
(36.8% (38/104) versus 35.5% (44/124), p=0.9).
Prior visibility and mammographic characteristics of interval cancers
At review, 47.1% (49/104) and 65.3% (81/124) of interval cancers were classified as occult (so-
called true interval cancers) at the prior screen-film or digital screening mammogram, respec-
tively. The percentages of missed interval breast cancer and interval breast cancer presenting 
as a minimal sign on the latest screen were 30.8% (32/104) and 22.1% (23/104) at screen-film 
mammography screening, and 20.2% (25/124) and 14.5% (18/124) at digital screening (p=0.02, 
Table 1).
A majority of the missed interval breast cancers and interval breast cancers characterized by a 
minimal sign lesion at the prior screen presented as a mass, both at SFM and FFDM (Table 2). 
Size distribution, average tumour size and distribution of breast density at the prior screening 
mammograms of interval cancers (whether missed, true negative or showing a minimal sign at re-
view) were comparable for SFM and FFDM (Table 2). Also the average size of all invasive interval 
cancers was similar for SFM and FFDM, 23.7 millimetre (range 1-100) and 27.0 millimetre (range 
2-90), respectively (p=0.2).
Tumour stage and tumour biology characteristics of interval cancers
Table 3 summarizes the tumour stage and tumour biology characteristics of interval breast can-
cers at SFM and FFDM. At both screening cohorts, a minority of interval cancers was ductal 
carcinoma in-situ and these cancers showed comparable grade distributions. A majority of the 
invasive interval breast cancers were of the ductal type, respectively 74.2% (72/97) at SFM and 
77.4% (89/115) at FFDM (p=0.49). Tumour stage (T1a-c versus T2+), lymph node status and the 
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proportion of advanced cancers were also comparable for interval cancers following SFM or 
FFDM screening mammography. We neither observed significant differences in the grading of 
invasive cancers (Nottingham grade I-III) or receptor status.
Type of breast cancer surgery
Compared to SFM screened women, a significantly higher proportion of FFDM screened women 
underwent breast conserving surgical treatment of their screen-detected cancer (82.9% versus 
75.1%, P = 0.04, Table 1). The number of women treated with breast conserving surgery was 3.7 
per 1,000-screened women at SFM and 5.5 per 1,000 women at FFDM (P = 0.04). A similar mas-
tectomy rate of 1.1 per 1,000 screened women was observed at SFM and FFDM. A majority of 
interval cancer cases were also treated by breast conserving surgery and we found no significant 
differences in surgical treatment of interval breast cancer in both screening cohorts (p=0.18).
Impact of digital screening mammography on interval cancer
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Screen-film mammography
  Fraction Rate (‰)
Mammograms, No 60,770
Referral, No 941 1.5%
    Positive predictive value of referral, % 31.6
Sensitivity,% (95% CI) 74.1% (69.8‐78.4%)
Breast cancers detected, No 297 4.9
    Ductal carcinoma in‐situ, No 44 14.8% 0.7
    Invasive carcinoma, No 253 85.2% 4.2
Interval cancers detected, No 104 1.7
     Ductal carcinoma in‐situ, No 7 6.7% 0.1
    Invasive carcinoma, No 97 93.3% 1.6
Prior visibility of interval cancers
    Missed, No 32 30.8% 0.5
    Minimal Sign, No 23 22.1% 0.4
    Occult, No 49 47.1% 0.8
Interval between screen and interval breast cancer
    ≤1 year, No 38 36.5% 0.6
    >1 year, No 66 63.5% 1.1
Type of surgery
  Screen detected cancer
    Breast conserving treatment, No 223 75.1% 3.7
    Mastectomy, No 69 23.2% 1.1
    None, No 5 1.7% 0.1
  Interval cancer
    Breast conserving treatment, No 67 64.4% 1.1
    Mastectomy, No 37 35.6% 0.6
    None, No 0 0.0% 0.0
Table 1. Overall screening results
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Digital mammography
  Fraction Rate (‰) p‐value
Mammograms, No 63,182
Referral, No 1.919 3.0% < 0.0001
    Positive predictive value of referral, % 22.3 < 0.0001
Sensitivity,% (95% CI) 77.5% (74.0‐81.0%) 0.2
Breast cancers detected, No 427 6.8 < 0.0001
    Ductal carcinoma in‐situ, No 100 23.8% 1.6 0.03
    Invasive carcinoma, No 320 76.2% 5.1
Interval cancers detected, No 124 2.0 0.3
     Ductal carcinoma in‐situ, No 9 7.3% 0.1 0.9
    Invasive carcinoma, No 114 91.9% 1.9
Prior visibility of interval cancers
    Missed, No 25 20.2% 0.4 0.02
    Minimal Sign, No 18 14.5% 0.3
    Occult, No 81 65.3% 1.3
Interval between screen and interval breast cancer 0.9
    ≤1 year, No 44 35.5% 0.7
    >1 year, No 80 64.5% 1.3
Type of surgery
  Screen detected cancer
    Breast conserving treatment, No 348 82.9% 5.5 0.04
    Mastectomy, No 68 16.2% 1.1
    None, No 4 1.0% 0.1
  Interval cancer
    Breast conserving treatment, No 78 62.9% 1.3 0.18
    Mastectomy, No 42 33.9% 0.7
    None, No 4 3.2% 0.1
Table 1. Overall screening results (continued)
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Screen-film 
mammography
Digital 
mammography
No.
Fraction 
(%)  No.
Fraction 
(%)  
p 
value
Missed interval cancer
  Mammographic abnormality
      Mass 21 65.6 15 60.0 0.78
      Clustered microcalcifications 1 3.1 2 8.0 0.58
      Mass and clustered micocalcifications 1 3.1 1 4.0 1
      Asymmetry 3 9.4 4 16.0 0.69
      Architectural distortion 5 15.6 3 12.0 1
      Other 1 3.1 0 0.0 1
  Size
    Ductal carcinoma in‐situ 1 3.1 2 8.0 0.4
    T1a‐b 3 9.4 2 8.0 0.9
    T1c 10 31.3 6 24.0 0.6
    T2+ 18 56.3 14 56.0 1
    Tx 0 0.0 1 4.0 0.3
    Size in mm (range) 27.6 (5‐100) 32.2 (7‐90) 0.58
  Breast density 0.8
    ACR I & II 18 56.3 13 52.0
    ACR III & IV 14 43.8  12 48.0   
Table 2. Mammographic features of interval breast cancer
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Screen-film 
mammography
Digital 
mammography
No.
Fraction 
(%)  No.
Fraction 
(%)  
p 
value
Interval breast cancer showing a minimal sign        
  Mammographic abnormality
      Mass 14 60.9 9 50.0 0.54
      Clustered microcalcifications 4 17.4 1 5.6 0.36
      Mass and clustered micocalcifications 0 0.0 1 5.6 0.44
      Asymmetry 0 0.0 2 11.1 0.19
      Architectural distortion 2 8.7 5 27.8 0.21
      Other 3 13.0 0 0.0 0.24
  Size
    Ductal carcinoma in‐situ 1 4.3 3 16.7 0.2
    T1a‐b 2 8.7 0 0.0 0.2
    T1c 6 26.1 6 33.3 0.6
    T2+ 14 60.9 9 50.0 0.5
    Tx 0 0.0 0 0.0 ‐
    Size in mm (range) 26.6 (1‐60) 30.2 (7‐80) 0.51
  Breast density 0.3
    ACR I & II 14 60.9 14 77.8
    ACR III & IV 9 39.1  4 22.2   
Occult interval breast cancer        
  Size
    Ductal carcinoma in‐situ 5 10.2 4 4.9 0.25
    T1a‐b 9 18.4 10 12.3 0.35
    T1c 14 28.6 28 34.6 0.48
    T2+ 21 42.9 38 46.9 0.65
    Tx 0 0.0 1 1.2 0.44
    Size in mm (range) 19.1 (2‐42) 24.6 (2‐80) 0.06
  Breast density 0.36
    ACR I & II 25 51.0 48 59.3
    ACR III & IV 24 49.0  33 40.7   
ACR = American college of radiology
Table 2. Mammographic features of interval breast cancer (continued)
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Screen-film mammography Digital mammography
 No. Fraction, % Rate (‰)± No. Fraction, % Rate (‰)± p‐value
Ductal carcinoma in-situ
 Grade 0.66
      Low grade 2 28.6 0.03 3 33.3 0.05
      Intermediate grade 3 42.9 0.05 2 22.2 0.03
      High grade 2 28.6 0.03 4 44.4 0.06
Invasive Carcinoma
  Type 0.49
      Ductal 72 74.2 1.2 89 77.4 1.4
      Lobular 16 16.5 0.3 17 14.8 0.3
      Mixed ductal/lobular 7 7.2 0.1 4 3.5 0.1
      Other 2 2.1 0.03 5 4.3 0.08
  Stage 0.43
      T1a‐c 44 45.4 0.7 52 45.2 0.8
      T2+ 53 54.6 0.9 61 53.0 1.0
      Unknown 0 0.0 0.0 2 1.7 0.0
  Lymph node status 0.42
      N+ 44 45.4 0.7 50 43.5 0.8
      N0 52 53.6 0.9 63 54.8 1.0
      Nx 1 1.0 0.02 2 1.7 0.03
  Advanced carcinoma 0.73
      Advanced 67 69.1 1.1 74 64.3 1.2
      Non‐advanced 29 29.9 0.5 39 33.9 0.6
      Unknown 1 1.0 0.02 2 1.7 0.03
Table 3. Tumor characteristics of interval breast cancer
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Screen-film mammography Digital mammography
 No. Fraction, % Rate (‰)± No. Fraction, % Rate (‰)± p‐value
      Nottingham I 34 35.1 0.6 31 27.0 0.5
      Nottingham II 42 43.3 0.7 63 54.8 1.0
      Nottingham III 20 20.6 0.3 18 15.7 0.3
      Unknown 1 1.0 0.02 3 2.6 0.05
  Estrogen receptor 0.87
      Positive 75 77.3 1.2 90 78.3 1.4
      Negative 22 22.7 0.4 25 21.7 0.4
  Progesterone receptor 0.24
      Positive 60 61.9 1.0 62 53.9 1.0
      Negative 37 38.1 0.6 53 46.1 0.8
  Her2/Neu receptor 0.79
      Positive 13 13.4 0.2 14 12.2 0.2
      Negative 84 86.6 1.4 101 87.8 1.6
      Triple receptor- negative 15 15.5 0.2 20 17.4 0.3 0.71
*Invasive cancers with Tumor-Node-Metastases (TNM) stage IIA or higher. i.e. tumor size exceeding 20 mm (T2) 
and/or presence of lymphatic metastasis in the sentinel node or axillary lymph nodes. 
± Per 1,000 screened women.
Impact of digital screening mammography on interval cancer
Table 3. Tumor characteristics of interval breast cancer (continued)
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Discussion
We found that the interval breast cancer rate and sensitivity was comparable for SFM and FFDM 
screening mammography, despite a significantly higher cancer detection rate at FFDM. A signifi-
cantly larger proportion of interval breast cancers was not visible on prior screens at FFDM than 
at SFM, whereas mammographic characteristics, tumour stage, tumour biology and surgical tre-
atment were similar for interval cancers diagnosed after SFM or FFDM screening mammography. 
In line with our results, the only previous study reporting on interval breast cancer at digital 
screening also found a similar screening sensitivity and interval breast cancer rate at SFM and 
FFDM14. Previous studies have reported increased cancer detection rates at FFDM screening 
mammography in the Netherlands22, Norway23 and Ireland24, whereas SFM and FFDM showed 
similar detection rates in a UK study and Spanish study25,26. US studies found comparable overall 
detection rates for both modalities, with a higher diagnostic accuracy for FFDM in younger wo-
men, women with dense breasts and premenopausal women2,27,28. In our preceding study1, we 
provided a thorough overview of the impact of transition of SFM to FFDM on screening outcome 
as well as on diagnostic workup and surgical treatment. This transition resulted in a significantly 
increased referral rate and detection rate of ductal carcinoma in-situ and invasive cancers, in 
combination with a significantly decreased positive predictive value of referral and biopsy and an 
almost fourfold increase in the use of stereotactic core needle biopsy. Invasive cancers at FFDM 
were more likely to be diagnosed at an earlier tumour stage, showed a more favourable tumour 
grade and comprised a significantly larger proportion of progesterone-receptor positive cancers. 
Unfortunately, the higher cancer detection rate at FFDM in our study neither improved screening 
sensitivity nor decreased the interval breast cancer rate. This inevitably leads to the discussion of 
so called over-diagnosis, i.e. diagnosis of breast cancers that, if left undiscovered, would never 
become clinically evident and, thus, would never become lethal. Over-diagnosis is more pro-
found at FFDM than at SFM screening mammography, mainly because of the higher detection 
rate of ductal carcinoma in-situ at digital screening1,29. However, as our study only comprised 
the first digital screening round, the results of future digital screening rounds are necessary to 
determine the long-term effects of digital screening mammography on cancer detection rate, 
sensitivity and the true extent of over-diagnosis. Another Dutch study found a decrease in referral 
rates at subsequent screening rounds and stabilization of the referral rate at a higher level than 
in conventional screening, yet with significantly enhanced cancer detection30. Based on these 
findings we do not expect to see any difference in interval cancer rate, as these rates are stable 
despite of the higher cancer detection rate.
Our observation of an unchanged proportion of ductal carcinoma in-situ among interval cancers, 
accompanied with an improved detection of these early cancers at FFDM, is in line with the 
results of a recent Norwegian study14. We also found that the proportion of interval cancers, di-
agnosed either within the first or second year after a negative screening examination, was similar 
for SFM and FFDM and, to our knowledge, we are the first to report on this issue. 
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Our proportions of missed, minimal sign and true negative interval breast cancers at SFM were 
comparable to those published in other studies on SFM screening13,31,32. A significantly higher 
proportion of interval breast cancers was not visible at the previous FFDM screen than at the 
previous SFM screen and the average tumour size of missed interval cancers was comparable 
for both groups. On the other hand, in a smaller series of 49 and 81 interval cancers diagnosed 
after respectively FFDM and SFM screening mammography, Hoff et al. observed equal propor-
tions of missed cancers at SFM and FFDM screening mammography and a smaller tumour size 
for cancers missed at digital FFDM screening14. These differences in outcome may be partly ex-
plained by differences in study population, reading strategy and screening outcome parameters 
(including lower referral rates and higher positive predictive value of referral). Moreover, women 
were included only once in the SFM or FFDM group in our series, whereas they may have been 
included several times in each group reported by Hoff et al. 
We recently reported that the conversion from SFM to FFDM screening mammography signifi-
cantly increased the detection of low to intermediate grade DCIS and the detection of smaller 
invasive tumours with more favourable tumour biology characteristics1. In the current study, no 
significant differences in tumour size, lymph node status, proportion of advanced cancers, tu-
mour grade or hormone receptor status were found between interval breast cancers diagnosed 
after SFM or FFDM screening mammography. Invasive tumour size was comparable for both SFM 
and FFDM, but the average tumour size of invasive cancers was approximately twice the size re-
ported by Hoff et al. This difference can probably be explained by different methods of measure-
ment. We measured tumour size on the surgical specimen, whereas Hoff et al. measured tumour 
size on imaging. It is known imaging can be imprecise in measuring tumour size, especially in 
dens breasts33. In contrast to an increased proportion of women treated with breast conserving 
surgery for their cancer detected at digital screening mammography, the surgical management of 
interval breast cancer was comparable for SFM and FFDM. Similar to screen-detected cancers, 
FFDM did not result in an altered mastectomy rate for interval breast cancer.
Our study has certain strengths and limitations. The current study is the second and the largest 
reporting on interval breast cancer at digital screening mammography. Moreover, we did not 
limit our analyses to mammographic characteristics of interval cancers and their tumour size, but 
we also provided insight in tumour biology and surgical management of interval breast cancers. 
Analysis of subsequent digital screening rounds is mandatory to fully understand the long-term 
impact of digital mammography on screening outcome. Another limitation lies in the fact that 
the Dutch screening program may differ from programs offered in other countries34. The Dutch 
nation-wide breast cancer screening program offers free biennial screening to women aged 50-
75 years, screening examinations are standardly double read by two screening radiologists and 
it is characterized by relatively low referral rates and a high positive predictive value of referral. 
Furthermore, in contrast to Hoff et al14, we were not able to review screen-detected cancers 
Impact of digital screening mammography on interval cancer
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for visibility on prior digital screens, as our digitally screened study population only comprised 
women who had undergone their first round of FFDM screening mammography.  Also, compara-
bility of the two groups is very important as slight changes in age distribution can lead to marked 
changes in cancer incidence, interval cancer rate and biology. Although statistically different, the 
age distributions of both groups were almost similar when looking at the percentages in each age 
category. It is very unlikely that these small differences will have affected the results. Finally, an 
increase in population breast cancer incidence could contribute to the higher cancer detection 
rate. According to the data of the Netherlands Cancer Registry35, breast cancer incidence in 
unscreened age groups did not change significantly in the 3-year period covered by the study, 
Incidence rates per 100,000 women were 45 in 2008, 41 in 2009 and 44 in 2010 for women 
aged 30-44 years and 166, 167 and 171 respectively for those aged 75 years or older. It is thus 
very unlikely that the background incidence will have increased for the screened age group of 
50-75 years during these three years.
In summary, FFDM screening mammography resulted in a significantly higher cancer detection 
rate, but a similar interval cancer rate and sensitivity when compared to SFM screening mam-
mography. Interval breast cancers are more frequently true negative at a prior digital screening 
mammogram, but show comparable mammographic abnormalities if visible at prior screening. 
Tumour stage, tumour biology and surgical treatment of interval cancers are similar in women 
screened with SFM or FFDM. 
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General discussion 
The first randomized trials on breast cancer screening were conducted in the 1960s and 1970s 
and took place in the United States, Canada, Sweden and the United Kingdom. The results have 
been summarized in a recently updated Cochrane review1. In this review of 8 trials, only the 
Malmo Trial, the UK age trial, and the Canadian trial were considered adequately randomized 
and not biased. The early results of these trials, published in the 1980s, were mostly promising 
and have been the basis to the global introduction of breast cancer screening in industrialized 
countries2. Since the introduction there has been debate about the effectiveness and in the 
late nineties, the first studies were published that questioned the effectiveness and focused on 
the side effects of breast cancer screening3,4. These studies provoked a fierce debate between 
those in favour of screening and those opposed. Some opponents of breast cancer screening 
state screening is obsolete because the lower mortality can mainly be contributed to improved 
systemic	treatment;	especially	since	interval	cancer	rate	remains	stable.	This	debate	is	still	far	
from over and both parties are to some extent right. The true effect of screening on breast can-
cer mortality remains uncertain and randomized controlled trials seem no longer feasible due 
to the worldwide implementation of screening. Because breast cancer screening has become 
so deeply rooted in society, stopping the programmes is not a realistic option anymore. The 
only sensible option is to optimize the effectiveness of the on-going screening programmes 
and to improve the diagnosis and treatment of breast cancer in all screened women. In this 
discussion these issues will be addressed, as well as the implications of the results of the studies 
described in this thesis for future research.
In recent years, the debate on breast cancer screening has become more and more polarized. 
In an attempt to end the discussion, an independent panel convened in the United Kingdom to 
reach conclusions about the benefits and harms of breast screening on the basis of a review of 
published work with both oral and written evidence presented by experts in the subject.  The 
panel was assembled by Professor Sir Michael Marmot and consisted of scientific experts who 
had not previously worked or published on the topic of breast cancer screening. Its conclusi-
ons were published in The Lancet in 20125. The panel estimated that screening had decreased 
breast cancer mortality by 20% in the United Kingdom, whereas overdiagnosis may be pre-
sent in about 11% of screen-detected cancers. Based on these findings, the panel concluded 
that breast cancer screening should be continued in the United Kingdom. In response to this 
overview, a multitude of letters to the editor was published, in which opponents of screening 
criticized the conclusions. On the other hand, some proponents stated that the panel had un-
derestimated the mortality reduction and overestimated the risk of overdiagnosis resulting from 
breast cancer screening6-15. These strongly opposing reactions again illustrate that the discus-
sion is far from over.
In addition to the previously mentioned panel, a committee of Dutch experts assessed the 
effectiveness of population screening for breast cancer in the Netherlands in response to a 
question by Minister of Health16. In their report, of January 2014, the committee concluded 
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that population screening for breast cancer is still worthwhile. They calculated a total of 775 
lives saved each year, at the cost of 8% overdiagnosed screen-detected cancers. Furthermore, 
they explored the potential benefits of tailor-made screening, in which the screening interval 
and the technique used are adjusted to the individual breast cancer risk of a woman, making 
screening more efficient. Just like the UK report, the Dutch report leaves room for discussion. 
Invasive carcinoma and ductal carcinoma in-situ have been considered together when des-
cribing the risk of overdiagnosis, whereas the risk is probably much more pronounced for the 
latter group. The absolute number of in-situ carcinomas in women aged 50-75 has increased 
six fold since 1989, from 252 to 1554 in 2011 (Figure 1a), while the absolute number of invasive 
carcinomas doubled in the same period, from 4,066 to 8,387 (Figure 1b)17. The introduction of 
digital mammography screening has led to a further increase in the detection of ductal carci-
noma in-situ and treatment involves mastectomy in 40 per cent of cases. 
The Swiss Medical Board of uninvolved professionals recently performed a review on screening 
mammography18. The Board advises against introduction of new population breast cancer 
screening and advises to gradually stop with existing breast cancer screening programmes 
Switzerland based on three primary considerations:
	 •	 results	of	outdated	clinical	trials	on	mammography	screening;
	 •	 benefits	of	screening	do	not	clearly	outweigh	the	harms;
	 •	 women’s	perceptions	of	screening	benefits	do	not	match	reality.
Non-surprisingly, the report provoked a fierce discussion. A main counterargument is the weig-
hed value of the very out-dated and inadequate Canadian trials on breast cancer screening19, 
which are under great debate due to questionable mammographic technology  applied in these 
studies. However, the argument that women’s perceptions of mammography benefits do not 
Figure 1a. Nation wide incidence of in-situ carcinoma in the Netherlands  Source: www.ikcnet.nl
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match reality seems to be a valid one which has also been stressed in another recent review20. 
It is important to optimize information given on the benefits and harms for women eligible for 
screening, in order to enable them to decide whether or not they should attend the screening 
programme. This thesis focuses more on the changing oncologic reality, with improved treat-
ment possibilities of both early and advanced breast cancer21,22.
As mentioned in the reports by the independent UK panel, the Dutch Health Council com-
mittee, and the Swiss Medical Board, each of the available studies has several methodological 
flaws.	To	provide	irrefutable	results,	complete	data	is	needed;	which	will	only	become	available	
during the process and long term follow-up. So due to the lack of any more randomized trials, 
prospective data collection is the sole basis of proving the value of mammography screening. 
Advanced breast cancer
Most breast cancer deaths occur in women who are diagnosed with breast cancer in an advan-
ced stage. Breast cancer screening aims to detect cancer before it has disseminated to lymph 
nodes or distant organs. Thus, for breast cancer screening to be effective it will have to lower 
the incidence of advanced breast cancer. If this assumption is true, the incidence of advanced 
breast cancer can be used to monitor the benefit of breast cancer screening23. Although the 
incidence of advanced breast cancer may also be affected by other determinants like changing 
age at first birth24.
Figure 1b. Nation wide incidence of invasive breast carcinoma in the Netherlands  Source: www.ikcnet.nl
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Recent trends
In Chapter 2 we found no decline in the incidence of advanced (T2+ and/or N+) breast cancer 
at screening mammography. The rates and proportions of advanced breast cancer remained 
stable over a 12-year time period (1997-2008). As most breast cancer deaths are due to advan-
ced disease, this finding raises the question about the effectiveness of screening. However, it is 
possible that without breast cancer screening the advanced cancer rate might have been even 
higher. This possibility is supported by the results of a Danish study, which shows an increase 
of the mammographic density of the breasts of women in more recent birth cohorts, which 
could have impaired the detection of smaller tumours. Furthermore, breast cancer incidence 
has increased significantly in the last decades, due to unfavourable changes in the exposure to 
risk factors. These risk factors include 
	 •	 Reproductive	history	
	 •	 Female	body	composition
	 •	 Nutritional	factors,	such	as	increased	alcohol	consumption24,25. 
Finally, the increased proportion of more aggressive tumours, as reflected by a higher mitotic 
activity index (MAI), might have had a negative effect on the incidence rates of advanced 
breast cancer26.
The stable advanced cancer rate in our study can be explained because of the exclusion of the 
first two years of screening, during which the rates of advanced cancer were higher. An Italian 
study showed a decrease in late-stage breast cancer from the third year of screening onward27. 
As our published data starts three years after the implementation of screening, this effect might 
be similar in our population. Another Dutch study, however, showed a decrease in advanced 
breast cancer incidence the first years after implementation of breast cancer screening, but this 
decrease was followed by a secular rise after five years28,29. Furthermore, as the composition 
of the group of screening radiologists showed only minor changes during the years and no 
significant changes in technology were made until the introduction of digital mammography 
screening in 2009, one can assume that a plateau phase was reached for the performance.
Prevention
In the study described in Chapter 2, two screening radiologists determined whether or not the 
advanced cancer had been visible at a prior screen, or whether the cancer was associated with 
so-called minimal sign at the previous screening round. Review showed that at least 59% of the 
screen-detected advanced cancers could not have been discovered earlier as the cancer had 
not been visible at the previous screen. The majority of the latter 41% that might have been 
discovered earlier was visible as a minimal sign (namely 62%, 191/307). These cases could 
theoretically have been detected earlier if these women had been referred, but adopting such a 
referral policy would have resulted in recall rates of approximately 10% and, consequently, in a 
dramatic decrease in the predictive value of a positive screening test30 and many more women 
experiencing unnecessary anxiety31. The remaining advanced cancers could have been detec-
ted at least one screening round before their actual diagnosis, this percentage (16%) is compa-
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rable to the percentage reported in other publications32,33. Despite quality control programmes 
and feedback of individual results to the screening radiologists, this rate did not decrease 
throughout the years. The percentage of missed advanced breast cancers shows that there is 
room left for improvement. Computer-aided detection might reduce the number of missed 
carcinomas in the future, but at present the computer cannot improve screening sensitivity 
without significantly lowering specificity and its contribution to routine screening remains a 
question of debate34-36. However, future improvements in computer software may improve the 
performance of CAD at screening mammography. Furthermore, digital breast tomosynthesis 
shows promising results37,38. Tomosynthesis is a three-dimensional reconstruction of the breast 
tissue, which can be viewed as slices through the breast. Recent studies have shown that the 
combination of conventional mammography and breast tomosynthesis decreases the referral 
rates, without lowering the cancer detection rate39-43. On the downside, one of the main dis-
advantages of breast tomosynthesis is the extra review time needed by screening radiologists44 
and higher radiation dose37. 
Furthermore, we observed that a prolonged screening interval was associated with a higher 
risk of advanced breast cancer. To reduce this risk factor, the importance of re-attendance 
should be emphasised and efforts should be made to convince women to re-attend within a 
few months of a missed screening round.
Interval cancer
As shown in Chapter 2 the majority of interval cancers are advanced carcinomas. This finding 
is in line with other studies on interval cancer32,33,45-51. The percentage of advanced cancers 
among women with interval breast cancer was almost twice as high as among women with 
screen-detected cancer and remained stable throughout our twelve-year screening period. 
The observation that the distribution of tumour stages of interval cancers was worse than those 
of screen-detected cancers is expected and also in line with previous reports33,45. Similar to 
advanced cancers detected at screening, half of the advanced interval cancers were mam-
mographically occult at the latest screening and a quarter had been missed, while the last half 
showed a minimal sign at the latest exam. Especially the 25% of missed interval carcinomas 
present a challenge for the screening radiologists, as these interval cancers could potentially 
have been avoided. The finding that a majority of both early stage and advanced interval can-
cers were diagnosed in the second year after the latest negative screen suggests that shortening 
of our screening interval may potentially lower the number of advanced interval cancers. Un-
derstandably, shortening the interval will compromise the cost-effectiveness of the screening 
programme and increase the risk of a false positive referral52.
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Trends in the management of referred women
Chapter 3 discusses the trends in the management of referred women. Several factors have in-
fluenced the diagnostic and therapeutic management of referred women throughout the years. 
The introduction of fine needle aspiration cytology and core-biopsy has led to a change in 
pre-surgical work-up. The implementation of breast-conserving treatment and neo-adjuvant 
chemotherapy, but also the growing awareness among patients about the available treatment 
options has led to changes in the surgical management.
Trends in biopsies
Different breast biopsy procedures may be used in the diagnostic work-up of referred women. 
The choice for a specific procedure is usually made by the radiologist and depends on various 
factors. Between 1997 and 2011, the use of surgical biopsies for diagnostic work-up of refer-
red women decreased from 37.8% to 1.4%. This dramatic decrease is probably due to the 
introduction of new national guidelines in 2000, which stated that at least 70% of women with 
breast cancer should have their cancer proven pre-operatively. In the revised guidelines, which 
were issued in 2008, this target was increased from 70% to 90%53. The decrease in the use 
of excisional biopsies is especially important for lesions that turn out to be benign, as recent 
studies have shown that benign surgery decreases future screening sensitivity54,55.
Half of the referred women underwent at least one biopsy procedure during diagnostic work-
up and this percentage has remained stable throughout the years. However, with increased 
referral rates at digital mammography screening, substantially more screened women will un-
dergo biopsies for lesions that turn out to be benign. In an attempt to lower the number of un-
necessary biopsies, Flowers et al. have suggested a higher threshold for biopsy, as well as the 
use of a six-month follow-up for low risk BI-RADS IV lesions56. This advice would contradict 
the current Dutch guidelines, stating that a BI-RADS III lesion could be biopsied rather than 
followed, at discretion of the attending radiologist57. This addition to the guideline58 is made 
because of the unnecessary anxiety a six-month follow-up might cause, although the difference 
in anxiety between the two regimes is disputed59.  The difference in impact on patient anxiety 
between early intervention with biopsy and regular follow-up visits needs to be investigated 
and weighed against the risk of higher mortality and morbidity from a longer delay in diagnosis. 
Trends in surgical treatment
Between 1997 and 2010 a doubling of the mastectomy rate was observed in the Eindhoven 
region among women with screen-detected cancer or interval cancer, whereas the breast con-
serving treatment rate and breast cancer incidence remained stable. Multivariate analysis sho-
wed that patients with micro-calcifications, larger tumours, lymph node metastasis and those 
treated in certain hospitals had an increased risk to undergo mastectomy. Similar variations 
between hospitals in the surgical treatment of screen-detected as well as clinically detected 
invasive and non-invasive breast cancers have been described in previous studies60-63.
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They show that not only treatment guidelines, but also surgeon and patient preferences play a 
major role in the decision-making process.
In Chapter 3.2 a decline in the risk of tumour-positive resection margins was noted, especially 
for patients with ductal carcinoma in-situ. The most important independent risk factors for 
tumour-positive resection margins of invasive cancers were
	 •	 Tumour	size	>20	mm,	
	 •	 Lobular	histology	
	 •	 Hospital	where	a	woman	was	treated	for	her	breast	cancer.	
Variations in the proportion of patients with tumour-positive margins of the surgical specimen 
among hospitals and individual surgeons have also been described in several other studies64,65. 
Feedback about performance to regional hospitals and surgeons treating referred women is 
important to improve treatment outcome.
Patients undergoing preoperative breast MRI had a lower risk of positive resection margins, but 
they also had a substantially increased risk to undergo mastectomy (Chapter 3.2). The role of 
breast MRI in the preoperative work-up is still controversial and various studies have produced 
conflicting results66-68. The lower risk of positive resection margins in women undergoing a pre-
operative MRI contradicts an earlier Dutch study in patients with non-palpable breast cancer, 
which showed a marked increase in positive resection margins after preoperative use of MRI66. 
This contradictory finding may at least be explained partially by smaller resection volumes 
following pre-operative MRI. Other studies did not find any difference in resection margins 
between patients with or without pre-operative MRI68-70. All these studies were completely or 
largely based on patients with symptomatic breast cancer. No studies are available on the use 
of MRI in women with breast cancer detected in a breast-screening programme. Analysis of 
the indications for the use of MRI in women with screen-detected breast cancer could lead to 
more clarity on the true risks and benefits of MRI in the pre-operative diagnostic trajectory of 
referred women.
Impact of digital mammography screening
Screening outcome
The introduction of digital mammography screening resulted in a significantly increased refer-
ral rate and detection rate of ductal carcinoma in-situ and invasive cancers, in combination 
with a significantly decreased positive predictive value of referral and biopsy and an almost 
fourfold increase in the use of stereotactic core needle biopsy. The negative effects of a lower 
positive predictive value of referral and biopsy (including patient anxiety and possible lower re-
attendance rates) have been addressed in Chapters 1 and 4, however the long-term effects of 
a lower positive predictive value on screening participation are not yet clear. Still, the positive 
predictive values of digital mammography screening in the Eindhoven region are well within 
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European standards and still high compared to other screening programmes71,72. 
The increased detection of ductal carcinoma in-situ at digital mammography intensifies the dis-
cussion on overdiagnosis and overtreatment. The current knowledge about the natural course 
of DCIS is still very limited and is largely based on autopsy studies and randomized studies on 
the effect of radiotherapy following local excision of DCIS. These trials show that radiotherapy 
reduces the risk of local relapse by a factor two and that about half of these relapses are inva-
sive disease73-76. However, the result of these trials, which were performed in the 1980’s and 
1990’s, do not necessarily reflect the behaviour of the many low-grade lesions found at breast 
cancer screening nowadays. Confronted with the growing numbers of patients with screen-
detected ductal carcinoma in-situ, many clinicians now believe that a randomized clinical trial 
is urgently needed for patients with low-risk DCIS, in which active monitoring and surgical 
intervention are compared with regard to the risk of invasive breast cancer and psychological 
sequelae of diagnosis and treatment77. Observational studies should be considered when these 
trials prove to be infeasible, also taking molecular and pathological characteristics into ac-
count. A recently published trial has listed 30 potential research topics on DCIS and identified 
the top 10 future research priorities, which include the 
 – validation of risk-stratification, 
 – comparison of treatment and follow-up strategies 
 – the assessment of the effect of DCIS management strategies on rates of invasive cancer78. 
A possibility to maximize public support of such trials is to eliminate the term ‘carcinoma’ from 
entities that cannot metastasize, in order to reduce confusion among patients and doctors79.
In Chapter 4.1 it was shown that invasive cancers at digital mammography screening were 
more likely to be diagnosed at an earlier tumour stage and had a more favourable grade. These 
findings might point at a greater portion of over-diagnosed cancers at digital screening when 
compared to screen film screening. Both a Norwegian and a Swedish study raised the possibi-
lity that the natural course of some screen-detected invasive breast cancers is to spontaneously 
regress80,81. In these studies, a higher incidence of breast cancer was found in the screened 
population. This finding leads to the hypothesis that many invasive breast cancers detected by 
screening mammography would not have persisted to be detected after 6 years of screening, 
suggesting that the natural course of many of the screen-detected cancers is to spontaneously 
regress. The authors of these studies suggest that a watchful waiting regime might not only be 
considered for patients with low grade DCIS but also for patients with small invasive cancers82.
Despite the higher cancer detection rate at digital mammography, Chapter 4.2 described an 
equal interval breast cancer rate and sensitivity for screen-film mammography and digital 
mammography screening. Because of its recent introduction, only limited data is available 
on interval cancers in women undergoing digital mammography screening, and thus the ef-
fects of digital mammography on screening sensitivity are not yet clear. An overview of digital 
mammography screening outcome in different countries is shown in Table 1, which shows a 
summary of studies comparing screen-film and digital mammography screening outcome that 
include interval cancer data83-91.
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First Author Lewin Skaane Skaane Pisano Juel Kerlikowske Hoff Nederend
Year of publication 2001 2003 2004 2005 2009 2011 2012 2013
Country USA Norway Norway USA Norway USA Norway Netherlands
Age group
>40 
years
50‐69 50‐69
>45 
years
50‐69 40‐79 50‐69 50‐75
Follow up 1 year 1 year 2 years 1 year 1 year 1 year 2 years 2 years
SF
M
Women screened, No 4945 3683 9903 42760 7442 638252 55435 60770
Women reffered, No 685 128 229 3765 174 63463 1402 941
Referral rate, No 13.9% 3.5% 2.3% 8.8% 2.3% 9.3% 2.5% 1.5%
SD, No 22 28 50 174 29 ‐* 258 297
CDR, ‰ 4.4 7.6 5.0 4.1 3.9 4.5 4.7 4.9
IC, No 17 13 30 161 12 ‐* 126 104
ICR, ‰ 3.4 3.5 3.0 3.8 1.6 0.8 2.3 1.7
Cancer incidence, ‰ 7.9 11.1 8.1 7.8 5.5 4.6 6.9 6.6
Sensitivity 56.4% 68.3% 62.5% 51.9% 70.7% 81.9% 67.2% 74.1%
Specificity 86.5% 97.3% 98.2% 91.6% 98.0% 91.0% 97.9% 98.9%
PPV of referral 3.2% 21.9% 21.8% 4.6% 16.7% 4.0% 18.4% 31.6%
FF
DM
Women screened, No 4945 3683 4009 42760 6932 231034 37977 63182
Women reffered, No 568 128 173 3648 168 26833 1312 1919
Referral rate 11.5% 3.5% 4.3% 8.5% 2.4% 10.0% 3.5% 3.0%
SD, No 21 23 32 185 33 ‐* 257 427
CDR, ‰ 4.2 6.2 8.0 4.3 4.8 3.8 6.8 6.8
IC, No 18 18 10 150 7 ‐* 92 124
ICR, ‰ 3.6 4.9 2.5 3.5 1.0 0.7 2.4 2.0
Cancer incidence, ‰ 7.9 11.1 10.5 7.8 5.8 4.6 9.2 8.7
Sensitivity 53.8% 56.1% 76.2% 55.2% 82.5% 84.0% 73.6% 77.5%
Specificity 88.9% 97.1% 96.5% 91.9% 98.0% 90.4% 97.2% 97.6%
PPV of referral 3.7% 18.0% 18.5% 5.1% 19.6% 3.8% 19.6% 22.3%
      * not mentioned in the publication
Table 1. Main results of the studies evaluating SFM and FFDM and reporting on sensitivity
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All studies only include one screening round of follow-up. Several more screening rounds are 
needed before the true effect of digital mammography on interval cancer rate and mortality 
would become apparent.
The study in Chapter 4.2 is the second report on interval cancers at digital mammography 
screening. A significantly higher proportion of interval breast cancers were not visible at pre 
digital mammography screens compared to screen-film mammography. Further monitoring of 
subsequent screening rounds is needed to determine whether interval cancer detected at digi-
tal mammography really exhibits different prior visibility than those diagnosed after screen-film 
mammography.
How to proceed with breast cancer screening?
With more knowledge about the potential harms of breast cancer screening a different strategy 
for breast cancer screening should be considered. Perhaps a personalized risk-based approach 
could optimize the effectiveness of breast cancer screening and reduce the risk of overdiagno-
sis, as is currently investigated by a Dutch study: “Breast cancer screening - from one-size-fits-
all to a personalised risk-based approach92”. 
This thesis shows the majority of interval cancers present in the second year after screening. A 
shortening of the screening interval for women at higher risk (i.e. high breast density, younger 
age) can possibly lower (advanced) interval cancer rate and improve mortality93,94. 
The amount of data available in Eindhoven region to evaluate the quality and the outcome of 
the screening programme is significantly higher than in other regions in the Netherlands but 
incomplete data impedes the proper evaluation of the screening programme. For a proper 
evaluation not only information on the screening process is needed but also on diagnostic 
procedures and treatment of women referred after a positive screening test. Also, more effort 
should be put in to the identification of the determinants of interval cancers to reduce their risk 
and improve the prognosis of this particular group of patients.
Quality control and extended data collection
This thesis stresses the need for quality control programs, both for the breast cancer screening 
programme and for the hospitals involved in the work-up and treatment of referred women. 
In the Netherlands, every regional screening group is visited once every three years and both 
the rates of cancer detection and interval cancer are evaluated, including the percentage of 
‘missed’ interval and ≥T2 cancers. Furthermore, interval cancers are reviewed on a regular 
basis with the complete group of screening radiologists and they receive a review of screening 
performance at an individual level twice a year. Also, strict rules apply for screening radiolo-
gists with respect to extra training and CME-credits in breast radiology. Despite these efforts, a 
substantial proportion of interval cancers and screen-detected were missed. Even though the 
proportion of missed cancers in the Eindhoven region remained well within acceptable limits 
set in the national guidelines, improvements can still be made95. It has well been documented 
that screening results significantly vary among screening radiologists96,97 and continuous efforts 
should be made to improve the performance of individual screening radiologists. 
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The digital era provides more opportunities for quality control, as more data is now digitalized 
and therefore easily accessible for analysis. Also, the linkage of different registries, hospitals 
and administrations offers many possibilities for quality improvement. However, in practice, 
making such linkages between registries appears to be harder than it looks, as proven by the 
lack of data on interval cancers in many countries, including the Netherlands98. Individual trai-
ning programmes, focusing on personal weak spots in cancer detection and referral behaviour 
can improve the performance of screening radiologists99,100.
A more user friendly individualized feedback system might be more effective, as much can be 
learned from errors101. The current software used in the breast cancer screening programme 
unfortunately does not provide a tailored quality control system, as there are very few possibi-
lities for a radiologist to review his or her referrals or interval cancers. This review can only be 
done in a very time-consuming way, as the screening patient database does not contain any 
information on follow-up, pathological results and does not contain the clinical mammogram 
in case of an interval carcinoma. This time-consuming review method raises the threshold 
to actively learn from ones mistakes and/or experience. Ideally, the software would have the 
possibility to automatically reproduce work-lists, which include information about screening 
outcome. To facilitate such an extensive patient record, extended data collection is mandatory. 
Currently the following data are routinely collected by the regional  screening organizations: 
	 •	 Number	of	invitations
	 •	 Number	of	screening	rounds
	 •	 Non-participants
	 •	 Non-responders
	 •	 Referrals
	 •	 False-positive	referrals
	 •	 Work-up	(invasive	or	non-invasive)
	 •	 Tumour	histology	and	stage
	 •	 Client	reactions.	
The	main	 objective	 of	 this	 extra	 data	 collection	must	 be	 the	 screened	woman;	 she	 should	
benefit most of the collected data, ideally with improved survival and as little overdiagnosis 
as possible. For quality control and scientific purposes we suggest the collection of more pa-
rameters, as shown in table 2. Improvements in screening on a basis of more efficient quality 
control can be achieved with relevant research questions, which can be answered using this 
extended data collection. Also, developing and testing a tailor-made screening design would 
become a lot easier with extended data available in the screening patient database. However, 
the complexity, multi-disciplinarity and pitfalls of creating, using and updating such an exten-
sive database should not be underestimated i.e. becoming a victim of big data. Ultimately, the 
wellbeing of the screened woman is at stake.
Finally, we found substantial differences among hospitals with respect to the workup and treat-
ment of referred women. Regular feedback on performance and comparison with other hospi-
tals is mandatory to ensure an optimal quality of diagnostic procedures and treatment outcome 
of referred women. 
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Table 2. Recommendations for extended data collection in breast screenees and patients with early breast 
 cancer
Indicators Data collection 
through
Purpose
Dates Date of diagnosis of screen detected cancer or interval cancer Screening 
programme
QC 
Risk factors Family history of breast cancer, type of previous breast surgery, 
hormone use
Screening 
programme
Prior mammographic 
visibility
Both screen-detected and interval cancer, occult, minimal sign 
and missed lesions
Radiologist QC + Sc
Breast density Screening mammogram Radiologist Sc
BI-RADS classification Screening mammogram and clinical mammogram of referred 
women and interval cancers
Radiologist Sc
Referral advice Discrepancies at double reading among screening radiologists Screening 
programme
QC
Work‐up - Imaging type and outcome: Mammography, digital breast
  tomosynthesis, ultrasound, MRI
- Biopsy procedures: FNAC, CB, vacuum assisted biopsy, surgical
  excision 
Radiologist, in 
combination with  
screening pro‐
gramme
Sc
Tumour biology Tumour grade and receptor status Pathologist Sc + PR
Type of breast cancer 
treatment
Surgery (breast conserving surgery, mastectomy), radiotherapy, 
systemic therapy (adjuvant, palliative)
Combined effort 
of surgeon, ra‐
diotherapist and 
oncologist
QC + Sc 
+ PR
Surgical characteristics Specimen margin status, lumpectomy volume Pathologist Sc + PR
Screening re-attendance 
after false positive referral
Screening
programme
QC
Clinical mammograms 
outside screening pro‐
gramme
Breast imaging outcome, indications for clinical mammography Screening
programme
Sc
Questionnaire Quality of Life assessment after referral, psychological impact 
on referral, work-up and/or treatment
Epidemiologist‐ 
psychologist
Sc + PR
Breast cancer incidence Background incidence, cancer detection rate, interval cancer 
rate
Epidemiologist PH
Breast cancer mortality Epidemiologist PH + QC 
  QC = Quality control; Sc = Scientific; PR = Prognostic parameter  PH = public health;
  FNAC = Fine Needle AspirationCytology; CB = Core Biopsy
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Conclusions
A substantial proportion of cancers in women participating in screening programmes still pre-
sent as interval cancers, most often as a palpable localised mass, but sometimes even as symp-
tomatic metastatic disease. The interval cancer rate was stable throughout the years and the 
rate did not decline, not even after the introduction of digital screening. Patients with interval 
cancers have a worse prognosis when compared to screen-detected cancers and it is therefore 
important to minimize the interval cancer rate in screening programmes, preferably without a 
shortening of the screening interval. Monitoring interval cancers is important in the assessment 
of the quality of the breast cancer screening programme and interval cancers should be used 
in quality assessments of screening programmes with the aim to improve screening sensitivity, 
as is common practice in the Dutch setting.
The higher false-positive rate has become of greater concern in the current era of digital mam-
mography screening. In the Netherlands, the positive predictive value of referral is still high 
when compared to screening programmes in other countries. Still, efforts should be made to 
reduce the number of false positives. We have shown that advanced breast cancer is inevitable 
in a breast cancer-screening programme, but possibilities exist to reduce the advanced breast 
cancer rate, also in the current setting of full-field digital mammography.
In order to improve the benefits to harms ratio of breast cancer screening, future digital mam-
mography related research should focus on the (simultaneous) reduction of the following three 
problems:
	 •	 The	rate	and	management	of	advanced	breast	cancers	among	screened	women
	 •	 The	risk	of	a	false	positive	screening	test	in	screened	women
	 •	 The	overdiagnosis	of	(low	grade)	DCIS.	
Such wide-ranging research may end the polarizing discussion between adversaries and sup-
porters of breast cancer screening and the start of a constructive discussion. With the chan-
ging oncologic reality and improved treatment, there might be a time where stage does not 
influence mortality anymore102. However, as long as breast cancer stage influences mortality, 
breast cancer screening will remain indispensable and efforts should be made to optimize 
breast-cancer screening for a maximal beneficiary outcome for women at risk for breast cancer. 
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Introduction
Despite a steady decrease of mortality from breast cancer, the incidence of breast cancer is still 
increasing. The incidence in the Netherlands is among the highest in Europe. Breast cancer is 
the leading cause of cancer death in women aged 35-64 worldwide. Early detection of breast 
cancer has become an important aspect of current breast cancer management, as most breast 
cancer related deaths are due to advanced disease. In the Netherlands, organized breast can-
cer screening was introduced around 1990 and a more than 30% decrease in breast cancer 
mortality has been established since then, probably as a result of early cancer detection in 
combination with improved therapeutic options. 
Despite the positive outcomes of several trials and population-based studies, the effectiveness 
of breast cancer screening has been under discussion for more than two decades now. The si-
multaneous and equal decrease of the mortality rate in unscreened women is a frequently used 
argument against screening, as well as possible harmful effects of breast cancer screening. One 
of the potential side-effects is so-called overdiagnosis, which is the diagnosis of cancer that 
will never cause symptoms or lead to death during a patient’s lifetime. Without breast cancer 
screening, such cancers would not have been discovered and treated. Estimates of the amount 
of screening induced overdiagnosis vary widely, from 2% in a Dutch study to 52% in an in-
ternational systematic review. However, it still remains unclear which part of the diagnosed 
cancers can be monitored rather than treated surgically. Another subject of debate are the false 
positive referrals, which are women referred for a benign lesion. The psychological distress in 
these women can be substantial and is an important issue to be acknowledged as false positive 
referral may negatively influence screening re-attendance. 
Digital mammography has been available for several years now and has proven its value in the 
clinical setting. Digital mammography has been introduced in most screening programmes. In 
many countries, the introduction of digital mammography in breast cancer screening resulted 
in higher cancer detection rates, especially in women with radiographically dense breasts. 
Data on interval cancers in the setting of digital mammography are sparse and data on the 
impact on breast cancer mortality are lacking. 
Aims
In the South of the Netherlands, the Eindhoven Cancer Registry is a long-standing, population-
based registry, which was started in 1955 as part of a programme for nation-wide cancer 
registration. Since the introduction of mammography screening in our region in 1995, data of 
the cancer registry have been combined with additional data on screening outcome collected 
by one of the screening radiologists, resulting in a unique database with extensive information 
on screening outcome. This database allowed the performance of the studies presented in this 
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thesis.  Data collected over a period of more than 15 years enabled evaluation of classification 
and surgical treatment of breast cancer detected and missed by mammography screening. 
The specific aims of this thesis are to describe the trends in the diagnosis of advanced breast 
cancer (Chapter 2), the trends in the use of biopsies and surgical management (Chapter 3) and 
to explore the effects of the introduction of digital mammography in breast cancer screening 
(Chapter 4).
Methods
The Dutch breast cancer-screening programme offers biennial mammography screening to wo-
men aged 50-75 years of age. The screening region of Eindhoven comprises about a third of the 
South of the Netherlands. Here, the breast cancer screening programme was implemented in 
1995. Between May 2009 and April 2010, screen-film mammography was gradually replaced 
by digital mammography. Since the start of the programme over 700,000 screens have been 
performed, over 14,000 women have been referred to the regional hospitals and more than 
3,500 cancers have been detected. Currently 13 certified screening radiologists double read 
60,000 screens annually. Screening outcome has been closely monitored and registered for 
all screened women. One radiologist (L.E.M. Duijm, MD, PhD) visits the regional hospitals on 
a regular basis to collect data on imaging procedures, type of breast biopsy and treatment of 
each referred woman. These data were combined with the data of the regional screening orga-
nization (Breast Cancer Screening South) and the Eindhoven Cancer Registry.
Interval cancers are breast cancers diagnosed in women after a screening mammogram has 
yielded negative results (defined as no recommendation for referral). Efforts were made by the 
screening office and L.E.M. Duijm to trace as many women with interval cancers as possible. 
Two experienced screening radiologists (L.E.M. Duijm and F.H. Jansen) reviewed the latest 
screening mammogram of all screen-detected cancers and interval cancers, as well as the clini-
cal mammogram obtained at the time of interval cancer detection. They categorised mammo-
graphic breast density and the cancers were classified as missed, minimal sign or true negative 
at the previous screen. Finally the reviewers classified the mammographic abnormality at the 
prior screening examination. 
Results
Advanced cancer in breast cancer screening
Most breast cancer deaths occur in women who are diagnosed with breast cancer in an ad-
vanced stage, i.e. with lymph node metastasis or distant metastases. Breast cancer screening 
aims to detect cancer when it is small, and not disseminated to lymph nodes or distant organs. 
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Several studies have shown that screening mammography is effective in reducing breast cancer 
mortality. These studies were carried out in an era before the use of anti-hormonal therapies 
and other adjuvant therapies. It remains a question of debate which part of mortality reduction 
can be attributed to screening and which part to adjuvant systemic treatment. If a mortality re-
duction were due to screening, one would expect that this reduction is preceded by a decrease 
in the risk of a diagnosis of advanced breast cancer.
This study determined the trends in the incidence of advanced breast cancer in 351,009 con-
secutive screens, during 1997-2011 (Chapter 2). Advanced breast cancers were defined as can-
cers with TNM stage IIA or higher, i.e. tumour size exceeding 20 mm (T2) and/or the presence 
of lymphatic metastasis in the sentinel node or axillary lymph nodes. 
In the South of the Netherlands we found no decline in the incidence of advanced screen 
detected cancers and advanced interval cancers during twelve years of screening mammo-
graphy. Advanced breast cancer comprised around one-third of screen-detected cancers and 
two-thirds of all interval carcinomas. Two experienced radiologists determined whether or not 
these advanced cancers were visible at the prior screening study. After review of this prior vi-
sibility, they concluded that the majority of these advanced cancers were not visible at a prior 
mammogram, or showed a minimal sign that did not warrant a recall. Multivariate analysis sho-
wed that a screening interval of 30 months or more significantly increased the risk of detecting 
breast cancer in an advanced stage.
Biopsy use and surgical management
The aim of these studies was to determine trends in breast biopsies used for the work-up of 
abnormalities detected at screening mammography (Chapter 3.1) and to determine trends in 
surgical management of both screen-detected and interval cancer (Chapter 3.2). 
Screened women with a mammographic abnormality are referred to a hospital for further 
diagnostic workup and, if necessary, treatment. There are various breast biopsy procedures, 
including 
 – Percutaneous fine-needle aspiration cytology, 
 – Percutaneous core-needle biopsy (ultrasound-guided or stereotactic vacuum-assisted)
 – invasive surgical biopsy. 
Surgical biopsies for diagnostic purposes should be avoided, as they increase unnecessary 
psychological distress in false-positive referrals and benign breast surgery complicates inter-
pretation of subsequent mammograms due to postoperative changes. All women screened in 
our screening region from 1997-2011 were included and time trends in types of breast biopsies 
for abnormalities detected at screening mammography were determined. Also, the proportion 
of referred women who experienced a delay in breast cancer diagnosis and the causes of these 
delays were determined. A delay was defined as a diagnosis of breast cancer more than three 
months after referral.
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Regarding surgical treatment, patient and tumour characteristics were compared between  wo-
men who underwent mastectomy or breast conserving surgery for their screen-detected or 
interval cancer and between women with a negative or positive resection margin after breast 
conserving surgery.
We found that in our screening region diagnostic surgical biopsy for the workup of a screening 
mammography abnormality has become very uncommon. Diagnostic surgical biopsies have 
mostly been replaced by percutaneous core biopsies. The replacement of surgical biopsies 
by percutaneous core biopsies did not increase the percentage of women who experienced a 
delay in breast cancer diagnosis.
During a 14-year screening period we observed a doubling of the mastectomy rate (per 1,000 
screened women), whereas the breast conserving surgery rate and breast cancer incidence 
remained stable. Multivariable analysis showed that patients with microcalcifications, large 
tumours, lymph node metastasis and those treated in certain hospitals had a higher risk to 
undergo mastectomy. Furthermore, we observed a decline over time in positive resection mar-
gins, with variation among hospitals. Main independent risk factors for the presence of positive 
resection margins of invasive cancers were 
 – Tumour size >20 mm, 
 – Lobular histology 
 – Non-palpable tumour
 – The hospital where a woman was treated for breast cancer. 
Having had a pre-operative MRI lowered the risk of positive resection margins, but resulted in 
a substantially higher risk to undergo mastectomy. Women with Interval cancers were not more 
likely to be treated with mastectomy when taking into account their less favourable tumour 
stage. The proportion of tumour positive resection margins decreased over time. However, 
substantial differences were seen among hospitals (6-20%). 
Digital mammography screening
In recent years, full-field digital mammography has replaced screen-film mammography in 
most breast screening programmes. Digital mammography has several advantages. It improves 
workflow and it is as least as effective as screen-film mammography in the detection of breast 
cancer. However, higher cancer detection rates at digital mammography may be accompanied 
by increased referral rates. In our region, screen-film mammography was gradually replaced by 
digital mammography between May 2009 and April 2010. We evaluated 60,770 screen-film 
screens and 63,182 digital screens from 2008-2011. The studies in Chapter 4.1 and Chapter 
4.2 describe the impact of the introduction of digital mammography screening on diagnostic 
workup, tumour characteristics and surgical treatment of screen-detected and interval cancers 
in our region. 
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The transition of screen-film mammography to digital mammography has resulted in an incre-
ased referral rate  and a significantly increased  detection rate  ductal carcinoma in-situ and 
invasive cancers, at the expense of a decreased positive predictive value of referral and biopsy. 
An almost fourfold increase in the use of stereotactic core needle biopsy was observed, which 
has a great impact on the daily practice of the regional breast clinics as it is much more time 
consuming than ultrasound guided biopsy.
Invasive cancers at digital mammography were more likely to
 – be diagnosed at an earlier tumour stage, 
 – show a more favourable tumour grade, 
 – show less lymph node involvement 
 – and comprised a significantly larger proportion of progesterone-receptor positive can
  cers. 
Women with breast cancer detected at digital mammography were more likely to be treated 
by breast-conserving surgery, whereas the mastectomy rate was similar at screen-film mam-
mography and digital mammography. 
The interval breast cancer rate and sensitivity were comparable for screen-film and digital 
screening mammography, despite a significantly higher cancer detection rate at digital mam-
mography. A significantly larger proportion of interval breast cancers was not visible on prior 
screens at digital mammography compared to screen-film mammography, whereas mammo-
graphic characteristics, tumour stage, tumour biology and surgical treatment were similar for 
interval cancers in both groups.
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Conclusions
The majority of the advanced breast cancers detected at biennial screening cannot be preven-
ted. In order to obtain a modest reduction of the risk of detecting breast cancer in an advan-
ced stage, efforts are needed to minimize the number of women with an extended screening 
interval. 
Quality control in hospitals treating breast cancer patients is important in order to ensure op-
timal care for women diagnosed with breast cancer, with special attention to cancers found in 
women referred by a breast cancer screening programme as these cancers differ from clinically 
detected cancers. Surgeons performing breast conserving surgery should try to pre-operatively 
identify patients with a high risk of positive resection margins, especially focusing on the role 
of microcalcifications since these are more commonly encountered in a screened population. 
Furthermore, continuous efforts should be made to improve the quality of the excision of non-
palpable tumours, either by using wire-guided localisation or iodine-125-radiolabelled seeds, 
and to benchmark the performance against that of peers.
In the South of the Netherlands, digital mammography significantly increased the referral rate 
and cancer detection rate, at the expense of a lower positive predictive value of referral and 
biopsy. Additional tumours detected at digital mammography are mostly low to intermediate 
grade ductal carcinoma in-situ and smaller invasive tumours, with more favourable tumour 
characteristics. Mastectomy rates did not increase. Digital mammography results in a signifi-
cantly higher cancer detection rate, but programme sensitivity was similar for both screen-film 
and digital mammography screening. Interval cancers are more likely to be true negative at 
prior digital mammography than at prior screen-film mammography, whereas their tumour 
characteristics and type of surgical treatment are comparable.
The quality of the screening programme and the performance of screening radiologists should 
be closely monitored, with the aim to continuously improve breast cancer screening results. 
Future research should focus on the following three issues in order to try to improve the bene-
fits to harms ratio by reduction of:
	 •	 The	proportion	of	advanced	breast	cancers	among	screened	women
	 •	 The	risk	of	a	false	positive	screening	test
	 •	 The	risk	of	overdiagnosis.
Such wide-ranging research initiatives may put an end to the polarizing discussion between 
adversaries and supporters of breast cancer screening and be the start of a constructive discus-
sion. As long as breast cancer stage influences mortality, breast cancer screening will remain 
indispensable and efforts should be made to optimize breast-cancer screening for a maximal 
beneficiary outcome for women at risk for breast cancer. 
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Achtergrond
Borstkankerscreening is niet meer weg te denken uit de Nederlandse maatschappij. Borstkan-
ker is een van de meest voorkomende maligniteiten bij vrouwen in de westerse wereld en de 
incidentie neemt nog steeds toe. In Nederland is in 2013 bij 14,600 vrouwen  borstkanker 
vastgesteld en de kans voor een vrouw om borstkanker te ontwikkelen is inmiddels 1 op 7. 
Borstkanker is wereldwijd de meest voorkomende oorzaak van sterfte door kanker bij vrou-
wen. Vroege detectie van borstkanker is belangrijk, omdat de sterfte aan borstkanker meestal 
het gevolg is van detectie van de ziekte in een te ver gevorderd stadium. De toename van het 
aantal vrouwen met borstkanker is toe te schrijven aan  verschillende factoren. Eén daarvan 
is de invoering van borstkankerscreening, een andere is een toegenomen blootstelling aan 
risicofactoren. Ook speelt een groeiende  bewustwording van het risico op borstkanker bij 
Nederlandse vrouwen een prominente rol. 
Ondanks de positieve conclusies van diverse studies is er al meer dan 20 jaar discussie over 
de effectiviteit van borstkankerscreening. De gedocumenteerde afname in mortaliteit van 30% 
wordt namelijk ook gezien in de leeftijdsgroepen die niet gescreend worden. Dit is voor critici 
reden om te beweren dat de gecostateerde daling van de mortaliteit geheel en al te danken 
is aan een betere behandeling en  niet aan de screening. Het is nu niet meer mogelijk om de 
exacte bijdrage van screening en behandeling op sterfte te bepalen, omdat beide veranderin-
gen min of meer gelijktijdig zijn ingetreden. Een ander nadelig effect van borstkankerscreening 
zijn de verwijzingen van vrouwen die bij verdere analyse in het ziekenhuis geen borstkanker 
blijken te hebben, de zogenaamde fout-positieve verwijzingen. Uit nationaal en internatio-
naal onderzoek is gebleken dat een dergelijke verwijzing leidt tot veel onnodige en mogelijk 
langdurige stress bij de vrouw. Bovendien zijn er aanwijzingen dat een dergelijke onterechte 
verwijzing kan leiden tot een lager opkomstpercentage in volgende rondes. Tenslotte wordt 
de zogenaamde overdiagnose als potentieel nadeel van de screening genoemd. Overdiagnose 
betekent dat borstkanker wordt gediagnosticeerd welke, indien niet ontdekt, niet tot het over-
lijden van de vrouw zou leiden. Zonder screening zouden deze kankers niet gediagnosticeerd 
en niet behandeld worden. De schattingen van het aandeel overdiagnosticeerde borstkankers 
lopen	erg	uiteen;	van	2,5%	in	een	Nederlandse	studie	tot	52%	in	een	internationale	review.	
Vooralsnog blijft het onduidelijk welke van de tumoren in de borstkankerscreening niet (direct) 
chirurgisch behandeld dienen te worden.
Digitale mammografie heeft zich bewezen in de klinische setting. De goede resultaten in de 
kliniek en de screening, alsmede de voortdurende technische ontwikkelingen, hebben ge-
leid tot de vervanging van analoge mammografie door digitale mammografie in de meeste 
screeningsprogramma’s . Digitale mammografie verbetert de workflow en verhoogt het kanker-
detectiecijfer. Data over intervalkankers bij digitale mammografie zijn nauwelijks voorhanden. 
Een intervalkanker is een kanker welke ontdekt wordt bij een vrouw tussen twee screenings-
ronden in, zonder dat zij bij de voorgaande screeningsronde verwezen is.
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Onderzoeksdoel
In het zuiden van Nederland is er sinds 1955 een kankerregistratie en sinds 1989 is deze kan-
kerregistratie een onderdeel van een programma voor landelijke kankerregistratie. Parallel aan 
deze registratie zijn er sinds de invoering van borstkankerscreening in 1995 in de regio Eindho-
ven gegevens verzameld over de gescreende vrouwen. In een systematisch opgezette databank 
werden door een van de screeeningsradiologen (Dr. L.E.M. Duijm) alle relevante gegevens van 
de gescreende vrouwen verzameld. In deze databank werd onder meer het diagnostisch- en 
eventueel behandeltraject van de verwezen vrouwen in kaart gebracht, alsmede informatie 
over de vrouwen die een intervalkanker bleken te hebben. Data verzameld over een periode 
van meer dan 15 jaar hebben evaluatie van trends in classificatie en chirurgische behandeling 
van borstkanker mogelijk gemaakt. Specifieke doelen van het proefschrift zijn het beschrijven 
van: 
	 •	 Trends	in	het	voorkomen	van	gevorderde	borstkanker	(Hoofdstuk	2)
	 •	 Trends	in	het	gebruik	van	diagnostiek	en	behandeling	van	borstkanker	(Hoofdstuk	3)
	 •	 De	effecten	van	de	introductie	van	digitale	mammografie	in	de	borstkankerscreening	
  (Hoofdstuk 4)
Materiaal en methode
Het Nederlandse screeningsprogramma bestaat uit  een tweejaarlijkse screening van vrouwen 
tussen de 50 en 75 jaar. De screeningsregio rond Eindhoven omvat ongeveer een derde van 
Zuid-Nederland. In deze regio werd borstkankerscreening geïmplementeerd in 1995, als een 
van de laatste regio’s in Nederland. Tussen mei 2009 en april 2010 zijn de analoge mam-
mografen gefaseerd vervangen door digitale mammografen. Sinds de start van de screening 
in deze regio zijn er meer dan 700.000 screeningsonderzoeken verricht, meer dan 14.000 
vrouwen verwezen naar regionale ziekenhuizen en is bij meer dan 3.000 vrouwen invasief 
borstkanker vastgesteld en bij meer dan 700 in-situ kanker. Anno 2014 zijn 13 gecertificeerde 
screeningsradiologen werkzaam bij het Bevolkingsonderzoek Zuid, die tezamen jaarlijks ruim 
60.000 screeningsonderzoeken beoordelen. De uitkomsten van screening worden nauwgezet 
gemonitord. De eerder genoemde screeningsradioloog bezoekt met regelmaat de regionale 
ziekenhuizen om data te verzamelen van de verwezen vrouwen, met betrekking tot verrichte 
diagnostische onderzoeken, biopsie procedures en type behandeling. Ook worden de inter-
valkankers opgespoord en toegevoegd aan de databank. Deze data zijn gecombineerd met die 
van de screeningsorganisatie en het Integraal Kankercentrum Zuid (IKZ, thans onderdeel van 
het IKNL) en vormden daarmee de basis van dit proefschrift. 
Twee ervaren radiologen (Dr. L.E.M. Duijm en Drs. F.H. Jansen) herbeoordeelden het laatste 
screeningsonderzoek van alle vrouwen bij wie  borstkanker was vastgesteld, zowel  interval-
kankers als kankers ontdekt tijdens een vervolg screeningsronde. 
157Samenvatting
C
h
a
p
te
r 
6
.2
De densiteit van het mammogram werd toegevoegd aan de databank en per kanker werd be-
paald of deze gemist was op het voorgaande screeningsmammogram, of er minimale tekenen 
van kanker zichtbaar waren, of dat de betreffende kanker niet eerder zichtbaar was. Tenslotte 
werd het type afwijking op het mammogram geclassificeerd.
Bevindingen
Hoofdstuk 2: trends in de detectie en incidentie van gevorderd borstkanker
De meeste vrouwen overlijden aan borstkanker nadat deze ziekte in een gevorderd stadium 
is vastgesteld. Een gevorderd stadium is kanker welke is uitgezaaid naar lymfklieren of andere 
organen. Het doel van borstkankerscreening is het ontdekken van tumoren wanneer deze 
klein zijn en nog beperkt zijn gebleven tot de borst. Studies hebben aangetoond dat borstkan-
kerscreening de mortaliteit van borstkanker verlaagt. Het blijft echter een discussie welk deel 
van de sterftereductie toe te wijzen is aan betere behandeling en welk deel aan de screening. 
Als de sterftedaling het gevolg is van de screening zou men verwachten dat de afname van de 
sterfte voorafgegaan wordt door een daling in het risico op gevorderde borstkanker. Eerdere 
studies hebben aangetoond dat screening kan leiden tot een afname van het aantal borstkan-
kers welke in een gevorderd stadium wordt gediagnosticeerd. 
In hoofdstuk twee bestudeerden  wij in een retrospectief onderzoek de trends in de incidentie 
van deze gevorderde kankers, gedefinieerd als kankers groter dan 2 centimeter en/of borstkan-
kers met lymfkliermetastasen. 
Gedurende een periode van 12 jaar bepaalden we bij 351.009 screeningsonderzoeken de 
incidentie van deze gevorderde kankers. Ook onderzochten we welk percentage van deze 
tumoren potentieel bij een eerdere screeningsronde hadden kunnen worden gedetecteerd. 
Tenslotte bepaalden we risicofactoren voor de diagnose van gevorderde kankers.  
In tegenstelling tot andere studies vonden we gedurende de studieperiode 1997-2008 geen 
afname in het percentage gevorderde kankers. Bij ongeveer een derde van de bij screening ont-
dekte kankers betrof het kanker in een gevorderd stadium. Van de intervalkankers bleek twee 
derde gevorderd. Tevens bleek dat het merendeel van de gevorderde kankers (59%) niet  in een 
vroeger stadium ontdekt had kunnen worden  bij de tweejaarlijkse screening. Veel van deze 
kankers waren namelijk niet zichtbaar bij een eerdere screeningsronde of ze werden vastge-
steld bij de eerste screeningsronde. Multivariate analyse toonde aan dat een screeningsinterval 
van meer dan 2 jaar een risicofactor blijkt te zijn voor gevorderde borstkanker.
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Hoofdstuk 3: trends in diagnostiek en behandeling van verwezen vrouwen
Het doel van deze studies was om trends in het diagnostisch traject van verwezen vrouwen in 
kaart te brengen. Ook wilden we trends beschrijven in de chirurgische behandeling van zowel 
borstkankers gevonden in de screening als van intervalkankers.
Gescreende vrouwen met een afwijkend screeningsmammogram worden verwezen naar een 
ziekenhuis voor verdere diagnostiek en, indien nodig, behandeling. Ongeveer de helft van de 
verwezen vrouwen krijgt alleen aanvullende beeldvorming, welke kan bestaan uit een aanvul-
lende mammografische opnames, tomosynthese, echografie en/of MRI. Bij de andere helft is 
(minimaal) invasieve diagnostiek nodig om de diagnose te stellen. Er zijn verschillende biopsie 
procedures: percutane dunne naald aspiratie cytologie, percutane holle naald biopsie, percu-
tane vacuüm-biopsie (echogeleid of stereotactisch) en invasieve chirurgische biopsie. Chirur-
gische biopten voor diagnostische doeleinden dienen zoveel mogelijk vermeden te worden, 
omdat ze voor meer onnodige stress zorgen bij vrouwen die zijn verwezen vanwege een be-
nigne afwijking  en omdat chirurgie  de beoordeling van latere mammografische onderzoeken 
bemoeilijkt. 
Alle vrouwen die hebben deelgenomen aan de borstkankerscreening tussen 1997 en 2011 
zijn geïncludeerd in deze studie. Veranderingen in die periode  in het gebruik van biopsiepro-
cedures werden bepaald. Tevens werd vastgesteld welk deel van de verwezen vrouwen met 
borstkanker een vertraging opliep in de diagnose, gedefinieerd als een diagnose meer dan drie 
maanden na verwijzing vanuit de screening.
We concludeerden dat vrouwen tegenwoordig nauwelijks meer (ca. 1%) geconfronteerd wor-
den met een diagnostisch chirurgisch excisiebiopt in het diagnostisch traject na verwijzing. 
Deze excisiebiopten zijn nagenoeg allemaal vervangen door percutane biopten. De vervanging 
heeft niet gezorgd voor een toename in het percentage vrouwen dat vertraging opliep in het 
stellen van de diagnose borstkanker.
Wat betreft de chirurgische behandeling werden patiënt- en tumorkarakteristieken vergeleken 
tussen  vrouwen die een mastectomie dan wel borstsparende behandeling ondergingen en 
vrouwen met met positieve dan wel negatieve snijranden na een borstsparende behandeling 
voor borstkanker.
Gedurende dezelfde 14 jaren (1997-2011) is (uitgedrukt per 1000 gescreende vrouwen) het 
aandeel dat een mastectomie ondergaat verdubbeld, terwijl het aandeel vrouwen dat borstspa-
rend behandeld werd en de borstkanker incidentie gelijk bleven. Multivariate analyse toonde 
aan dat vrouwen met microcalcificaties op het mammogram, grote tumoren, lymfkliermetasta-
sen en vrouwen behandeld in bepaalde ziekenhuizen een hoger risico hadden op een mas-
tectomie. 
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Verder observeerden wij in de loop der tijd een afname in het aantal tumoren met tumorpo-
sitieve snijranden, met een grote variatie tussen de verschillende ziekenhuizen. De belangrijk-
ste onafhankelijke risicofactoren voor tumorpositieve snijranden waren: een tumorgrootte van 
meer dan 20 millimeter, lobulaire histologie en het ziekenhuis waar de behandeling heeft plaats 
gevonden. Het verrichten van een preoperatieve MRI verlaagde het risico op tumorpositieve 
snijranden, maar verhoogde het risico op een mastectomie. Vrouwen met een intervalkanker 
hadden geen hoger risico op een mastectomie, wanneer rekening werd gehouden  met het 
gemiddeld ongunstiger stadium van deze tumoren. 
Hoofdstuk 4: impact van de introductie van digitale mammografie in de 
screening
In het afgelopen decennium is in de meeste borstkankerscreening programma’s analoge mam-
mografie vervangen door digitale mammografie. Digitale mammografie heeft verschillende 
voordelen. Het verbetert de workflow en is minstens zo effectief in de detectie van borstkan-
ker en waarschijnlijk zelfs beter. De hogere borstkankerdetectie bij digitale mammografie heeft 
echter ook een prijs, namelijk  een hoger verwijspercentage. In onze screeningsregio is analoge 
mammografie gefaseerd vervangen door digitale mammografie tussen mei 2009 en april 2010. 
Wij onderzochten 60.770 analoge en 63.182 digitale screeningsonderzoeken tussen 2008 en 
2011. De studies in hoofdstuk 4 beschrijven de impact van de introductie van digitale mam-
mografie op het diagnostisch natraject, tumorkarakteristieken en chirurgische behandeling van 
zowel door screening ontdekte borstkanker als intervalkankers. 
De implementatie van digitale mammografie leidde tot een significant hoger kankerdetectiecij-
fer van zowel invasieve tumoren als in-situ tumoren. Dit ging ten koste van een hoger verwijs-
cijfer en een lagere positief voorspellende waarde van verwijzing en biopsie. Het gebruik van 
stereotactische biopten in het natraject is bijna verviervoudigd, met grote consequenties voor 
de regionale ziekenhuizen die het natraject verzorgen. Deze biopten kosten namelijk veel tijd. 
Invasieve tumoren gedetecteerd bij digitale mammografie waren vaker kleinere kankers, met 
een lage tumorgraad, zonder positieve okselklieren en met positieve progesteron receptoren. 
Vrouwen met borstkanker, vastgesteld met  digitale mammografie, hadden een hogere kans om 
een borstsparende behandeling te ondergaan, terwijl het aantal vrouwen dat een mastectomie 
onderging, per 1000 gescreende vrouwen, gelijk blijft.
Het aandeel intervalkankers en de sensitiviteit van het screeningsprogramma waren vergelijk-
baar voor analoge en digitale mammografie, ondanks het significant hogere kankerdetectiecij-
fer bij digitale screening. Hierbij  was een groter aandeel van de intervalkankers  niet zichtbaar 
op het laatste screeningsonderzoek. Mammografische kenmerken, tumor stadium, tumor bio-
logie en chirurgische behandeling van de intervalkankers waren gelijk in beide groepen.
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Conclusie
Het  merendeel van de gevorderde borstkanker kan niet worden voorkomen met een twee-
jaarlijkse screening. Om een bescheiden reductie van het aantal vrouwen met gevorderde 
borstkanker te bewerkstelligen moet moeite gedaan worden om het aantal vrouwen met een 
screeningsinterval van meer dan twee jaar te verminderen. Kwaliteitscontrole binnen zieken-
huizen, die betrokken zijn in de diagnostiek en behandeling van verwezen vrouwen, is be-
langrijk om optimale zorg voor de gescreende vrouwen te waarborgen. Chirurgen die borst-
sparende behandelingen uitvoeren moeten vooraf rekening houden met factoren die het risico 
op tumorpositieve snijranden vergroten, met een speciaal focus op micro-calcificaties. Er moet 
meer aandacht komen voor de kwaliteit van röntgen-geleide excisies om de resultaten hiervan 
tussen oncologische centra onderling te kunnen vergelijken 
De introductie van digitale mammografie in de screening heeft geleid tot een 35 procent hoger 
kanker detectiecijfer en een verdubbeling van het verwijscijfer, ten koste van een 10 procent 
lagere positief voorspellende waarde van verwijzing en een 20 procent lagere voorspellende 
waarde van biopsie. De extra tumoren, ontdekt bij digitale mammografie, waren grotendeels 
laag- tot intermediair-gradige in-situ tumoren en kleine invasieve tumoren, met gunstigere tu-
morkarakteristieken. Ondanks het hogere kankerdetectiecijfer bleef de sensitiviteit (de “gevoe-
ligheid”) van het screeningsprogramma gelijk. Intervalkankers waren bij digitale mammografie 
20 procent vaker niet zichtbaar op het laatste screeningsmammogram, terwijl karakteristieken 
als tumorgrootte, tumorstadium, lymfklierstatus en chirurgische behandelingen gelijk waren. 
De kwaliteit van de borstkankerscreening en de prestaties van screeningsradiologen moeten 
gemonitord worden, teneinde de screeningsresultaten te verbeteren en daarmee uiteindelijk 
de mortaliteit te verminderen. Om de voordelen en nadelen van de screening beter in kaart te 
brengen zou toekomstig onderzoek moeten focussen op het verminderen van:
	 •	 het	aandeel	gevorderde	borstkankers	bij	vrouwen	die	deelnemen	aan	de	screening
	 •	 het	risico	op	een	fout-positieve	verwijzing
	 •	 het	risico	op	overdiagnose.
Hierbij kan gedacht worden aan onderzoek naar nieuwe technieken als tomosynthese, hier-
mee kunnen als het ware driedimensionale foto’s van de borst gemaakt worden. Dit zou het 
risico op een fout-positieve verwijzing kunnen verminderen en wellicht ook bijdragen aan het 
verlagen van het aandeel gevorderde kankers. Het minder- of niet-invasief behandelen van in-
situ kankers en kleine invasieve kankers kan een oplossing zijn voor de overdiagnose. Dergelijk 
onderzoek kan een einde betekenen van de gepolariseerde discussie tussen voor- en tegen-
standers van de borstkankerscreening en het begin van een constructieve discussie. 
Zolang het stadium waarin borstkanker verkeert invloed heeft op de mortaliteit, zal de nood-
zaak voor vroege detectie van borstkanker blijven bestaan. Dit rechtvaardigt het bestaansrecht 
van borstkankerscreening. Het verder optimaliseren van de borstkanker screening is noodza-
kelijk om het voordeel voor de gescreende vrouw te maximaliseren.
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Veel dank ben ik verschuldigd aan allen die hebben meegewerkt aan de totstandkoming van 
dit proefschrift. De volgende personen wil ik in het bijzonder bedanken.
Mijn promotor, professor J.W. Coebergh, na enkele minuten al Jan Willem. Hoewel je pas hal-
verwege bij mijn onderzoek betrokken bent geraakt, heb ik veel gehad aan je enthousiasme, 
kennis en betrokkenheid. Dank voor je doortastendheid in het afronden van dit boekwerk.
Dr. Lucien Duijm, mijn copromotor. Jij hebt me enthousiast gemaakt voor wetenschappelijk 
onderzoek en zonder jou was het waarschijnlijk bij een half-af manuscript ergens op een harde 
schijf thuis gebleven. Ik bewonder met name je ongelooflijke gedrevenheid, en ik wil je van 
harte bedanken voor alle tijd die je in ons onderzoek hebt gestoken. Je opmerkingen en verbe-
teringen zorgden meer dan eens voor een volledig roodgekleurd manuscript, gelukkig werd dit 
naarmate het traject vorderde steeds iets minder. Ik ben blij dat ik nu af en toe ook iets terug 
kan doen. 
Dr. Adri Voogd, ook copromotor. Wij hebben elkaar leren kennen via Lucien en ik heb altijd 
genoten van je snelle reacties op mails en ook van de altijd zeer uitgebreide commentaren op 
de artikelen. Waar een radioloog in een oogopslag een afwijking ziet, zie jij die in een ma-
nuscript. Nadat Lucien het artikel al ondersteboven had gekeerd wist jij toch altijd weer met 
scherpe opmerkingen en talloze extra referenties te komen. 
De leden van de kleine commissie, Prof. van den Bosch, Dr. Broeders,  en Prof. Verhoef heb-
ben allen tijd genomen voor de inhoudelijke beoordeling van mijn proefschrift, waarvoor ik 
allen hartelijk wil danken.
Tom en Joep, fijn dat jullie mijn paranimfen willen zijn. Tom, broertje en vriend. Bedankt voor 
je tekstuele hulp bij het Nederlands deel van dit proefschrift. Joep, begonnen als teamgenoten, 
nu als tegenstanders in het water, maar vrienden buiten het water. Veel mooie herinneringen 
met jullie beiden. Dat er nog maar vele mogen volgen.
Vivian, jij was de eerste van ‘ons’ drietal die promoveerde en plaveide daarmee vast de weg. 
Jouw betrokkenheid en doorzettingsvermogen zorgden ervoor dat ik ook verder ging, want als 
jij kan promoveren en tegelijk twee kinderen opvoeden, dan moest ik dat zeker ook kunnen! 
Verder ben je altijd beschikbaar voor discussie en steun, bedankt!  
Wikke, collega en mede-promovenda. Jij staat altijd voor iedereen klaar met een ongelooflijke 
inzet. Klagen hoor ik jou zelden doen, zelfs niet tijdens de afronding van je eigen proefschrift. 
Ik heb heel veel bewondering voor je.
Lisa, jij maakt een kwartet promovendi onder de vleugels van Lucien. Je bent altijd eigenwijs 
en dat waardeer ik aan je.  Met kritische vragen liet je me meer dan eens twijfelen aan mezelf. 
Bedankt voor de kritische noot en succes met je eigen promotie.
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Dr. Marieke Louwman. Jouw statistiek kennis is onmisbaar geweest bij de totstandkoming van 
mijn proefschrift. De afstand tussen Eindhoven en het Franse platteland en dagelijkse sores op 
de boerderij zorgden soms voor wat vertraging, maar uiteindelijk zijn alle ingewikkelde analy-
ses afgerond, met een zeer fraai resultaat. Mijn dank daarvoor! 
Frits Jansen, jij hebt een ongelooflijke hoeveelheid mammogrammen opnieuw beoordeeld en 
hebt daarmee een aanzienlijke bijdrage geleverd aan mijn proefschrift. Toch is jouw bijdrage 
aan het plezier op de werkvloer ontzettend veel belangrijker. Jij bent een fantastische collega 
en opleider, maar bovenal altijd een vrolijke noot.
Harrie van de Bosch, mijn vice-opleider, collega, vriend en eeuwig promovendus. Min of meer 
door jouw toedoen ben ik in Eindhoven beland, maar ook op vele andere mooie plaatsen over 
de wereld, waarvoor ik je hartelijk wil bedanken. Ik kan nog veel van je leren! 
Philip Jurgens, het gelach op de gang zal nog lang doorklinken. Ik heb veel van je geleerd, ra-
diologie maar nog meer over alles wat er bij een afdeling radiologie en het leven komt kijken. 
Bewust of onbewust heb jij ook gezorgd voor de inspiratie voor de kaft.
Matt Holland, dear friend. Thank you for the necessary grammatical corrections of the intro-
duction, discussion and summary.
Mijn dank gaat ook uit naar de overige coauteurs van dit  proefschrift, Astrid Donkers, Han-
nie Groenewoud, Jan Roukema, Liza van Steenbergen, Marianne Hooijen, Matthieu Rutten, 
Menno Plaisier, Mike van Beek, Miranda Ernst, Paul Lohle en Rudi Roumen.
De overige leden van de maatschap radiologie van het Catharina Ziekenhuis wil ik ook graag 
bedanken voor de mogelijkheid om de opleiding radiologie te combineren met een promotie-
traject. Zonder jullie steun en bijdragen was het niet mogelijk geweest om dit proefschrift af 
te krijgen of de bijbehorende voordrachten te houden. Hartelijk dank voor jullie enthousiasme 
en steun.
Henk Swinkels, bedankt voor de fantastische vormgeving van zowel kaft als inhoud.
Teamgenoten, bedankt voor het begrip wanneer ik door ‘het werk’ weer eens niet op kom op-
dagen voor een training. (Bijna) dagelijks geniet ik van jullie gezelschap, jullie houden me jong!
Lieve schoonfamilie, bedankt voor jullie oprechte interesse. 
Lieve ouders, dank voor een stevig fundament. De laatste jaren kom ik niet meer zo vaak in het 
ouderlijk huis als ik zou willen. Jullie betekenen ontzettend veel voor me. 
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Ineke, Annelies en Marieke, ook jullie zie ik veel minder. Toch is onze band hecht als altijd. Als 
het stil is in huis denk ik vaak terug aan ons oude ‘huishouden van Jan Steen’.
Mijn allerliefste Veronie, iedere dag met jou samen is weer een feest. 
Jouw steun, vrolijkheid en begrip zijn onmisbaar geweest bij het schrijven van dit proefschrift.
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Curriculum Vitae
Joost Nederend werd geboren op 21 november 1984 te ’s-Gravenhage.
In 2002 behaalde hij zijn atheneum diploma aan het Sint-Antonius College te Gouda. Hij werd 
direct ingeloot voor de studie geneeskunde aan de Universiteit Leiden. Tijdens deze studie liep 
hij co-schappen in verschillende ziekenhuizen, waaronder het Leids Universitair Medisch Cen-
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